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ABSTRACT OF DISSERTATION 
ROLE OF SEX CHROMOSOMES IN SEXUAL DIMORPHISM OF ANGII-
INDUCED ABDOMINAL AORTIC ANEURYSMS 
Abdominal aortic aneurysms (AAAs), a permanent dilation in the 
abdominal region of the aorta, is a highly sexually dimorphic disease. AAAs 
prevalence is ranging from 4-10 fold higher in males than females. Defining the 
mechanistic basis for reduced (in females) or increased (in males) AAA formation 
and progression may uncover potential therapeutic targets. The majority of 
studies examining sexual dimorphism focus on the role of sex hormones. 
However, genes residing on sex chromosomes, in addition to sex hormones, 
may contribute to sexual dimorphism of AAAs.  For example, the X chromosome 
contains about 5% of the whole genome, but the role of sex chromosomes genes 
to sexual dimorphism of cardiovascular diseases such as AAAs is largely 
unknown. The purpose of this study was to determine the role of sex 
chromosomes as mediators of sex differences for angiotensin II (AngII)-induced 
AAAs in hypercholesterolemic mice. 
We used the four core genotype murine model, which enables the creation 
of phenotypically normal male and female mice with an XX versus XY sex 
chromosome complement, to test the hypothesis that an XY sex chromosome 
complement promotes AngII-induced AAAs. Transgenic male mice expressing the 
Sry gene on an autosome, but not on the Y-chromosome, were bred to female 
low-density lipoprotein receptor deficient mice to create male and female mice with 
an XX or an XY sex chromosome complement.  
In females, an XY sex chromosome complement doubled the incidence 
and markedly increased the severity of AngII-induced AAAs. To define 
mechanisms, we examined gene expression patterns in abdominal aortas and 
demonstrated elevated expression of inflammatory genes that were linked to 
increased MMP activity and oxidative stress in aortas from XY females.  
Moreover, administration of testosterone to XY females, to mimic males, resulted 
in a striking level of aneurysm rupture.  
In males, transcriptional profiling of abdominal aortas revealed 450 genes 
that were influenced by sex chromosomes. Infusion of AngII to XY males resulted 
in diffuse pathology along the length of the aorta, while XX males developed 
focal AAAs, with pathology reduced by orchiectomy in both genotypes. Thoracic 
aortas of XY males exhibited adventitial thickening which was not exist in thoracic 
aortas from XX males. Following a prolonged period (3 months) of AngII 
infusions XY males had AAAs with expanded aortic walls, while XX males had 
thin walled dilated AAAs. 
In summary, our findings demonstrate a remarkable effect of sex 
chromosome complement to regulate aortic vasculature and disease
development. Aside from demonstrating mechanisms of sexual dimorphism of 
aortic diseases, these findings indicate that chronic sex hormone therapy in the 
aging and transgender population may have cardiovascular ramifications.  
Moreover, identification of targets influenced by sex chromosomes and/or sex 
hormones in a manner that predicts disease development may identify sex-
specific approaches to cardiovascular therapy. 
KEYWORDS: Sexual dimorphism, Sex chromosomes, Testosterone, Abdominal 
aortic aneurysm, Angiotensin 
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CHAPTER I. INTRODUCTION 
1.1 Abdominal Aortic Aneurysms 
1.1.1 Background 
Abdominal Aortic Aneurysms (AAA) are asymptomatic vascular 
diseases with a high mortality rate due to aortic rupture that is manifest in 
older adults. AAAs are permanent dilations of the abdominal region of the 
aorta, the major blood vessel supplying blood from the heart to all major 
organs. In the United States, AAAs are defined as an expansion of the 
infrarenal aorta by more than 50% of the normal internal lumen diameter 
(Lederle FA, Johnson GR et al. 2000). In Europe, lumen diameter equal or 
greater than 3 cm is considered aneurysmal (Ashton HA, Buxton MJ et al. 
2002), and because of the high probability of rupture, surgical intervention 
is recommended when the diameter reaches a 5.5 cm limit (Powell and 
Brady 2004; Jamrozik K et al. 2001). Because no medical treatment has 
proven effective against AAA progression, intervention by open or 
endovascular surgical repair is the only available option to reduce the 
potential for aortic rupture. However, there is still a high mortality rate after 
repair (Chang DC, Parine RP et al. 2015; Pecoraro F, Gloekler S et al. 
2017). The mean 30-day mortality rate for this surgical procedure is 1.1%- 
7%, which varies among surgical centers and surgeons (Sakalihasan N, 
Limet R et al 2005). 
Men are more susceptible to AAAs than women. The prevalence of 
AAAs is about 1% in women and 4% in men between 50-79 years old, and 
2 
the disease is responsible for 1.3% of all deaths in men aged 65-85 
(Lederle FA, Johnson GR et al. 2000; Lederle FA, Johnson GR et al. 2001; 
Best VA et al. 2003; Sakalihasan N, Limet R et al. 2005). In the last three 
decades, the incidence of AAAs has increased dramatically (Best VA, Price 
JF, et al. 2003; Collin J 1988; Fowkes FG, Macintyre CC et al. 1989; Nasim 
A, Sayers RD et al. 1995). Compared to data in 1981, AAA mortality rate 
and hospital admissions due to AAAs increased by 2.6 fold and 3 fold, 
respectively, in 2000, which could be due either to an increase in disease 
awareness or to an increase in the aged population, or both (Best VA, 
Price JF, et al. 2003). In 1991, in the United States, there was about 
16,696 deaths due to a ruptured aortic aneurysm or surgical complication 
of aneurysm repair (Gillum 1995). AAAs are estimated to rupture at a rate 
of 5.6 cases/ 100,000 people/ year (Bengtsson and Bergqvist, 1993), with 
an increased likelihood of AAA rupture as aneurysm size progresses. 
According to Lardaro et al, in the Journal of Emergency Medical 
Services JEMS, aortic rupture, also they named it as “aortic catastrophe”, 
is considered one of the five most common causes of sudden unexpected 
death and urge every emergency medical service provider to take this 
condition seriously during their early diagnosis of the patient specially if 
the patient is old and presented with abdominal or back pain (Thomas 
Lardaro, Jared Mckinney et al. 2015). Unfortunately, the risk of death 
(85%) is astonishingly high following aneurysmal rupture, and many 
patients die before ever reaching the hospital. 
3 
1.1.2 AAA Pathogenesis 
AAA is a complex multifactorial disease, and many destructive 
factors and cells are involved in damaging the essential components of 
the aortic wall (elastin and collagen). The pathophysiology behind the 
cellular and molecular mechanisms that are involved in the development 
of human AAAs is not well understood. Histologically, AAAs in humans is 
characterized by medial degeneration, intensive inflammation, thrombus 
formation, break in the elastic media, and remodeling of wall layers 
(Busuttil RW et al. 1982; Campa JS, Greenhalgh Rm et al. 1987; Holmes 
DR, Liao S et al. 1995). AAA tissue sections exhibit infiltration of 
macrophages, T cells, and B cells (Curci JA, Liao S et al. 1998; Galle C, 
Schandene L et al. 2005; Xiong W, Zhao Y et al. 2004; Chang TW, 
Gracon AS et al. 2015) that secrete degradation factors like proteases 
and elastases which degrade the elastic media (loss of elastin leads to 
dilation) and collagen (loss of collagen leads to rupture) in the aorta. This 
combination of degradation will lead to a decrease in the stretching 
strength of the wall allowing dilation and AAA formation (Saraff K et al. 
2003, Barisione C, Charnigo R et al. 2006). Indeed, a frequently used 
animal model of AAAs targets the elastin in the aortic wall by infusing the 
aorta with elastase to induce AAA formation. Further, it has been shown 
that a high proteases enzyme activity in the aorta is positively associated 
with AAA formation (Alsiraj Y et al. 2017, Halpern VJ et al. 1994). There is 
a plethora of evidence that matrix metalloproteinases (MMPs) have a 
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principal role in AAA development. Proteinases are usually enriched in 
AAA tissue sections (Vine N and Powell JT 1991; Herron GS, Unemori E 
et al. 1991; Thompson RW, Holmes DR et al. 1995; Freestone T et al. 
1995).  Additionally, there is a positive correlation between MMP9 
(gelatinase) plasma concentration (Lindholt JS et al. 2000), gelatinase 
mRNA abundance in the abdominal aorta (McMillan WD, Tamarina NA et 
al.1997) and AAA size. Moreover, transgenic mice with genetic deletions 
of MMPs exhibit reduced experimental AAA development (Pyo R, Lee JK 
et al. 2000, Longo GM et al, 2002). MMP inhibition using the antimicrobial 
drug, doxycycline, or chemically modified tetracyclines, which also have 
MMP inhibition properties, have been proven effective in reducing 
experimental AAAs in most commonly used animal models when given 
prior to the initiation of the disease (Petrinec D, Liao S et al. 1996; Curci 
JA, Petrinec D et al. 1998; Bigatel DA, Elmore JR et al. 1999; Manning 
MW, Daugherty A et al. 2003; Takai S, Jin D et al. 2013). However, MMP 
inhibition was not effective in blunting AAA progression when administered 
to mice with an established AAA (Xie X, Daugherty A et al. 2012). In 
humans, there was no benefit of doxycycline in reducing the growth rate of 
small AAAs (Meijer CA, Stijnen T et al. 2013; Baxter BT, Pearce WH, et 
al. 2002). In addition to MMPs, proinflammatory markers are also believed 
to be involved in AAA formation like interleukin-6, interleukin-1β, 
interleukin-17, and C-reactive protein (Kokje VBC, Gabel G et al. 2016; 
Takagi H, Watanabe T et al. 2014; Lindberg S, Zarrouk M et al. 2016; 
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Badger SA, Soong CV et al 2009; Stather PW, Sidloff DA et al. 2014). 
Genetic deletion or antagonism of these cytokines attenuated 
experimental AAA formation (Johnston WF, Salmon M et al. 2013; Wei Z, 
Wang Y et al. 2014, Nishihara M, Aoki H et al. 2017). Biochemical factors 
like cyclooxygenases, prostaglandin E2 and NADPH have also been 
implicated in AAA development (Ghoshal S and Loftin CD 2012; Chapple 
KS, Parry DJ et al. 2007; Holmes DR, Wester W et al. 1997; Gavrila D, Li 
WG et al. 2005). 
1.1.3 Risk Factors 
There are many risk factors that are positively associated with 
AAAs which include age, male sex, cigarette smoking, genetics, ethnicity, 
obesity, hyperlipidemia, low high-density lipoprotein, and atherosclerosis 
(Derubertis BG, Trocciola SM et al. 2007; Lederle FA, Johnson GR et al. 
2000; Kent KC, Zwolak RM et al. 2010). AAA prevalence increases with 
age in both sexes (Singh K, Bonaa KH et al. 2001). The risk for AAAs 
increases significantly in people above 60 years old, and the prevalence 
increases by 2-4% every ten years afterward (Singh K, Bonaa KH et al. 
2001). 
Smoking is a significant risk factor for AAA formation. Studies found 
that smokers have 7 fold greater risk for AAA development than non-
smokers (Benson RA, Poole R et al. 2016; Norman PE and Curci JA 
2013). There is a direct correlation between the number of smoking years 
and AAA formation and that risk decreases after smoking discontinuation 
6 
(Norman PE and Curci JA 2013). Although males and females have a 
similar association between smoking and AAAs development the decline 
in the risk after smoking cessation is faster in females than males (Kent 
KC, Zwolak RM et al. 2010; Lederle FA, Johnson GR et al. 2001; 
Stackelberg O, Björck M et al. 2014). Smoking also affects the AAA 
endovascular surgical repair as smokers need more stents and they have 
a higher risk of stent graft migration than non-smokers (Koole D, Moll FL 
et al. 2012). 
Aside from age, male sex, and smoking, AAAs are at a higher 
prevalence in Caucasians compared to other races (Benson RA, Poole R 
et al. 2016; Kent KC, Zwolak RM et al. 2010). Genetic inheritance also 
increases AAA risk, as AAA prevalence is very high in siblings of AAA patients, 
especially male siblings they have about 4 fold increased risk for AAAs, 
and they develop AAAs at an earlier age than people with no family history 
and it is recommended to start screening the male siblings of patients with 
AAA at a younger age than males with no family history (Linné A, 
Lindström D et al. 2012; Salo JA et al. 1999; Linné A, Forsberg J et al. 
2016; Linné A, Forsberg J et al. 2017). Obesity has similarly been found to have 
a positive correlation with AAA formation (Stackelberg O, Björck M 
et al. 2013; Cronin O, Walker PJ et al. 2013). In contrast, diabetes mellitus 
has a negative correlation with AAA development (Pafili K, Gouni-
Berthold I et al. 2015; Lederle FA, Johnson GR et al. 2000; Le MT, 
Jamrozik K et al. 2007; Theivacumar NS, Stephenson MA et al. 2014). 
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Several studies have found no association between the serum 
concentrations of cholesterol, triglyceride, and low-density lipoprotein and 
AAA development (Blanchard, Armenian et al, 2000; Golledge J, van 
Bockxmeer F et al 2010). However, other studies have reported that 
hyperlipidemia, ischemic heart diseases, and high blood pressure are 
independently associated with AAAs (Törnwall ME, Virtamo J et al 2001; 
Derubertis BG, Trocciola SM et al 2007; Kent KC, Zwolak RM et al. 2010).
1.2 Sex Differences in AAAs 
AAAs are a highly sexually dimorphic disease, with male sex 
considered the strongest non-modifiable risk factor (Wanhainen, Bergqvist 
et al. 2005; Forsdahl SH, Singh K et al. 2009). The AAA incidence in 
males is 4 times higher than females (Lederle FA, Johnson GR et al. 
2001; Katz DJ, Stanley JC, et al. 1997). Despite females protection from 
AAAs, if females develop an AAA they have higher growth rates, higher 
rupture rates, rupture at smaller sizes, and worse prognosis after surgical 
repair compared to males (Noel AA, Gloviczki P et al. 2001; Forbes TL, 
Lawlor DK et al. 2006; Solberg, Singh et al. 2005; Mofidi R, Goldie VJ et 
al. 2007). Importantly, female protection against AAAs is diminished after 
menopause (Bengtsson H, Sonesson B et al. 1996), and the surgical 
repair for AAA in females is more difficult because AAAs develop at an 
older age (Bengtsson H, Sonesson B et al. 1996). 
Ultrasound screening for AAA is recommended for males aged 65 
to 75 years and especially those with a family history of AAAs and 
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smokers (Hirsch AT, Haskal ZJ et al. 2006). However, because females 
have a lower incidence, the Society of Vascular Surgery only recommends 
screening for female smokers and those that have a family history of 
AAAs (Hannawa K, Eliason et al. 2009; Kent K et al 2004; Derubertis B, 
Trocciola EJ et al. 2007). 
One potential mechanism of sexual dimorphism of AAAs is 
differences in the vascular anatomy between males and females. Due to 
size differences, males tend to have larger and stronger aortas than 
females, and this results in a divergence in their vessel biomechanical 
properties (Ninomiya OH, Tavares Monteiro JA et al. 2015). The same 
study also showed that male aortas had a higher failure load and failure 
tension than female aortas. Another small study showed that the peak wall 
rupture risk was higher in females (Larsson E, Labruto F et al. 2011). 
Furthermore, males and females have anatomic differences that result in 
different hemodynamics between the two sexes. For example, the 
presence of the uterus in females direct the blood to move away from the 
iliac and infrarenal aorta and reduce the amount of stress on these 
vessels (Taylor WR, Iffrig E et al. 2016). This results in divergence in 
oscillatory stress between males and females. In males, due to the 
absence of a uterus, there is a high amount of blood circulation that stress 
the infrarenal aorta and might activate the inflammatory system in the 
endothelium (Taylor WR, Iffrig E et al. 2016). 
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While these anatomical differences are known to exist between the 
sexes, recent studies have examined whether sex hormone replacement 
therapy also influences AAA development. Clinical studies in females 
have demonstrated that sex hormone replacement for greater than 5 
years decreased the odds ratio of developing an AAA (Lederle FA, Larson 
JC et al. 2008). Interestingly, it has been shown that females that reach 
their menopause at a younger age have larger AAAs than females that 
reach their menopause at an older age (Villard C, Swedenborg J et al. 
2011).  
1.3     AAAs and The Renin-Angiotensin System 
The renin-angiotensin system (RAS) has been implicated in aortic 
aneurysms as the chronic subcutaneous infusion of AngII to mice led to 
AAA formation (Daugherty A, Cassis LA et al. 2000, Henriques TA et al. 
2004; Henriques TA et al 2008, Zhang X et al 2012; Xie X, Daugherty et 
al. 2012; Thatcher SE et al. 2014; Thatcher SE et al. 2015; Zhang X et al. 
2015; Alsiraj Y et al. 2017). The RAS is a system that consists of multiple 
components that are produced in different organs and work in harmony to 
regulate blood volume, blood flow, blood pressure, and electrolyte 
balance. In this system, angiotensinogen, the main precursor peptide, is 
produced in the liver and is cleaved to form angiotensin I in the circulation 
by the enzyme renin secreted from the kidney (Matsusaka T, Niimura F et 
al. 2012). Angiotensin I is cleaved to form AngII by angiotensin-converting 
enzyme (ACE) that is primarily distributed in endothelial cells of the 
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pulmonary circulation. AngII increases the production of reactive oxygen 
species along with the induction of several other important factors via 
angiotensin type 1 receptors (AT1Rs) resulting in vasoconstriction, 
endothelial dysfunction, inflammation, increased level of oxidative stress, 
as well as migration/proliferation of vascular cells (Rajagopalan S, Kurz S 
et al. 1996; Daugherty A and Cassis L1999; Daugherty A, Cassis LA et 
al. 2000; Braun-Dullaeus RC, Mann MJ et al. 1999).   
Since 1999, in collaboration with Dr. Alan Daugherty at the 
University of Kentucky, our laboratory has demonstrated that chronic 
infusion of AngII to hypercholesterolemic mice results in reproducible AAA 
formation in the suprarenal abdominal aorta (Daugherty A, Cassis LA et al. 
2000, Henriques TA et al. 2004; Henriques TA et al. 2008, Zhang X et al. 
2012; Xie X, Daugherty et al. 2012; Thatcher SE et al. 2014; Thatcher SE 
et al. 2015; Zhang X et al. 2015; Alsiraj Y et al. 2017). The cellular and 
molecular consequences in AAAs that produced by AngII infusion are 
medial and adventitial macrophage accumulation, medial dissection, 
elastin breaks, that lead to lumen expansion, thrombus formation, and 
adventitial inflammation (Saraff K, Babamusta F et al. 2003). In 
hypercholesterolemic mice, AngII infusions lead to AAAs in more than 
75% of the males and 10%-20% of the females (Henriques TA et al. 2004; 
Henriques TA et al. 2008; Zhang X et al. 2012). Similarly, in the elastase 
perfusion model of AAAs, male rats had larger and more frequent AAAs 
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than females when aortic dilation was induced by intraluminal elastase 
perfusion (Ailawadi G, Eliason JL et al. 2004). 
Our laboratory demonstrated previously that sex hormones, 
specifically androgens, are primary contributors to higher AAA 
susceptibility in male compared to female mice, as ovariectomy had no 
effect on AAA formation while orchiectomy decreased AAA incidence to 
the level of females (Henriques TA et al. 2004). Further studies 
demonstrated that testosterone is a primary mediator of the high 
prevalence of AAAs in male mice by increasing AT1aR mRNA abundance 
specifically in the abdominal region of the aorta (Henriques TA et al. 
2008; Zhang X et al. 2012).  
The RAS, an important contributor to experimental AAAs, display 
sex differences in the gene expression of a number of its important 
elements (Wang Y, Pringle KG et al. 2012; Maric-Bilkan C and Manigrasso 
MB 2012). Interestingly, genes of some of the essential components of this 
system, including, prorenin receptor, angiotensin I converting enzyme 2 
(ACE2), and angiotensin II type 2 receptor (AT2R) are located on the X 
chromosome. However, previous studies concentrated on gonadal 
hormones as the primary mediator of sexual dimorphism in the RAS.  
The two most important classes of drugs inhibiting the RAS are 
ACE inhibitors (ACEi) that are used to block the conversion of angiotensin 
I to AngII, and selective AT1R antagonists (also known as ARBs) that 
antagonize the binding of AngII to AT1 receptors (Robles NR, Cerezo I et 
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al. 2014). These drugs suppress the activity of the RAS. Unfortunately, 
probably due to difficulties in obtaining sufficient sample sizes of AAA 
patients for large-scale RAS inhibition studies, or because so many AAA 
patients are already prescribed inhibitors of the RAS, few studies have 
investigated effects of RAS inhibitors on human AAAs. Studies to date 
have an inconsistent agreement about the beneficial effect of RAS 
inhibition in AAA (Table 1.1). In a nationwide cohort study, administration 
of ACEi reduced all-cause mortality in patients with AAAs who had not 
undergone endovascular repair (Kristensen KE, Top-Pedersen C et al. 
2015). In a population-based case-control study, AAA patients treated with 
ACEi had less chance of aortic rupture, and this beneficial effect was not 
seen in patients treated with other antihypertensive drugs, surprisingly 
including ARBs (although the patient sample size in this group was small) 
(Hackam DG et al. 2006). In contrast, retrospective analysis over 25 years 
suggested that ARBs reduced the rate of AAA growth while ACEi was not 
effective in slowing AAA growth rates (Thompson A, Hafez H 2010). In 
another retrospective analysis study over a period of 15 years (from 1995 
to 2010) using the data files from 3 medical centers in the USA found no 
effect of ACEi or ARBs on AAA enlargement (Lederle FA, Noorbaloochi S 
et al. 2015). Surprisingly, a retrospective study in the United Kingdom 
reported that ACEi increases AAA expansion (Sweeting MJ, Thompson 
SG et al. 2010). Most recently, a randomized placebo-controlled trial 
conducted in 14 hospitals in England found no significant effect of
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perindopril, an ACEi, on the growth rates of small AAAs when 
compared to AAA patients who received placebo or a calcium 
channel blocker (Bicknell CD, Kiru G et al. 2016).  
In standard AAA animal models, modulation of the RAS 
components pharmacologically or genetically influences AAA formation 
(table 1.2). Deletion of AT1aR inhibited AAA formation in AngII-infused 
male mice (Cassis LA, Rateri DL et al. 2007) and in aortic elastase-
perfused male mice (Xuan H, Dalman RL et al. 2017). Drug antagonism of 
AT1R completely inhibited AAA formation in AngII-infused male mice 
(Daugherty A, Cassis LA et al. 2001) and in aortic elastase-perfused male 
mice (Iida Y, Xu B, Dalman RL et al. 2012; Xuan H, Dalman RL et al. 2017), 
while drug antagonism of AT2R increased the severity of AngII-induced 
AAAs (Daugherty A, Cassis LA et al. 2001). Furthermore, Liao et al. 
reported that ACEi blunted the development of AAA in elastase-perfused 
rats (Liao S, Miralles M et al. 2001). Moreover, administration of aliskiren, a 
direct renin inhibitor, to ApoE-/- mice limited the progression of AngII-
induced AAAs (Seto SW, Krishna SM et al. 2014). Additionally, 
pharmacological activation of ACE2 reduced internal and external aortic 
diameters as well as decreased the incidence of AngII-induced AAAs in 
male mice (Thatcher SE, Zhang X et al. 2014) and ACE2 deletion resulted 
in increased aortic diameter and AAA incidence in AngII-infused male mice 
(Moran CS, Biros E et al. 2017). These results illustrate that RAS blockade 
is effective at inhibiting the formation of experimental AAAs, but there is 
insufficient evidence supporting a role for RAS blockade in human AAAs.
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Perhaps these differences arise from the heavy focus on the role of 
the RAS in AAA formation in experimental studies, versus a need to 
develop therapies blunting progression of an established AAA in 
humans. 
1.4 Role of Sex Hormones and Sex Chromosomes in AAAs 
Both human and rodent males are much more susceptible to AAAs 
than females. Males are known to differ from females in three ways: sex 
chromosomes, sex organs, and sex hormones. These three produce 
multiple phenotypic differences between males and females. Sex 
chromosomes determine the sex of the fetus. Male and female sex organs 
produce different sex hormones that generate the main differences 
between the two sexes. 
1.4.1 Sex Hormones 
In males, testosterone is the main androgen that is important for 
many essential physiological functions. Testosterone is responsible for the 
development and maintenance of testes, sexual drive, secondary sex 
characteristics, sperm production, sexual behavior, bone density, muscle 
growth and strength (Murashima A, Kishigami S et al. 2015; Carson JA 
and Manolagas SC 2015; Windahl SH, Andersson N et al. 2011). 
Testosterone is synthesized in the Leydig cells of the testes, and its 
production is regulated by the hypothalamic-pituitary axis, this axis 
secretes hormones like a gonadotropin-releasing hormone, luteinizing 
hormone, and follicular stimulating hormones in response to the low level 
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of testosterone (Tremblay JJ 2015, Potter SJ, Kumar DL et al. 2016). By 
the action of the enzyme 5α-reductase, small portion of circulating 
testosterone is converted to the more active form, dihydrotestosterone 
(DHT). Both testosterone and DHT are binding to androgen receptors 
(AR). Unlike testosterone, DHT strongly binds to the AR and slowly 
dissociates from the receptor. That is why DHT has a more augmented 
action than testosterone (Tóth M and Zakár T 1982; Zakár T, Kaufmann G 
et al. 1986; Lemus AE, Enríquez J et al. 1997). Testosterone also gets 
converted to estradiol by aromatization through the action of the enzyme 
aromatase (Ishikawa T, Glidewell-Kenney C et al. 2006).  
In females, the main sex hormones are estrogens, which are a 
group of steroid hormones that have an important role in female sexual 
functions. Estradiol is the main estrogen; it is synthesized mainly in the 
ovary, but estrogens are also produced by the adrenal glands and adipose 
tissues. Estrogens act by interacting with estrogen receptors (ER alpha or 
ER beta) (Eyster KM 2016; Fietz D et al. 2014, Walter et al. 1985, 
Mosselman et al. 1996, Nelsson S and Gustafsson JA 2011). 
Many studies on the sexual dimorphism of AAAs have focused on 
sex hormones (table 1.3). It has been shown that testosterone is a primary 
mediator for the development of AAAs in both male and female rodents 
(Henriques T et al. 2004; Zhang X et al. 2015; Zhang X et al. 2012; Davis 
J, Salmon M et al. 2016; Cho BS, Woodrum DT et al. 2009; Alsiraj Y et al. 
2017). Orchiectomy reduced AngII-induced AAA formation (Henriques TA 
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et al. 2004; Henriques TA et al. 2008, Alsiraj Y et al. 2017) and progression 
in male mice (Zhang X et al. 2015), and orchiectomy also reduced AAA 
formation in aortic elastase perfused male rats (Cho BS, Upchurch GR et 
al. 2009). Furthermore, androgen deletion inhibited AAA formation in both 
AngII and elastase-induced AAAs of male mice (Huang CK, Chang C et al. 
2015; Davis JP, Upchurch GR et al. 2016). Additionally, blockade of 
androgen receptors reduces AAA formation in elastase perfused male mice 
(Davis JP, Upchurch GR et al. 2016). In one study, using the AngII-infusion 
model, it was shown that testosterone increases the expression of AT1aR 
in abdominal aortas of male mice, and further, this correlated positively 
with AAA incidence (Henriques T et al. 2008). It has also been shown that 
exposure of neonatal female mice to a single dose of testosterone 
increased AT1aR mRNA abundance in abdominal aortas and AAA 
incidence of adult females (Zhang X et al. 2012; Alsiraj Y et al. 2017).  
Besides increasing the expression of AT1aR, androgen effects on AAAs 
have also been attributed to increased oxidative stress (Chignalia A et al. 
2012; Alsiraj Y et al. 2017), inflammation (Razmara A et al. 2005; Sinha I et 
al. 2006), and augmented MMP activity (Woodrum D et al. 2005; Laser A 
et al. 2014; Alsiraj Y et al. 2017).  
In contrast to testosterone, multiple studies have shown that 
estrogen has a protective effect on AAA development and progression in 
female and male mice and rats (Martin-McNulty B 2003; Thatcher SE et 
al. 2015; Laser A et al. 2014; Grigoryants V et al. 2005, Wu XF, Zhang J 
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et al. 2009). Estrogen decreased inflammatory pathways (Sinha I et al. 
2006) and MMP activity in rat aortic explants (Woodrum D, Ford JW et 
al. 2005). However, our laboratory reported that removal of endogenous 
estrogen by ovariectomy had no effect on AngII-induced AAAs in female 
mice (Henriques TA et al. 2004). In contrast, orchiectomy of male mice 
reduced the formation of AngII-induced AAAs to the level of females 
(Henriques TA et al. 2004), with AAA incidence restored to normal levels 
by administration of DHT (Henriques T et al. 2008). Similar to our results, 
studies in the aortic elastase perfusion model in rats reported a similar 
conclusion, removal of testosterone from male rats by orchiectomy 
decreased AAAs while removal of estrogen from females by ovariectomy 
had no effect on AAAs (Cho BS, Upchurch GR Jr et al. 2009). 
1.4.2 Sex Chromosomes 
Although testosterone is a primary contributor to sex differences in 
AngII-induced AAAs, it is unlikely to be the only causative factor. Previous 
studies in our laboratory demonstrated that hypercholesterolemic female 
mice administered a single dose of testosterone when they are one day 
old resulted in a high increase in AT1aR mRNA abundance in the 
abdominal region of the aorta, and substantially increased the 
susceptibility to AngII-induced AAA when they are adults (Zhang X et al. 
2012). Interestingly, the neonatal testosterone effect was permanent and 
did not necessitate continued exposure to testosterone. Surprisingly, male 
and female mice reacted differently to the administration of neonatal 
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testosterone. The same dose of testosterone administered to one-day old 
males didn’t change the susceptibility of adult males to AngII-induced AAA 
development. Moreover, continuous levels of circulating testosterone are 
required in males to maintain AAA susceptibility (Zhang X et al. 2012), while 
females were rendered susceptible after a single androgen exposure.  
In addition to sex hormones, sex chromosomes have been 
suggested to contribute to sexual dimorphism of cardiovascular diseases 
(Winham SJ, de Andade M et al. 2015). Probably the most compelling 
association between sex chromosomes and vascular disease 
development is in Turner’s Syndrome, also called monosomy X. Turner’s 
Syndrome results from the partial or complete absence of the second X 
chromosome in females, and is associated with significant vascular 
abnormalities. Specifically, the risk of aortic dissection is increased 100-
fold in patients with Turner’s Syndrome (Wong SC et al. 2014; Bondy CA 
2008). Moreover, recent studies revealed that sex chromosome 
complement affects the blood pressure in AngII infused mice (Ji H, Zheng 
W et al. 2010), which could indicate that other AngII-mediated effects may 
also be influenced by sex chromosome complement. 
Each cell in the human body has a sex, cells carry the genetic 
information in 23 pairs of chromosomes that are structured of nucleic 
acids and proteins. One pair of which, because they are related to sex, is 
called the sex chromosomes while the rest are called autosomes. The 
autosome pairs are named by numbers from 1 to 22 while the sex 
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chromosomes are named as X and Y. Male cells have a pair of X and Y 
while female cells have a pair of two X chromosomes (Buchholz JT 1947; 
Mirsky AE and Ris H 1951).  The male and female reproductive cells, 
sperm and ovum respectively, are haploid cells and contain only one copy 
of sex chromosome, the sperm has either the X or the Y chromosome 
while the ovum has only X chromosome (Munger SC and Capel B, 2012). 
During reproduction, sperm and ovum combine together to produce the 
zygote. The sex chromosome of the sperm is the only one that will 
determine the sex of the fetus; if the sperm that combines with the ovum 
contains the Y chromosome then the fetus will be a male, but if the sperm 
contains the X chromosome then the fetus will be a female (Munger SC 
and Capel B, 2012; Brennan J and Capel B 2004).  
There is a small number of genes on the Y chromosome compared 
to any other chromosome. This is due to the fact that the Y chromosome 
does not recombine normally as the rest of the genome which result in 
losing most of its genes during evolution. In fact, other species, like 
orthoptera, has lost the entire Y chromosome. (Charlesworth B and 
Charlesworth D 2000; Lahn et al. 2001; Bachtrog et al. 2008; Hughes et 
al. 2012; Castillo ER, Bidau CJ et al. 2010). The Y chromosome consists 
of two regions: the pseudoautosomal region and the male-specific region 
of the Y chromosome (MSY). The pseudoautosomal region is the region 
at which the Y chromosome exchanges genetic material with the X 
chromosome during meiosis (Helena Mangs A and Morris BJ, 2007; 
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Dhanoa JK et al. 2016). The MSY, which represent about 95% of the Y 
chromosome, consists of the euchromatic and heterochromatic region 
(Skaletsky H et al. 2003; Jangravi Z et al. 2013). Most of the Y 
chromosome genes have sex functions (Dhanoa JK et al. 2016). The key 
gene on the Y chromosome is the Sry (sex determining region on the Y), 
this gene is responsible for testes formation (Prokop JW and C.F. 
Deschepper CF, 2015). The Sry has also been implicated in the regulation 
of some of the RAS genes (Ely D, Boehme S et al. 2011; Araujo FC, 
Milsted A et al. 2015). In contrast, the X chromosome is morphologically 
larger and contains more genes than the Y chromosome. In fact, the X 
chromosome represents about 5 % of the cell genome (Johnson N.A. and 
Lachance J. 2012; Warburton PE et al. 2004).  
The presence of two X chromosomes in females leads to a higher 
gene expression than males, but females inactivate one of the two X 
chromosomes by the process of X chromosome inactivation (XCI). This 
process is important to create a balance in gene quantity between XX and 
XY cells (Lyon MF 1961; Lyon MF 1962; Jeppesen P and Turner BM, 
1993; Ines Pinheiro and Edith Heard, 2017). The inactivated X 
chromosome remains inactive throughout the lifetime of the cell (Barakat 
TS and Gribnau JX 2012). The mechanism of XCI is complex and highly 
organized, and the precise mechanism is still unclear. The X chromosome 
that is going to be inactivated express long non-coding RNA called Xist 
(Pinheiro I and Heard E 2017; Cerase A, Pintacuda G et al. 2015). The 
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expressed Xist recruit proteins followed by several epigenetic changes that 
result in chromatin modifications. Genes close to the X-inactivation center 
are silenced first and the silencing spread along the length of the 
chromosome until the whole chromosome is packed and condensed in an 
inactive form called a Barr body (Barr ML and Bertram EG 1949; Lyon MF 
1961; Chaligné R and Heard E, 2014; Huynh KD, Lee JT 2003; Jeppesen 
P and Turner BM, 1993; Ines Pinheiro and Edith Heard, 2017). There are 
two types of XCI: random XCI and imprinted XCI. In mice, the X 
chromosome undergoes imprinted XCI. Here, the inactivation is selective 
where the X chromosome from the paternal side is selected for inactivation 
during the early stages of the embryo development (Sado T, Wang Z et al. 
2001; Matsui J, Goto Y et al. 2001). However, this paternal X chromosome 
is later activated in the development cycle and random XCI occurs, that 
means there is no preference for inactivation, either the maternal or the 
paternal X chromosome is randomly selected and inactivated (Mak W., 
Nesterova T.B. et al. 2004; Okamoto I, Arnaud D et al. 2005). In humans 
and most mammals, the X chromosome is inactivated by the random XCI 
(Moreira de Mello JC, de Arajo ES et al. 2010; Clerc P, Avner P. 2006; 
Van den Berg IM, Laven JS et al. 2009). However, some of the genes of 
the inactive X chromosome are expressed at varying levels (Berletch et al. 
2010; Yang F, Babak T et al. 2010; Berletch JB, Yang F et al. 2011; Li N 
and Carrel L, 2008). In humans, 15% of female X-linked genes escape 
inactivation while in mice only 3% of the genes from inactive X allele are 
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expressed (Berletch JB, Yang F et al. 2011). Of interest, several genes of 
the RAS components are located on the X chromosome which includes 
prorenin receptor, ACE2, and AT2 receptors; the presence of two X 
chromosomes in females could result in gene dosage effects between 
males and females. This potential difference is supposedly balanced by X-
inactivation that inhibits the transcription of one of the two X chromosomes. 
However, there are some genes that escape the inactivation. Males have 
only one X chromosome, and most of the genes on the X chromosome 
have no equivalent on the Y chromosome. Therefore, genes on the X 
chromosome, even if recessive in females, will be expressed in males.  
An example of an X-linked disease is Turner’s Syndrome, this 
disease is associated with a 100-fold increase in the risk of aortic 
dissection (Wong SC et al, 2014; Bondy CA 2008). Another disease linked 
to the X-chromosome includes cardiac valvular dysplasia (Bernstein JA, 
Bernstein D et al. 2011; Ritelli M, Morlino S, Giacopuzzi E et al. 2017). 
Cardiac valvular dysplasia are caused by mutations in the FLNA gene on 
the X chromosome. This disease is characterized by a thickened heart 
valve that does not function normally (Monteleone PL, Fagan LF 1969; 
Kyndt F, Gueffet JP, Probst V et al. 2007; Norris RA, Moreno-Rodriguez 
R, Wessels A et al. 2010). Unlike females, males, because they have only 
one X chromosome that they received from the mother, manifest this 
disease even if only one copy of the genes exist. While females need to 
have two copies of the genes to cause the condition (Bernstein JA, 
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Bernstein D et al. 201; Ritelli M, Morlino S, Giacopuzzi E et al. 2017). In 
this way, females that carry the disease can transfer the condition to her 
offspring. Males, on the other hand, cannot pass X-linked traits to their 
sons since they inherit the Y chromosome only (Meroni G 1993). 
A number of diseases have also been linked to the MSY, such as 
high incidence of hypertension and heart disease in men (Bloomer LD et 
al. 2013; Charchar Fj et al. 2012; Voskarides K et al. 2014). Further data 
have shown that the Y chromosome is linked with inheritance of high 
blood pressure, the concentrations of total cholesterol and LDL in the 
blood as well as the coronary artery disease (Shankar RR, Charchar FJ et 
al. 2007; Charchar FJ, Tomaszewski M, Lacka B, et al. 2004; Charchar 
FJ, Tomaszewski M, Padmanabhan S, et al. 2002; Ellis JA, Stebbing M, 
Harrap SB 2000; Charchar Fj et al. 2012). However, mechanisms for this 
association are unknown. Sadly, the sex chromosomes are not included in 
the genome-wide association study (GWAS) and the X chromosome 
despite being assayed on all GWAS studies only 33% of these studies 
included the X chromosome in the analyses (Wise AL, Manolio et al. TA 
2013). 
1.5   Four Core Genotype Mouse Model 
The four core genotype mouse model (FCG), produces mice with 
gonadal organs that are independent of their sex chromosome 
complement and this allows dissection of the relative role of sex 
chromosome complement versus sex hormones. This model has been 
24 
used by multiple investigators and demonstrates that sex chromosome 
complement contributes to sexual dimorphism of the brain and other 
tissues in mice (Arnold AP and Chen X 2009; De Vries GJ et al. 2002). 
Other studies using this model identified that blood pressure responses to 
infusion of AngII were influenced by both sex hormones and sex 
chromosomes (Ji H, Zheng W et al. 2010). The FCG was generated from a 
natural mutation of the gene that is responsible for testes formation, Sry 
gene, from the Y chromosome (Lovell-Badge R and Robertson E, 1990; 
Mahadevaiah SK, Odorisio T et al. 1998). This mutation resulted in a 
mouse that has the XY- (lacking Sry) sex chromosome complement, this 
mouse does not develop testes but will develop ovaries instead, making it 
a female that has male sex chromosome complement and female gonads. 
The insertion of the Sry gene onto an autosome in XY- mouse result in 
generating a male mouse that expresses Sry (on an autosome but not on 
the Y chromosome) denoted as XY- (+ Sry). The presence of the Sry gene 
on an autosome in this mouse lead to the development of testes, allowing 
the male to breed normally. When XY-(+ Sry) males are mated with 
normal XX females, 4 genotypes are produced (Figure 1.1): 
1. XY- females (abbreviated as XYF, have ovaries)
2. XX females (abbreviated as XXF, have ovaries)
3. XY males (abbreviated as XYM, have testes)
4. XX males (abbreviated as XXM, have testes)
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Previous studies using this mouse model indicate that testosterone 
concentrations are not different between XY and XX males (Gatewood JD, Wills 
A et al. 2006). If there is a difference in a certain phenotype between XX and XY 
mice that have the same gonadal phenotype, then the difference is caused by 
sex chromosomes. That difference could be due to (a) Gene dosage effects from 
the Y chromosome, because XY mice are affected by Y genes while XX mice are 
not; (b) Gene dosage effects from the X chromosomes, because XX mice have 
two X chromosomes, and for genes that escape X-inactivation there could be 
gene dosage effects; (c) Parental origin of the X chromosome, XY mice receive 
only maternal X chromosomes while XX mice receive both the paternal and 
maternal X chromosomes.
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CHAPTER IA. STATEMENT OF THE PROBLEM 
AAA development is significantly different between sexes. Males are 
much more susceptible to AAAs than females. Similar to humans, male mice 
infused with AngII have a fourfold higher prevalence of AAAs compared to 
females. Paradoxically, while females are less susceptible to AAAs, female AAAs 
progress more rapidly and rupture at smaller sizes than males. Previous studies 
focused on gonadal hormones as primary contributors to sexual dimorphism in 
AngII-induced AAAs. Our laboratory previously demonstrated that sex hormones, 
specifically testosterone, are primary mediators to marked differences in AngII-
induced AAAs between male and female hypercholesterolemic mice. 
Our laboratory recently demonstrated that exposing one-day-old 
hypercholesterolemic female mice to a single dose of testosterone resulted in a 
high increase in AAA development when adult females were infused with AngII. 
Interestingly, female mice become susceptible to AAA formation from only a 
single androgen exposure during neonatal life while males require continued 
circulating levels of testosterone to stay susceptible to AAA, as gonadectomy 
decrease AAAs incidence in males and has no effect in females (Henriques TA 
et al. 2004). Results from these studies indicate that while important, gonadal 
hormones cannot fully account for the sexual dimorphism of AAA development. 
Recent studies indicated that in addition to gonadal hormones, sex 
chromosome complement influence the blood pressure in AngII-infused mice (Ji 
H, Zheng W et al. 2010). Moreover, several studies showed that the Sry gene 
of the Y chromosome regulates the gene expression of some of the RAS 
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components (Ely D, Boehme S et al. 2011; Araujo FC, Milsted A et al. 2015). In 
fact, several genes of the RAS are X-linked, genes that escape X inactivation 
could result in a gene dosage effect. Finally, in human, loss of X chromosome in 
females, as in Turner’s syndrome, is associated with a high risk of aortic 
dilations and dissections (Wong SC et al. 2014; Bondy CA 2008). We 
hypothesize that an XY sex chromosome complement, in addition to sex 
hormones, promotes AngII-induced AAAs in hypercholesterolemic mice.  
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CHAPTER IB. Hypothesis 
Sex chromosome effects, in addition to sex hormones, contribute to the sexual 
dimorphism of AngII-induced AAAs. 
The following specific aims tested this general working hypothesis: 
Specific Aim 1: Determine the role of an XY sex chromosome complement with 
and without exogenous androgen in AngII-induced AAAs in hypercholesterolemic 
female mice. 
Specific Aim 2: Examine the role of an XX sex chromosome complement with 
and without the presence of endogenous androgen in AngII-induced AAAs in 
hypercholesterolemic male mice.
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Table 1.1: Summary of findings of human AAAs studies using RAS inhibitors 
Drug analyzed Effect on AAA Reference 
ACEI Reduced risk of ruptured AAA Hackam DG et al 2006 
ACEI No effect on AAA growth rate Thompson A et al 2010 
ARBs Reduced the AAA growth rate Thompson A et al 2010 
ACEI Increased the AAA growth rate Sweeting MJ et al 2010 
ACEI Reduced the risk of surgery for AAA Kristensen KE et al 2015 
ARBs Reduction in all-cause mortality Kristensen KE et al 2015 
ACEI No effect on AAA enlargement Lederle FA et al 2015 
ARBs No effect on AAA enlargement Lederle FA et al 2015 
ACEI No effect on AAA growth rate Bicknell CD et al 2016 
ACEI No effect on AAA growth rate Kortekaas KE et al 2014 
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Table 1.2: Summary of animal AAA studies modulating the RAS 
Application Mouse model Effect References 
AT1aR deletion AngII-induced AAA in mice decrease Cassis et al 2007 
AT1aR deletion elastase-induced AAA in mice decrease Xuan H et al 2017 
ACE inhibition elastase-induced AAA in rats decrease Liao S et al 2001 
AT1R antagonism AngII-induced AAA in mice decrease Daugherty A et al 2001 
AT1R anatagonism elastase-induced AAA in mice decrease Iida Y, Dalman et al 2012 
AT1R antagonism elastase-induced AAA in rats decrease Xuan H et al 2017 
AT2R antagonism AngII-induced AAA in mice increase Daugherty A et al 2001 
Renin inhibition AngII-induced AAA in mice decrease Seto SW et al 2014 
ACE2 activation AngII-induced AAA in mice decrease Thatcher SE et al 2014 
ACE2 deletion AngII-induced AAA in mice increase Moran CS et al 2017 
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Table 1.3: Summary of animal AAA studies modulating sex hormones 
Application model findings or effect on 
AAA 
Reference 
Estradiol treatment AngII infused male mice decrease AAA Martin-McNulty B, 
Tham DM et al 2003 
Orchiectomy AngII infused male mice decrease AAA Henriques TA, Cassis 
LA et al 2004 
Ovariectomy AngII infused female 
mice 
no effect Henriques TA, Cassis 
LA et al 2004 
male vs females, 
estradiol treatment 
elastase perfusion in 
male and female rats 
M>F, estradiol decrease 
AAA 
Ailawadi G, Upchurch 
GR et al 2004 
Tamoxifen elastase perfusion in 
male rats 
decrease AAA Grigoryants V, 
Upchurch GR et al 
2005 
Orchiectomy AngII infused male mice decrease AAA Henriques TA, Cassis 
LA et al 2008 
DHT administration AngII infused male and 
female mice 
increase AAA Henriques TA, Cassis 
LA et al 2008 
castration, estradiol 
treatment 
elastase perfusion in 
male and female rats 
decrease AAA in males Cho BS Upchurch 
GR et al 2009 
Ovariectomy, estradiol 
treatment 
elastase perfusion in 
female rats 
ovariectomy increase, 
estradiol decrease AAA 
Wu XF, Zhang J et al 
2009 
Neonatal testosterone 
administration 
AngII infused female 
mice 
increase AAA Zhang X, Cassis LA 
et al 2012 
Orchiectomy AngII infused male mice decrease progression of 
established AAA 
Zhang X, Cassis LA 
et al 2015 
Ovariectomy elastase perfusion in 
female mice 
increase AAA Johnston WF, 
Upchurch GR et al 
2015 
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Table 1.3 continued 
Deletion of androgen 
receptor 
AngII infused in male 
mice 
decrease AAA Huang CK, Chang C 
et al 2015 
Androgen receptor 
blockage 
elastase perfusion in 
male mice 
decrease AAA Davis JP, Upchurch 
GR et al 2016 
Deletion of androgen 
receptor 
elastase perfusion in 
male mice 
decrease AAA Davis JP, Upchurch 
GR et al 2016 
Neonatal testosterone 
administration 
AngII infused female 
mice 
increase AAA Alsiraj Y, Cassis LA 
et al 2017 
DHT administration AngII infused female 
mice 
increase AAA Alsiraj Y, Cassis LA 
et al 2017 
Orchiectomy AngII infused male mice decrease AAA Alsiraj Y, Cassis LA 
et al 2017 
Ovariectomy AngII infused female 
mice 
no effect Alsiraj Y, Cassis LA 
et al 2017 
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Figure 1.1. The four core genotype mouse model. XXF is mated to male mice lacking 
Sry on sex chromosomes but expressing Sry on autosomes to create four core 
genotypes. 
Copyright © Yasir Alsiraj 2018
CHAPTER II. SPECIFIC AIM 1
Female Mice with an XY Sex Chromosome Complement Develop Severe 
Angiotensin II-Induced Abdominal Aortic Aneurysms (Published in the 
journal of Circulation)
Authors: Yasir Alsiraj, Sean Thatcher, Richard Charnigo, Kuey Chen, Eric 
Blalock, Alan Daugherty, and Lisa Cassis. 
Circulation. 2017;135:379-391 
URL:http://circ.ahajournals.org/content/135/4/379.full?ijkey=w6Z9bijRtCzO4PR&k 
eytype=ref 
Summary 
Background: Abdominal aortic aneurysms (AAAs) are a deadly pathology with 
strong sexual dimorphism. Similar to humans, female mice exhibit far lower 
incidences of angiotensin II (AngII)-induced AAAs than males. In addition to sex 
hormones, the X and Y sex chromosomes, and their unique complements of 
genes, may contribute to sexually dimorphic AAA pathology. Here, we defined the 
effect of female (XX) versus male (XY) sex chromosome complement on AngII- 
induced AAA formation and rupture in phenotypically female mice. 
Methods: Female low density lipoprotein receptor (Ldlr) deficient mice with an 
XX or XY sex chromosome complement were infused with AngII for 28 days to 
induce AAAs. Abdominal aortic lumen  diameters  were  quantified  by 
ultrasound, while AAA diameters were quantified at study endpoint. DNA 
microarrays were performed on abdominal aortas. To mimic males, female mice 
were administered a single dose of testosterone as neonates or as adults prior to 
AngII infusions. 
Results: Female Ldlr-/- deficient mice with an XX and XY sex chromosome 
complement had similar sex organ weights and low serum testosterone 
concentrations.  Abdominal aortas from female XY mice selectively expressed Y 
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chromosome genes, while genes known to escape X-inactivation were higher in 
XX females. The majority of aortic gene differences in XY versus XX females fell 
within inflammatory pathways. AAA incidences doubled and aneurysms ruptured 
in XY females. AAAs from XY females exhibited inflammation, and plasma IL1β 
concentrations were increased in XY females. Moreover, aortas from XY females 
had augmented matrix metalloproteinase activity and increased oxidative stress. 
Finally, testosterone exposure applied chronically, or as a single bolus at postnatal 
day 1, markedly worsened AAA outcomes in XY compared to XX adult females. 
Conclusions: An XY sex chromosome complement in phenotypic females 
profoundly influenced aortic gene expression profiles and promoted AAA severity. 
When XY females were exposed to testosterone, aneurysm rupture rates were 
striking. Mechanisms for augmented AAA severity in XY females include 
increased inflammation, augmented matrix metalloproteineases and oxidative 
stress. Our results demonstrate that genes on the sex chromosomes regulate 
aortic vascular biology and contribute to sexual dimorphism of AAAs. Sex 
chromosome genes may serve as novel targets for sex-specific AAA therapeutics. 
2.1 Introduction 
Genes on sex chromosomes have been implicated in inherited forms of 
cardiovascular diseases (Charchar, Bloomer et al. 2012, Bloomer, Nelson et al. 
2013), but much less is known about the influence of sex chromosomes, and 
their interplay with sex hormones, on development of common complex 
cardiovascular diseases. Turner’s Syndrome (monosomy X) is associated with 
significant risk of aortic dissection (Wong, Burgess et al. 2014), suggesting an 
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important role for sex chromosomes in the regulation of aortic homeostasis. 
Abdominal aortic aneurysms (AAAs), an insidious vascular disorder without 
effective drug therapies, are another example of an aortic disease exhibiting 
genetic inheritance (Clifton 1977; Johansen and Koepsell 1986; Blanchard, 
Armenian et al. 2000; Rossaak, Hill et al. 2001) and pronounced sexual 
dimorphism (Morris, Hubbard et al. 1994; Pleumeekers, Hoes et al. 1994; 
Wilmink, Pleumeekers et al. 1998; Weiss, Rodionov et al. 2014). Understanding 
the combined influences of sex hormones and chromosomes on aortic vascular 
biology and disease may identify novel therapeutic targets that are beneficial for 
treatment of vascular diseases in one sex versus the other. Moreover, as chronic 
sex hormone therapy is on the rise in aging males and females, as well as in the 
transgender population, it is important to increase knowledge regarding sex 
hormone and chromosome effects on the vasculature. We demonstrated 
previously that AAAs induced in mice by angiotensin II (AngII) infusion exhibit 
pronounced sex differences. Similar to humans, there is a 4-fold higher AAA 
prevalence in male compared to female mice infused with AngII (Henriques, 
Huang et al. 2004). Testosterone was demonstrated  as  a  primary  regulator 
of the formation and severity of AngII-induced AAAs in male mice (Henriques, 
Huang et al. 2004; Henriques, Zhang et al. 2008). However, not all differences 
in AAA susceptibility and severity between male and female mice could be 
explained by chronic presence of testosterone (Zhang, Thatcher et al. 2012). 
Recent studies demonstrated that blood pressure responses to AngII in mice 
were influenced by sex chromosomes (Ji, Zheng et al. 2010). Herein, we 
embarked on an analysis of effects of an XX versus an XY sex chromosome 
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complement on aortic gene expression profiles and on development and 
severity of AngII-induced AAAs in phenotypically female mice. Gene 
expression profiles demonstrated enriched inflammatory genes in abdominal 
aortas from XY compared to XX females. When XY females were infused with 
AngII, AAA incidences doubled and aneurysms ruptured. 
Exposure of XY females to testosterone, to mimic the male sex hormone 
environment, led to striking levels of AAA rupture. Our results indicate a previously 
unrecognized role for sex chromosomes to influence aortic gene expression 
patterns and profoundly affect AAA severity. 
2.2 Methods 
2.2.1 Animals 
Male mice with an XY-Sry genotype {8-12 weeks of age; 10 times 
backcrossed on C57BL/6J background, Stock#010905}, were obtained from The 
Jackson Laboratories and bred to low density liproprotein receptor deficient 
(Ldlr-/-) females (Stock# 002207). Genomic DNA was isolated from tail clips and 
subjected to PCR using a commercial PCR mix (Promega 2X Master Mix, 
cat#m7123) and specific primers (Table 2.2). DNA fragments were recognized as 
350 (mutation) and 200 bp (internal positive control) bands, while XX females 
displayed only a 200 bp band. Mice were placed on a high fat diet (TD88137, 
Harlan Teklad, Indianapolis, IN) for the duration of the experiment. In mice 
administered testosterone as neonates, within 24 hours of birth female mice were 
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injected subcutaneously with a single dose of testosterone propionate (400 
μg/mouse, n=6-12 mice/genotype; Sigma Aldrich, St. Louis, MO). At 8 weeks of 
age, all females were ovariectomized (OVX) to eliminate any potential 
confounding influence of female sex hormones (Henriques, Huang et al. 2004). 
In mice administered DHT as adults, OVX females (8-12 weeks of age) were 
implanted with a dihydrotestosterone (DHT) pellet (10 mg pellets/60 day 
sustained release; 0.16 mg/d; n=11-18 mice/genotype) two weeks prior to AngII 
infusion and continued through study endpoint (Henriques, Zhang et al. 2008) All 
procedures were in accordance with institutional guidelines and were approved 
by the animal care and use committee at the University of Kentucky. 
2.2.2 Isolation of Bone Marrow Cells 
Bone marrow was extracted from the tibias and femurs of XX and XY female 
mice (2 months of age; n=3 mice/genotype), and bone marrow cells were 
differentiated into macrophages by supplementing the culture media (RPMI 
medium, 2% penicillin/ streptomycin, 1% fungizone) with 1 ng/ml of CSF (Colony 
Stimulating Factor) for 6 days. Total RNA was extracted using the Rneasy fibrous 
tissue mini kit (Qiagen, cat#74704). 
2.2.3 Gonadectomy 
Female XX and XY Ldlr-/- mice (8-12 weeks of age) were OVX as 
described previously (Henriques, Huang et al. 2004). Two weeks later (to clear 
endogenous ovarian- derived hormones), mice were infused with AngII. 
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2.2.4 AngII Infusions. 
Mice  were  infused  with  saline  or  AngII  (1,000  ng/kg/min,  Bachem, 
Torrance, CA) by osmotic micropumps (Alzet model 1004 for 28 day infusions, 
Durect Co., Cupertino, CA). At study endpoint, all mice were euthanized using 
a ketamine/xylazine mixture (100:10 mg/kg, IP) in sterile saline and blood 
collection was performed via cardiac  puncture. 
2.2.5 Quantification of AAAs by ultrasound, ex-vivo AAA measurements, and 3D 
volume analysis. 
Internal suprarenal lumen diameters were quantified on day 0, 7, 14, and 28 
of AngII infusions using a 55-MHz probe with a Vevo 2100 high-resolution 
imaging system (VisualSonics, Inc.). Mice were anesthetized (2-3% isoflurane) 
and abdominal hair was removed by shaving and applying a depilatory cream. 
Mice were imaged and allowed to recover on a heating pad. Images were 
analyzed by two independent observers who were blinded to the study design. 
Mice with a 50% increase in abdominal aortic lumen diameter from baseline (day 
0) were diagnosed with an AAA, and included in statistical analysis for each
measure if they completed study protocol. External abdominal aortic diameters 
were measured at study end point on aortas mounted on a black wax 
background. Images were taken using a Nikon SMZ800 dissecting microscope 
and image analysis to obtain maximal AAA diameters was performed using 
Nikon Elements Version 3.2. AAA incidence was defined as a 50% increase in 
abdominal aortic lumen diameter on day 28 of AngII infusions and included mice 
that died from aneurysm rupture. Percent of rupture was calculated as the % of 
mice within each group that died from a verified rupture of the aorta upon 
necropsy. Grading of AAA severity was defined previously (Daugherty, Manning 
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et al. 2001). Three-dimensional volume analysis was performed on abdominal 
aortas of OVX XY and XX females (n=5 mice/genotype) using the Vevo 2100 
system with the 55-MHz probe. Abdominal aortas were scanned at 51μm 
intervals and a total of 295 images were collected. Each image was analyzed for 
lumen and wall volume and images were summed to obtain total cubic millimeter 
volume of abdominal aortas. 
2.2.6 Blood pressure measurements. 
Systolic blood pressure was measured on conscious mice using a non- 
invasive computerized tail-cuff system (BP-2000; Visitech Systems, Apex, NC) 
during week 3 of AngII infusions. Mice were acclimated to the blood pressure 
system for 2 days and measurements were taken over 5 subsequent days. 
2.2.7 Measurements of plasma and serum components. 
Total serum cholesterol concentrations were quantified using enzymatic 
assay kits (Wako Pure Chemical, Richmond, VA, cat#439-17501). Plasma renin 
concentrations were determined by quantifying angiotensin I concentrations 
generated in the absence or presence of an excess of exogenous rat 
angiotensinogen as described previously (Zhang, Thatcher et al. 2012). 
Angiotensin I was quantified by radioimmunoassay using a commercial kit 
(DiaSorin, CA-1553, Stillwater, MN). Plasma concentrations of IL1β were 
quantified using a commercial Quantikine ELISA (R&D Systems, Minneapolis, 
MN). 
2.2.8 Quantification of atherosclerosis. 
Aortas were cleaned, opened longitudinally and mounted on a black wax 
40
background to quantify atherosclerosis in the aortic arch and thoracic aorta. Arch 
and thoracic aorta areas were defined and lesions within this area were summed 
and normalized to total region area to calculate the percent intimal surface area 
covered by an atherosclerotic lesion. Quantification was performed using Nikon 
Elements Version 3.2. 
2.2.9 Abdominal aorta RNA extraction 
Female (8 weeks of age) XX and XY mice (n=5 mice/surgical 
group/genotype) underwent sham surgery or OVX, and two weeks later mice 
were fed the Western diet for 1 week. Aortas were cleaned from extraneous 
tissues under a dissecting microscope and placed in RNA Later (Ambion, 
cat#AM7021). Abdominal aortas (diaphragm to the ileac bifurcation) were used 
for RNA extraction. RNA was extracted using the Rneasy fibrous tissue mini kit 
(Qiagen, cat#74704), and RNA concentration and quality was quantified by 
Agilent 2100 bioanalyzer using RNA 6000 Nano labchip kits (Agilent 
Technologies, Cat# 5067-151). Samples with RIN (RNA Integrity Number) 
> 8 were used for either DNA microarray or RT-PCR. 
2.2.10 DNA microarrays 
Harvested abdominal aortic RNA samples (n=5 mice/surgical 
group/genotype) did not differ significantly among treatment groups (Agilent 
Bioanalyzer RNA Integrity Number [RIN]: 9.51 ± 0.07, p= 0.25; [RNA] (ng/ul): 
39.5 ± 3.4, p=0.93; 28s:18s ratio: 2.83 ± 0.89, p=0.33- all statistical tests by 
ANOVA). Extracted RNA was labeled and hybridized to Affymetrix Mouse 
Transcriptome Assay 1.0 arrays (one array per subject).  Signal intensities were 
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calculated using the RMA algorithm (Bolstad, Irizarry et al. 2003) at the transcript 
level using Genomics Suite software (Partek, St Louis). Data were transferred to 
flat files in Excel and associated with vendor-provided annotation data. Pre- 
statistical filtering retained unique, annotated probe sets with adequate signal 
intensity (signal intensity ≥ 4.2 on at least 4 arrays in the study). Filtered signal 
intensities were analyzed by two-way ANOVA to identify significant main effects 
of genotype (XX versus XY), surgery (sham vs OVX), as well as interaction. The 
False Discovery Rate (FDR) procedure (Hochberg and Benjamini 1990) as 
modified by Storey (Storey 2002) was used to control error associated with 
multiple testing, with an FDR q- value < 0.05 defining significance. The complete 
list of significant results is provided in table 2.3. Functional categorization for 
each expression pattern was determined with the prestatistically filtered gene 
list as a background using DAVID bioinformatic tools (Huang da, Sherman et 
al. 2009). Currently, DAVID does not support Affymetrix MTA 1.0 IDs, and 
therefore best match IDs from Affymetrix Mouse 1.0 Exon arrays were used, 
covering more than 90% of the filtered MTA data set. Raw data are available 
through the Gene Expression Omnibus (GSE #:81580 
www.ncbi.nlm.nih.gov/geo/). 
2.2.11 Zymography 
Female mice (n=4 mice/genotype) were infused with AngII (1,000 ng/kg/ 
min) for 24 hours, aortic protein (10 μg) was extracted and resolved using SDS- 
PAGE (7.5%) polymerized in the presence of gelatin (2 mg/ml) to detect MMP 
activity.  Gels were washed with 2.5% Triton X-100 (1 hr) followed by distilled 
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water (30 min), and incubated overnight (37°C) in Tris buffer containing 10 mM 
calcium chloride and 0.02% sodium azide. Gels were stained with Coomassie 
Brilliant Blue for 3 hours and destained using distilled water. Gel images were 
captured using a Syngene PXi imager; the unstained, translucent digested 
regions represented areas of MMP2 activity. 
2.2.12 Quantification of oxidative stress in aortic tissue explants 
Aortas (thoracic and abdominal segments) from XX and XY Ldlr-/- females 
were cleaned of adherent tissue and placed in culture media (DMEM; 1:1 without 
phenol red). Aortic explants were incubated with vehicle (saline) or AngII (10 μM) 
plus testosterone (10 nM) for 24 hrs to simulate conditions of high AAA incidence 
and severity. Tissues were snap frozen (OCT) in molds for serial tissue sections 
(10 μm). Aortic sections were incubated with dihydroethidium (DHE, 10 μmol/L) 
in phosphate buffered saline for 30 min (37°C), and counterstained with DAPI. 
Images were obtained (100X; 3-5 images/slide) on a Nikon Eclipse microscope 
(TE2000-U) with a monochrome camera (exposure=300ms). Histogram plots 
were generated for each image using Nikon Elements software, and areas under 
the curve for pixel intensities (250-2500) were calculated. 
2.2.13 Statistical Analysis 
Numerical data are generally illustrated as mean ± SEM and were 
analyzed using unpaired t-test or Mann-Whitney tests to compare two groups, 
by two-way repeated measures ANOVA on time for longitudinal data with 
between group factor of surgery or genotype, or by two-way ANOVA with 
between group factors of surgery, treatment (e.g., testosterone in some studies), 
or genotype. Brown-Forsythe tests for homogeneity of variance were performed 
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in some cases, which led to the modification of two of the two-way ANOVA’s; 
these were modified by weighting observations inversely proportionally to their 
within-group variances. The Kaplan-Meier method was used to estimate 
survival curves. The incidence of aneurysm formation was analyzed using 
Fisher’s exact tests. Statistical analysis was performed using SigmaPlot (Systat 
Software Inc., San Jose CA) or SAS (SAS Institute Inc., Cary NC), and statistical 
significance was determined at P< 0.05. 
2.3 Results 
2.3.1 An XY sex  chromosome  complement  promotes  expression  of 
inflammatory  genes in abdominal aortas. 
To define a role of sex chromosomes in regulating aortic gene expression 
profiles, we bred male mice expressing autosomal Sry (the testes determining 
gene) to Ldlr deficient females to create XX and XY female offspring (Arnold 
and Chen 2009). We focused on female XX and XY mice to enable definition 
of the role of sex chromosomes under experimentally controlled exposures 
to testosterone, since testosterone is known to promote AngII-induced AAAs 
in male mice (Henriques, Huang et al. 2004). We first determined effects of 
sex chromosome complement on gene expression profiles in abdominal aortas 
from non-infused (AngII-naïve) XX and XY females in the presence (sham- 
operated) or absence (OVX) of endogenous female sex hormones. Body 
weights were similar between genotypes prior to surgery (data not shown). 
Body weights of XX (sham, 22.4 ± 1.0; OVX, 26.8 ± 0.8g; P<0.05), but not of 
XY females (sham, 22.6 ± 1.5; OVX, 23.1 ± 0.7g; p=0.75) were increased
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significantly by OVX compared to sham- operated controls. We performed 
transcriptome analyses on RNA extracted from abdominal aortas of XX and 
XY female mice using Affymetrix Mouse Transcriptome Assay 1.0 arrays. A 
total of 88 genes exhibited highly significant differences (two-way ANOVA, FDR 
≤ 0.05, Figure 2.1A, Table 2.3). Remarkably, all 88 genes were significant by 
the main effect of chromosome only. Volcano plots of the chromosome effect 
with highly stringent cutoffs (>  2-fold  change,  P< 1x10-6)  demonstrated  that, 
as  expected,  the expression of genes on sex-chromosomes was strongly 
influenced. Genes (Ddx3y, Uty, Kdm5d, Eif2s3y) within the male-specific 
region of the Y chromosome (MSY) were significantly increased in female 
abdominal XY aortas (Figure 2.1B, fold increase in XY). These genes are of 
interest as the MSY constitutes approximately 95% of the length of the Y 
chromosome (Skaletsky, Kuroda-Kawaguchi et al. 2003), does not recombine 
with the X chromosome during meiosis, is inherited from father to son, and 
has been linked to cardiovascular risk in humans (Skaletsky, Kuroda-
Kawaguchi et al. 2003, Bloomer, Nelson et al. 2013). A second group of 
genes (Kdm5c, Eif2s3x, Kdm6a, Ddx3x) known to escape X- inactivation in 
mice (Berletch, Yang et al. 2011), were increased in abdominal aortas of XX 
females (Figure 2.1B, fold increase in XX). A third group of genes (Msl3,
Tlr7, Tlr8, Prps2, Arhgap6) are X-linked genes, but were increased in 
abdominal aortas from XY compared to XX females (Figure 2.1B, fold 
increase in XY). Further, genes across multiple chromosomes were strongly 
influenced by the presence of the Y chromosome. 
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Real-time PCR on abdominal aortas validated selected microarray 
results (Kdm5d, Eif2s3y, Xist) for the main effect of an XY sex 
chromosome complement (Figure 1C) and verified microarray findings for 
genes not exhibiting significant differences between genotypes (GAPDH, 
Figure 2.7). However, mRNA abundance of Uty, a gene on the Y 
chromosome, was not significantly different between aortas from sham-
operated female XX compared to XY mice, and expression was increased by 
OVX in aortas from XY females, but not XX females (Figure 2.1C). Biological 
pathway analyses (Table 2.1) revealed prominent upregulation of 
inflammatory genes in abdominal aortas from XY females (Figure 2.8). 
These results demonstrate that sex chromosomes influence gene 
expression profiles of abdominal aortas, with increased expression of 
inflammatory pathway gene targets in XY compared to XX. Enrichment of 
genes on the Y chromosome in aortas from XY females, coupled with 
increased expression of genes known to escape X-inactivation in aortas 
from XX females, confirm validity of sex chromosome manipulation in 
phenotypically female mice. 
2.3.2 An XY sex chromosome complement results in aggressive AAA formation 
and severity. 
Female (XX) Ldlr-/- mice exhibit far lower incidences (≈ 25-40%) of AngII- 
induced AAAs compared to age-matched males (≈ 75-90%) (Henriques, Huang et 
al. 2004, Henriques, Zhang et al. 2008). To define the role of sex chromosome 
complement on formation and severity of AngII-induced AAAs, sham-operated and 
OVX female Ldlr-/- mice were infused with AngII for 1 month.  Body weights of 
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AngII-infused OVX XY female mice were decreased significantly compared to 
OVX XX females (Table 2.4). Plasma renin concentrations were not significantly 
different between XX and XY AngII-infused females (Table 2.4). Serum 
testosterone concentrations were modestly, but significantly increased in AngII- 
infused sham-operated XY compared to XX females, and elevations of serum 
testosterone concentrations in XY females were eliminated by OVX (Table 2.4). 
While sex organ weights of XX and XY females were significantly decreased by 
OVX in XX and XY females, there were no differences between genotypes (Table 
2.4). At study endpoint, internal abdominal aortic lumen diameters of XY females 
with an AAA (as defined by a 50% increase in lumen diameter) were elevated (by 
66%) significantly compared to XX females (Figure 2.2A; OVX groups). 
Moreover, external AAA diameters were increased significantly in XY 
compared to XX females (Figure 2.2B; OVX groups). AAA incidence (including 
aneurysm ruptures) increased (by 31%) in XY females (Figure 2.2C) to levels 
observed previously in XY male mice (Henriques, Huang et al. 2004, Henriques, 
Zhang et al. 2008). In XX females (sham or OVX), there were no aneurysm 
ruptures (Figure 2.2D). In contrast, 35% of XY sham-operated females infused 
with AngII exhibited aneurysm ruptures, with high rupture rates also observed 
in OVX XY females (29%). Aortas from XY females demonstrated severe 
aneurysm pathology that frequently extended the entire length of the aorta and 
was associated with aneurysm rupture (Figure 2.2E; Figure 2.9). As these 
effects were observed in OVX XY females (Figure 2.2A-E), results suggest that 
an XY sex chromosome complement augments AAA formation and severity 
independent of female sex hormones. 
47
To define characteristics of AAAs from XY females, we performed ex vivo
3-D ultrasound on AAAs from each genotype (Figure 2.10). Results 
demonstrate increased aneurysm wall volume in AAAs from XY compared to 
XX females, and 3-D remodeling from a representative AAA from each 
genotype illustrates lumen dilation with marked vascular wall remodeling. There 
were no overt differences in aortic wall morphology of abdominal aortic tissue 
sections from non-infused XX versus XY female mice (Figure 2.11). However, 
AAA tissue sections from AngII-infused XY females exhibited CD68 
macrophage immunostaining in areas exhibiting breaks in medial elastin (Figure 
2.12). An XY sex chromosome complement also increased significantly systolic 
blood pressure responses of female mice infused with AngII (both sham and 
OVX; Table 2.4). As infusion of AngII augments atherosclerosis in Ldlr-/- female 
mice (Daugherty, Manning et al. 2000), we quantified the percent of the intimal 
aortic surface within the aortic arch and thoracic aorta covered by atherosclerotic 
lesions. There was not a significant effect of genotype on AngII-induced 
atherosclerosis in thoracic aortas (Figure 2.13) or aortic arches (data not 
shown). Moreover, there were no significant differences in serum cholesterol 
concentrations between genotypes (Table 2.4). 
2.3.3 Aortas from XY females exhibit augmented inflammatory gene expression, 
matrix metalloproteinase (MMP) activity, and oxidative stress. 
Gene arrays on abdominal aortas from non-infused  XY  females 
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demonstrated increased expression of genes within inflammatory pathways 
(Table 2.1), and AAA tissue sections of XY females exhibited positive CD68 
immunostaining in areas exhibiting breaks in medial elastin (Figure 2.12). We 
confirmed by RT-PCR increased mRNA abundance of IL1-β, a component of the 
inflammasome linked to AAA formation, in abdominal aortas from XY Ldlr-/-
females (Figure 2.3A). Moreover, mRNA abundance of Tlr8 was increased 
significantly in abdominal aortas of XY compared to XX females (OVX groups: 
XX, 1.1 ± 0.2; XY, 2.4 ± 0.4 ∆∆Ct; p=0.017). Since immune cell gene pathways 
were altered in abdominal aortas from XY females, we harvested bone marrow 
cells from XX and XY Ldlr-/- females and differentiated them to macrophages. 
Similar to findings from abdominal aortas, Tlr8 mRNA abundance was increased 
significantly in bone marrow macrophages (BMM) from XY compared to XX 
females (XX, 1.1 ± 0.2; XY, 2.3 ± 0.2 ∆∆Ct; p=0.0001). Moreover, IL1β protein 
concentrations were increased significantly in media from incubated BMM of 
Ldlr-/- XY compared to XX females (Figure 2.3B). Finally, plasma concentrations 
of IL1β were increased significantly in AngII-infused XY compared to XX Ldlr-/-
females (Figure 2.3C). As inflammatory genes with increased expression in 
abdominal aortas from XY females have been linked to activation of MMPs and 
oxidative stress, two mechanisms implicated in AAA formation and severity 
(Kadoglou and Liapis 2004, Keeling, Armstrong et al. 2005, Emeto, Moxon et al. 
2016), we quantified MMP activity in aortas of female XX and XY mice infused 
for 1 day with AngII. Aortas from XY females infused with AngII exhibited 
significant increases in MMP2 activity compared to XX females (Figure 2.4A,  
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B). Moreover, when aortas were incubated in vitro with AngII and testosterone 
to simulate conditions where AAA incidence and severity are augmented, 
DHE fluorescence was pronounced in aortas from XY compared to XX 
females (Figure 2.4C, D). 
2.3.4 Testosterone exposure (as neonates or adults) results in a striking level of 
aneurysm rupture in XY females. 
Castration of male mice has been demonstrated to reduce the incidence of 
AngII- induced AAAs (Henriques, Huang et al. 2004), while administration of DHT 
augments AAA formation in adult female hypercholesterolemic mice (Henriques, 
Zhang et al. 2008). To determine if testosterone exerted similar effects to promote 
AAAs in females with an XX versus an XY sex chromosome complement, we 
used two different paradigms to androgenize females of each genotype by 
administering an equivalent dose of androgen. We administered the non- 
aromatizable ligand of the androgen receptor, DHT, to adult female Ldlr-/- XX and 
XY mice prior to and throughout AngII infusions. There were no significant 
differences in body weight (XX, 28 ± 1; XY, 27 ± 1g; P=0.45), sex organ weights 
(XX, 0.09 ± 0.01; XY, 0.07 ± 0.02 g; P=0.46) and systolic blood pressures (XX, 
129 ± 4; XY, 128 ± 7 mmHg; p=0.90) between AngII-infused XX and XY females. 
Plasma IL1β concentrations were increased significantly in XY compared to XX 
AngII-infused females (XX, 1.8 ± 0.9; XY, 15.5 ± 4.8; P<0.05). Both genotypes 
AAA incidences when exposed to DHT (XX, 94%; XY, 100%), and abdominal 
aortic lumen diameters were similar (Figure 2.14A).  However, while 44% of XX 
females administered  DHT  died  of  aneurysm  rupture, 73%  of  XY females 
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succumbed to rupture (Figure 2.5A; Figure 2.14B). External AAA diameters of 
the few surviving XY females administered DHT were increased significantly 
compared to XX females (Figure 2.5B). Due to the extreme incidence of 
aneurysm rupture and extensive pathology of aortas from XY female mice 
administered DHT, atherosclerosis could not be quantified. Recent studies 
demonstrated that transient neonatal exposure of female hypercholesterolemic 
mice to testosterone resulted in increased adult susceptibility to AngII-induced 
AAAs (Zhang, Thatcher et al. 2012). Therefore, we administered testosterone to 
1 day old XX and XY female Ldlr-/- mice and examined effects of AngII infusions 
on AAA formation and severity in adult OVX females. There were no significant 
differences in body weight, serum cholesterol concentrations and systolic blood 
pressures between AngII-infused XX and XY females (data not shown). As 
reported previously, transient neonatal exposure to testosterone promoted a high 
incidence of AngII-induced AAAs in adult XX (50%) and XY (58%) females. 
However, aneurysm ruptures increased significantly in XY (58%) compared to XX 
(0%) females administered testosterone as neonates (Figure 2.6) 
2.4 Discussion 
The field of sexual dimorphism in normal vascular physiology and disease 
is in its infancy as relates to the influence of sex chromosomes. However, the sex 
chromosomes are one of the most unusual chromosomal differences in mammals, 
with approximately 1,098 genes (Ross, Grafham et al. 2005) and more than 300 
diseases alone mapped to the X chromosome. While there are fewer protein- 
coding genes on the Y chromosome, genes within the MSY have been linked to 
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different forms of cardiovascular diseases (Bloomer, Nelson et al. 2013). As an 
example of sex chromosome influences on the vasculature, females with 
monosomy X exhibit a 100-fold increased risk of aortic dissection (Wong, Burgess 
et al. 2014), but mechanisms for these effects are unknown. Our results 
demonstrate that an XY sex chromosome complement results in increased 
expression of inflammatory gene pathways in abdominal aortas of female mice. 
Further, the incidence and severity of AngII-induced AAAs, a vascular disease 
associated with pronounced inflammation, was increased profoundly in XY 
females. We demonstrate that elevated expression of inflammatory genes is linked 
to increased MMP activity and oxidative stress in aortas of XY females, effects 
known to promote AAA formation and severity. Finally, exposure of XY females 
to testosterone to mimic the male sex hormone milieu resulted in a striking level 
of aneurysm rupture. These results advance knowledge by demonstrating a 
profound effect of sex chromosome complement on aortic biology and vascular 
disease development. Moreover, results indicate a complex interplay between 
sex hormones (e.g., testosterone) and sex chromosomes to regulate aortic biology 
and vascular diseases, which may have cardiovascular implications for chronic sex 
hormone therapy in the aging and/or trans- gender population. A positive family 
history of AAA in a first degree relative has been suggested to increase the risk of 
aortic aneurysm by up to 10-fold (Johansen and Koepsell 1986), indicating genetic 
contribution to AAA pathogenesis. However, despite the strong predisposition for 
AAA formation in males, the contribution of sex chromosome effects to AAA 
inheritance and sexual dimorphism of this vascular disease has not been 
investigated extensively. Clifton et al, originally described a family of three affected 
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brothers diagnosed with an AAA (Clifton 1977). Follow-up studies demonstrated 
that 77% of affected individuals in a cohort of 233 families were male and 79% of 
disease transmissions were between father and son (Kuivaniemi, Shibamura et 
al. 2003), suggesting male-lineage transmission of risk. It is unclear from the 
present study whether  increased AAA incidence and severity of XY females 
resulted from the absence of a second X chromosome, or from presence of genes 
on the Y chromosome. However, as XY females exhibiting high AAA incidence 
and severity inherited the Y-chromosome from male fathers, these results suggest 
that male-lineage may contribute to increased inherited risk of AAAs through 
influences of the Y chromosome. These results are the first to demonstrate that 
sex chromosome complement influences expression levels of 88 genes in 
abdominal aortas of phenotypically normal females. Of note, the high 
preponderance of changes in expression levels of inflammatory genes indicates 
potential predisposition to effects of an inflammatory aneurysm stimulus such as 
AngII. Recent studies identified sex differences in immune cells as contributors 
to sexual dimorphism of blood pressure responses to AngII (Ji, Zheng et al. 
2010; Pollow, Uhrlaub et al. 2014). Our results demonstrate increased mRNA 
abundance of two inflammatory pathways typically associated with immune 
cells, namely IL- 1β and Tlr8, in abdominal aortas of XY compared to XX aortas, 
and elevated plasma IL1β concentrations in XY compared to XX AngII-infused 
females. As elevated Tlr8 expression was also detected in BMM from XY 
females, these results suggest a contribution of immune cells to baseline 
differences in abdominal aortic inflammatory gene expression profiles between 
XX and XY females. Following infusion of AngII, AAAs in XY females had 
pronounced macrophage composition, elevated MMp-2 activity and aortas from
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XY females responded to AngII and testosterone with increased oxidative stress, 
suggesting a robust inflammatory immune cell response that contributed to 
increased AAA severity. These results are in agreement with recent findings 
demonstrating immune cells as mediators of sex differences in response to AngII 
infusions (Ji, Zheng et al. 2010; Pollow, Uhrlaub et al. 2014), and suggest that 
sex chromosomes may contribute to sexual dimorphism of this immune cell 
response. Previous findings from our laboratory demonstrated a prominent role 
for testosterone to promote AngII-induced AAAs (Henriques, Huang et al. 2004; 
Henriques, Zhang et al. 2008). In this study, an XY sex chromosome 
complement increased the severity of AngII- induced AAAs in female mice. 
These results are the first to demonstrate a profound effect of sex  chromosome 
complement, independent of sex hormones, to regulate the severity of AngII-
induced AAAs. As testosterone is also a powerful positive regulator of AAA 
susceptibility in this experimental model, we used two different paradigms of 
testosterone exposure to examine interactions between sex hormones (e.g., 
testosterone) and sex chromosomes. Moreover, as serum testosterone 
concentrations were modestly different between XX and XY females, 
administration of DHT to adult females to normalize androgen concentrations 
between genotypes minimized the possibility that modest differences in serum 
testosterone are a primary mechanism for augmented formation and severity of 
AngII-induced AAAs in XY females. Results demonstrate a striking level of 
aneurysm rupture (up to 73%) when XY females were exposed to testosterone 
as neonates (Zhang, Thatcher et al. 2012) or adults (Henriques, Zhang et al. 
2008). The magnitude of the effect of testosterone  to promote the aneurysm 
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rupture, larger than exhibited previously by XY males infused with AngII 
(Daugherty, Manning et al. 2000; Henriques, Huang et al. 2004; Henriques, Zhang 
et al. 2008), may have resulted from the dose of androgen. In addition, while 
females are typically resistant to AAA development (both humans and AngII- 
induced mice), AAAs in females grow at more rapid rates and rupture at smaller 
sizes (Grootenboer, Bosch et al. 2009; Sweeting, Thompson et al. 2012; 
Thompson, Brown et al. 2013; Skibba, Evans et al. 2015). Differences in the 
physical size, compliance or stiffness of female abdominal aortas (Ninomiya, 
Tavares Monteiro et al. 2015) may have contributed to more severe effects of 
androgen to promote aneurysmal rupture of XY female mice. An interesting finding 
from this study was increased blood pressure responses, as well as modest 
elevations in thoracic aorta atherosclerotic lesion surface area in AngII- infused 
XY compared to XX female mice. These results suggest that an XY sex 
chromosome complement influences distinct cardiovascular responses (AAA, 
hypertension, atherosclerosis) to AngII. In contrast to these findings, recent studies 
demonstrated that an XX sex chromosome complement in gonadectomized MF1 
mice contributed to a greater blood pressure response to AngII (Ji, Zheng et al. 
2010). Differences in genetic background (MF1 versus Ldlr-/-) or diet (standard 
murine diet versus Western diet) may have contributed to diverging influences of 
sex chromosome complement on AngII-induced hypertension between studies. 
Regardless, it is unlikely that the augmented hypertensive responsiveness to AngII 
of XY females contributed to the robust severity of AAAs, as previous studies 
suggested that blood pressure was not a major contributor to AngII-induced AAAs 
(Cassis, Gupte et al. 2009). Future studies will address whether similar or distinct 
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mechanisms contribute to augmentation of three different cardiovascular effects 
of AngII in mice with an XY sex chromosome complement. However, as results 
from DNA arrays do not indicate differences in expression levels of angiotensin 
receptors in abdominal aortas of XX versus XY females, and plasma renin 
concentrations were not significantly different between AngII-infused XX and XY 
females, these results do not support generalized enhanced responsiveness of XY 
females to AngII. Using computer program scanned electronic medical records, 
prevalence of confirmed transgender individuals was 4.4 (per 100,000) in 2006, 
and 38.7 in 2014 (Roblin, Barzilay et al. 2016). Despite the growing prevalence of 
the transgender population, literature on specific health outcomes for transgender 
individuals consists of modest cross-sectional studies, some large retrospective 
studies, small series and case reports. Of these, recent data suggest increased 
risk of cardiovascular morbidity/mortality in transgender women (Elamin, Garcia et 
al. 2010). However, the influence of chronic sex hormone therapy on 
cardiovascular health in transgender women or men has not been examined 
extensively. In addition to the transgender population, the use of sex hormone 
therapy, specifically testosterone to improve sexual function in aging males and 
females, has also increased. Our results suggest that sex chromosome 
complement influences aortic biology and the development of AAAs, with an XY 
sex chromosome complement having a profound effect to promote AAA severity. 
As these effects were augmented in XY females administered testosterone, these 
results suggest interactions between sex hormones and genes affected by sex 
chromosomes. These results may have implications related to chronic sex 
hormone therapy and the cardiovascular system in aging males or females, or in 
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the growing transgender population. 
In summary, we demonstrate that an XY sex chromosome complement 
promotes expression of inflammatory genes in abdominal aortas of female mice 
and predisposes to markedly severe AngII-induced AAAs. As 73% of XY female 
mice exposed to testosterone (to mimic the male sex hormone milieu) exhibited 
aneurysm rupture, these results demonstrate interactions between sex hormones 
and genes influenced by sex chromosomes on aortic biology, vascular disease 
development and severity. Future studies will use this information to develop AAA 
therapies that have sex-specific efficacy. 
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Table 2.1. Biological pathway analysis (DAVID) for genes overexpressed in XY 
females.  Gene Ontology categories, the number of significant genes (n) and 
the probability that a greater or equal number would be found by chance (P 
Value ≤ 0.01) are listed. 
Upregulated in XY in Comparison 
With XX n P Value
Immune response 40 8.10E-21 
Chemotaxis 17 3.06E-13 
Leukocyte activation 21 2.84E-11 
Cell surface 23 3.82E-10 
Positive regulation of response to stimulus 18 5.09E-09 
Response to bacterium 13 3.73E-07 
Carbohydrate  binding 17 2.80E-06 
Regulation of cytokine production 12 5.30E-06 
Immune response–regulating signal 
transduction 8 1.07E-05 
Hemopoiesis 14 3.61E-05 
Regulation of interferon-γ 
production 6 6.28E-05 
Positive regulation of defense response 7 7.86E-05 
Positive regulation of cytokine biosynthetic 
process 6 3.83E-04 
Phagocytosis 6 4.32E-04 
Antigen processing and presentation of 
peptide antigen 5 5.43E-04 
Positive regulation of macromolecule 
metabolic process 20 5.89E-04 
Positive regulation of signal transduction 9 0.002015298 
Regulation of inflammatory response 5 0.006337282 
Lytic vacuole 9 0.006726649 
Regulation of phosphorylation 11 0.006752388 
Chemokine activity 4 0.009335703 
Positive regulation of cell activation 6 0.009424794 
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Table 2.2. Primer sequences. 
Genes screened Primers 
XX 
female 
genotype 
Forward: 5’- 
CAAATGTTGCTTGTCTCGGTG-3’ 
Reverse: 5’- GTCAGTCGAGTGCACAGTTT- 
3’ 
XY 
female 
genotype 
Forward: 5’- CTGGAGCTCTACAGTGATGA- 
3’ 
Reverse: 5’- 
CAGTTACCAATCAACACATCAC-3’ 
IL1ß Forward: 5’-TGC CAC CTT TTG ACA 
GTG ATG-3’ 
Reverse: 5’-ATG TGC TGC TGC GAG 
ATT TG-3’ 
Tlr8 Forward: 5’-TGG TTT TCA GTG GAA 
ATC GT-3’ 
Reverse: 5’-CTC TGA GGC AAA TTG 
AGG AA-3’ 
Beta actin Forward: 5’-GCT CTG GCT CCT AGC 
ACC AT-3’ 
Reverse: 5’-GCC ACC GAT CCA CAC 
AGA GT-3’ 
GAPDH Forward: 5’- GCCAAAAGGGTCATCATCTC- 
3’ 
Reverse: 5’- 
GGCCATCCACAGTCTTCT-3’ 
Kdm5d Purchased from QIAGEN catalog #QT00155106 
Uty Purchased from QIAGEN catalog #QT00108157 
Eif2s3y Purchased from QIAGEN catalog #QT00149436 
Xist Purchased from QIAGEN catalog #330001 PRM68756B 
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Table 2.3. Complete list of DNA array results. Summary Statistics  two way ANOVA p-values  two way ANOVA q-values Chromo 
Probe Set ID Gene Description Location   XX OVX XX sh XY OVX XY sh Chromo     Ovari Intrxn Chromo     Ovari Intrxn 
Fold 
Change 
TC0500002508.mm.1 Apbb2 amyloid beta (A4) precursor protein-binding, family B, membchr5   0.000345   0.257841   0.889473   0.037033   1.164919   1.111467 1.19 
TC0600003071.mm.1 Apobec1   apolipoprotein B mRNA editing enzyme, catalytic polypeptid chr6  0.000137   0.487314   0.326819   0.004874   1.06745   1.613141 -1.50 
TC0X00001700.mm.1 Arhgap6    Rho GTPase activating protein 6 chrX   1.26E-07   0.695655   0.413062    3.22E-07   1.016022   1.443566 -2.16 
TC0600003079.mm.1 C3ar1 complement component 3a receptor 1 chr6  0.000648   0.32801   0.318426   0.046839   1.119491   1.628218 -1.50 
TC0100003146.mm.1 Camsap2   calmodulin regulated spectrin-associated protein family, me chr1    0.000735   0.005569   0.470016   0.048576   1.163697   1.358128 1.11 
TC1100003401.mm.1 Ccl3 chemokine (C-C motif) ligand 3 chr11   3.15E-05   0.980155   0.120149   0.000106   1.001036   2.40378 -1.35 
TC0800001624.mm.1 Cd209b   CD209b antigen chr8  0.000433   0.27764 0.54   0.038526   1.149303   1.283321 1.58 
TC1100004059.mm.1 Cd300e CD300e antigen chr11   4.28E-06   0.830034   0.553348 1.6E-06   1.007484   1.268139 -2.78 
TC0500000468.mm.1 Cd38 CD38 antigen chr5  0.000108   0.058844   0.714304   0.004664   1.421551   1.169321 -1.46 
TC1100003055.mm.1 Cd68 CD68 antigen chr11  0.000155   0.683757   0.900525   0.010205   1.019112   1.108882 -2.12 
TC0600001532.mm.1 Clec12a     C-type lectin domain family 12, member a chr6  0.000699   0.83046   0.41952   0.047298   1.007475   1.435849 -1.52 
TC0600001397.mm.1 Clec4a1     C-type lectin domain family 4, member a1 chr6   9.26E-05   0.710377   0.288328   0.003467   1.014658   1.73007 -1.89 
TC0600001398.mm.1 Clec4a3     C-type lectin domain family 4, member a3 chr6  0.000335   0.664626   0.728257   0.037015   1.023691   1.164646 -1.96 
TC1500000641.mm.1 Csf2rb colony stimulating factor 2 receptor, beta, low-affinity (gran chr15  0.000504   0.651629   0.774829   0.039305   1.026858   1.149171 -1.50 
TC0300000903.mm.1 Ctss cathepsin S chr3    0.000744   0.356963   0.69331   0.049345   1.112081   1.178238 -2.02 
TC0X00001829.mm.1 Cybb cytochrome b-245, beta polypeptide chrX   9.71E-05   0.925871   0.701381   0.004066   1.002422   1.173661 -1.77 
TC0X00000166.mm.1 Ddx3x DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked    chrX    2.23E-08   0.139071   0.645657    1.31E-07     1.33292   1.202931 1.57 
TC0Y00000235.mm.1 Ddx3y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked chrY   3.66E-15   0.375221   0.298022    1.03E-11   1.104861   1.695561 -86.63 
TC0Y00000006.mm.1 Eif2s3y eukaryotic translation initiation factor 2, subunit 3, structurachrY   6.66E-15   0.421577   0.553468    1.33E-11   1.083873   1.267791 -16.67 
TC1500001300.mm.1 Fam105a   family with sequence similarity 105, member A chr15  0.00053   0.894979   0.984008   0.041936   1.003472   1.087295 -1.24 
TC1400001439.mm.1 Fam107a   family with sequence similarity 107, member A chr14   1.73E-05   0.868094   0.712431    5.36E-05   1.006558   1.170395 2.14 
TC0100003533.mm.1 Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide chr1   0.000723   0.586716   0.918285   0.047971   1.036311   1.105141 -1.66 
TC0100001574.mm.1 Fcgr4 Fc receptor, IgG, low affinity IV chr1   7.03E-06   0.459132   0.483174    1.16E-05   1.076754   1.344875 -3.94 
TC0300000695.mm.1 Fcrl5 Fc receptor-like 5 chr3   0.000286   0.541518   0.242513   0.026099   1.045654   1.850602 -1.66 
TC0500000361.mm.1 Fgfr3 fibroblast growth factor receptor 3 chr5  0.000112   0.725643   0.848324   0.004825   1.013585   1.124339 1.19 
TC0400001599.mm.1 Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homol chr4 1.4E-05   0.616178   0.697492    1.93E-05   1.032865   1.176624 -1.36 
TC1300002654.mm.1 Grb2-binding adaptor, transmembrane chr13  0.000569   0.848676   0.112749   0.042833   1.007232   2.423412 1.28 
TC1000003213.mm.1 glycoprotein 49 A chr10   8.14E-05   0.725819   0.730542   0.002533   1.013582   1.163499 -1.80 
TC1700002343.mm.1 general transcription factor IIF, polypeptide 1 chr17 3.7E-05   0.082951   0.048839   0.000131   1.411203   3.121616 1.12 
TC1100000475.mm.1 hepatitis A virus cellular receptor 2 chr11   0.000468   0.059858   0.788712   0.038915   1.422871   1.141877 -1.39 
TC0X00003376.mm.1 holocytochrome c synthetase chrX   1.12E-06   0.683081   0.957103    3.82E-07   1.019503   1.094368 -1.78 
TC0200002308.mm.1 hemopoietic cell kinase chr2   8.52E-05   0.530356   0.272399   0.002954   1.051434   1.790958 -1.49 
TC0600002404.mm.1 hematopoietic prostaglandin D synthase chr6  0.000175   0.78459   0.975462   0.01048   1.008278   1.088956 -1.31 
TC0700004207.mm.1 immunoglobulin superfamily, member 6 chr7   8.64E-05   0.626271   0.216542   0.003211   1.031983   1.934873 -1.45 
TC0900002197.mm.1 interleukin 10 receptor, alpha chr9   0.000331   0.408151   0.072737   0.030845   1.086046   2.814019 -1.43 
TC0200004602.mm.1 interleukin 1 beta chr2   0.000368   0.786215   0.781576   0.03733   1.008255   1.146221 -1.49 
TC0700001877.mm.1 integrin, alpha D chr7  0.000313   0.611081   0.249165   0.027611   1.033999   1.828807 -1.13 
TC0700001876.mm.1 integrin alpha X chr7   6.08E-06   0.038162   0.378912    2.76E-06   1.399297   1.499077 -1.68 
TC0300000767.mm.1 potassium intermediate/small conductance calcium-activate chr3  0.000569   0.933502   0.610502   0.043013   1.002113   1.232068 1.50 
TC0X00001541.mm.1 lysine (K)-specific demethylase 5C chrX   3.26E-14   0.016949   0.115453 1.4E-11   1.300452   2.411896 1.89 
TC0Y00000005.mm.1 lysine (K)-specific demethylase 5D chrY 1E-15   0.634494   0.793738    1.46E-11   1.031604   1.140753 -7.68 
TC0X00000190.mm.1 lysine (K)-specific demethylase 6A chrX 2.1E-10   0.644227   0.736706 1.7E-11   1.030776   1.160713 2.04 
TC0500000710.mm.1 kit oncogene chr5  0.000169   0.075816   0.74018   0.01044   1.41461   1.158979 -1.83 
TC0700000773.mm.1 kallikrein related-peptidase 10 chr7   6.56E-05   0.766636   0.788322   0.002111   1.00968   1.141941 2.56 
TC0700002143.mm.1 leukocyte-associated Ig-like receptor 1 chr7   5.96E-05   0.423855   0.275352   0.001598   1.083382   1.778139 -1.39 
TC1400001054.mm.1 lymphocyte cytosolic protein 1 chr14   0.000539   0.605799   0.311689   0.042227   1.034705   1.646642 -1.61 
Fgr 
Gapt 
Gp49a 
Gtf2f1 
Havcr2 
Hccs 
Hck 
Hpgds 
Igsf6 
Il10ra 
Il1b 
Itgad 
Itgax 
Kcnn3 
Kdm5c 
Kdm5d 
Kdm6a 
Kit 
Klk10 
Lair1 
Lcp1 
 9.53 ± 0.02    9.46 ± 0.06    9.28 ± 0.06    9.22 ± 0.06 
 8.81 ± 0.09    8.78 ± 0.05 9.3 ± 0.14    9.51 ± 0.18  
 6.14 ± 0.13    6.29 ± 0.14    7.35 ± 0.09 7.3 ± 0.12  
 6.98 ± 0.16    6.98 ± 0.11    7.45 ± 0.15    7.75 ± 0.14  
11.43 ± 0.06  11.33 ± 0.02  11.29 ± 0.03  11.13 ± 0.04 
4.7 ± 0.03    4.82 ± 0.06    5.24 ± 0.09    5.12 ± 0.07  
 6.78 ± 0.18    7.04 ± 0.08    6.22 ± 0.12    6.29 ± 0.21  
5 ± 0.16    4.91 ± 0.07    6.36 ± 0.22    6.54 ± 0.38  
8.54 ± 0.1    8.28 ± 0.12    9.03 ± 0.09 8.85 ± 0.1  
 8.81 ± 0.13    8.93 ± 0.17    9.93 ± 0.26    9.99 ± 0.28  
 6.83 ± 0.12    6.68 ± 0.05    7.33 ± 0.17    7.42 ± 0.19  
 7.49 ± 0.18    7.36 ± 0.11    8.24 ± 0.17    8.51 ± 0.27  
 7.58 ± 0.22    7.59 ± 0.15    8.48 ± 0.24    8.66 ± 0.22  
 6.55 ± 0.15    6.53 ± 0.08    7.16 ± 0.12    7.06 ± 0.18  
10.86 ± 0.19  10.53 ± 0.26  11.76 ± 0.25  11.63 ± 0.23 
  9.67 ± 0.08    9.59 ± 0.17  10.43 ± 0.18  10.48 ± 0.18  
15.98 ± 0.09  15.84 ± 0.05  15.29 ± 0.05  15.22 ± 0.05  
5.4 ± 0.43    4.95 ± 0.09  11.59 ± 0.05  11.63 ± 0.04  
 5.34 ± 0.24    5.13 ± 0.06 9.3 ± 0.09    9.27 ± 0.14  
 6.61 ± 0.05    6.62 ± 0.05    6.92 ± 0.07    6.93 ± 0.11  
 7.87 ± 0.21    7.78 ± 0.15    6.71 ± 0.17    6.75 ± 0.17  
 7.96 ± 0.15    8.04 ± 0.15    8.68 ± 0.14 8.8 ± 0.28 
4.23 ± 0.1    4.24 ± 0.11    6.03 ± 0.27    6.49 ± 0.63  
 4.53 ± 0.08    4.44 ± 0.08    5.09 ± 0.19 5.4 ± 0.25 
 5.93 ± 0.06    5.96 ± 0.03    5.68 ± 0.05    5.69 ± 0.06  
 4.94 ± 0.04    4.95 ± 0.05    5.37 ± 0.09    5.43 ± 0.09 
 5.05 ± 0.05 4.9 ± 0.09 4.56 ± 0.1    4.68 ± 0.06  
 6.02 ± 0.14    6.02 ± 0.12    6.82 ± 0.18    6.93 ± 0.19  
 9.85 ± 0.03    9.74 ± 0.03    9.63 ± 0.02    9.63 ± 0.03 
 5.05 ± 0.07    4.81 ± 0.09    5.48 ± 0.12 5.3 ± 0.12 
 7.09 ± 0.13    7.05 ± 0.05    7.92 ± 0.12    7.87 ± 0.09  
 6.04 ± 0.04    5.98 ± 0.09 6.5 ± 0.15    6.71 ± 0.12  
 6.68 ± 0.07 6.7 ± 0.06    7.07 ± 0.09    7.09 ± 0.09  
 8.25 ± 0.13    8.17 ± 0.07    8.67 ± 0.11    8.86 ± 0.09  
 6.39 ± 0.03    6.07 ± 0.13 6.7 ± 0.09    6.82 ± 0.19 
 4.79 ± 0.12    4.79 ± 0.11 5.4 ± 0.14    5.33 ± 0.11 
 4.31 ± 0.02    4.24 ± 0.03    4.44 ± 0.03    4.46 ± 0.08  
5.4 ± 0.03    5.26 ± 0.07    6.21 ± 0.15 5.87 ± 0.1  
 7.21 ± 0.14    7.13 ± 0.13    6.57 ± 0.13    6.62 ± 0.14  
 9.81 ± 0.03    9.97 ± 0.05    8.96 ± 0.04    8.99 ± 0.01  
 4.55 ± 0.07    4.59 ± 0.04    7.51 ± 0.06    7.52 ± 0.05 
 10.45 ± 0.1  10.44 ± 0.08    9.44 ± 0.04    9.38 ± 0.06 
 8.24 ± 0.12 7.98 ± 0.1 9.13 ± 0.2    8.75 ± 0.22  
 8.15 ± 0.33 8.3 ± 0.25    6.86 ± 0.19    6.87 ± 0.21  
 5.67 ± 0.03    5.64 ± 0.08    6.06 ± 0.09    6.24 ± 0.16  
 9.19 ± 0.12    8.93 ± 0.16    9.72 ± 0.15 9.8 ± 0.22 
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Table 2.3.  Continued. 
TC0X00003371.mm.1 Msl3 male-specific lethal 3 homolog (Drosophila) chrX   1.26E-10   0.339326   0.716102    1.46E-11   1.116578   1.168088 -2.53 
TC1700000585.mm.1 Myo1f myosin IF chr17  0.000141   0.469721   0.819952   0.009742   1.074857   1.13266 -1.37 
TC1900001156.mm.1 Olfr76 olfactory receptor 76 chr19 
8.07 ± 0.12    7.97 ± 0.13    8.63 ± 0.16    8.78 ± 0.22       
5.65 ± 0.07    5.66 ± 0.09    6.13 ± 0.15    6.44 ± 0.17
9.27 ± 0.16    9.21 ± 0.05  10.63 ± 0.04  10.51 ± 0.06   
6.23 ± 0.07    6.27 ± 0.07    6.66 ± 0.11    6.75 ± 0.11   
4.61 ± 0.06    4.56 ± 0.08    4.22 ± 0.06    4.29 ± 0.09   0.00028   0.87454   0.405389   0.019951   1.00546   1.451715  1.26 
TC0X00001054.mm.1 Pbdc1 polysaccharide biosynthesis domain containing 1 chrX  6.58 ± 0.03 6.5 ± 0.04    5.99 ± 0.04 6.1 ± 0.06    1.89E-09   0.729163   0.026451    4.93E-11   1.013275   3.654528  1.42 
TC1900001506.mm.1 Pik3ap1     phosphoinositide-3-kinase adaptor protein 1 chr19  7.18 ± 0.11    7.06 ± 0.14    7.65 ± 0.13 7.8 ± 0.2   0.000729   0.938059   0.369391   0.048274   1.001983   1.510876 -1.51 
TC0500003463.mm.1 Pilra paired immunoglobin-like type 2 receptor alpha chr5  5.52 ± 0.08    5.45 ± 0.04 6.04 ± 0.1    6.18 ± 0.11    2.32E-06   0.711264   0.264537    4.15E-07   1.014596   1.805698 -1.53 
TC0500003464.mm.1 Pilrb1 paired immunoglobin-like type 2 receptor beta 1 chr5  5.35 ± 0.11    5.48 ± 0.06 5.7 ± 0.08 5.9 ± 0.1   0.000556   0.087026   0.679615   0.042653   1.408737   1.187089 -1.29 
TC0500003465.mm.1 Pilrb2 paired immunoglobin-like type 2 receptor beta 2 chr5  4.73 ± 0.05    4.73 ± 0.07    5.09 ± 0.13    5.32 ± 0.11   0.000268   0.277427   0.274974   0.018807   1.149346   1.779109 -1.37 
TC1200001272.mm.1 Pld4 phospholipase D family, member 4 chr12  9.14 ± 0.13    9.02 ± 0.08    9.77 ± 0.22    9.99 ± 0.28   0.000653   0.805511   0.390389   0.047068   1.007883   1.472034 -1.71 
TC1200001972.mm.1 Plek2 pleckstrin 2 chr12  7.51 ± 0.19    7.81 ± 0.11 6.9 ± 0.13 6.98 ± 0.2   0.000305   0.23856   0.518322   0.026275   1.180392   1.305382 1.66 
TC0X00003361.mm.1 Prps2 phosphoribosyl pyrophosphate synthetase 2 chrX 10.34 ± 0.07 10 ± 0.11    11.21 ± 0.1  11.21 ± 0.17    7.14E-08   0.154443   0.137585    2.62E-07   1.300452   2.344969 -2.06 
TC1000001688.mm.1 Rgs17 regulator of G-protein signaling 17 chr10   6.92 ± 0.08 6.58 ± 0.1    6.07 ± 0.12    6.04 ± 0.21 5.2E-05   0.176329   0.255403   0.001084   1.250181   1.818168 1.62 
TC0800000368.mm.1 Rnf122 ring finger protein 122 chr8 5.5 ± 0.04    5.45 ± 0.05    5.78 ± 0.07    5.78 ± 0.08   0.000138   0.689827   0.640737   0.007076   1.017779   1.206437 -1.23 
TC1500001520.mm.1 Samd12     sterile alpha motif domain containing 12 chr15  8.29 ± 0.15    8.16 ± 0.13    7.67 ± 0.13 7.6 ± 0.13   0.000574   0.483599   0.793837   0.044926   1.068686   1.140749 1.50 
TC1400000325.mm.1 Sema3g     sema domain, immunoglobulin domain (Ig), short basic dom chr14  6.96 ± 0.12    7.29 ± 0.13    6.65 ± 0.13    6.46 ± 0.09   0.000298   0.571623   0.052304   0.026187   1.038478   3.099271 1.47 
TC1900001390.mm.1 Sgms1 sphingomyelin synthase 1 chr19  7.25 ± 0.04    7.27 ± 0.05    7.05 ± 0.03    7.08 ± 0.02   0.00014   0.436602   0.908711   0.009278   1.080684   1.108114 1.15 
TC0100001568.mm.1 Sh2d1b1    SH2 domain protein 1B1 chr1  4.75 ± 0.07    4.86 ± 0.03    5.22 ± 0.08    5.36 ± 0.16    5.05E-05   0.198437   0.900978   0.000608   1.224489   1.108823 -1.39 
TC0100003550.mm.1 Slamf7 SLAM family member 7 chr1  6.27 ± 0.13 5.78 ± 0.2    6.86 ± 0.18    6.89 ± 0.23   0.000329   0.24069   0.178183   0.029896   1.179961   2.143261 -1.80 
TC0100001615.mm.1 Slamf9 SLAM family member 9 chr1  6.69 ± 0.22    6.67 ± 0.13    7.28 ± 0.13    7.43 ± 0.09   0.000553   0.67779   0.60797   0.042585   1.02067 1.2337 -1.58 
TC0100000632.mm.1 Slc11a1     solute carrier family 11 (proton-coupled divalent metal ion t chr1  7.15 ± 0.11    7.22 ± 0.06    7.57 ± 0.09    7.76 ± 0.15   0.000321   0.224467   0.563606   0.028946   1.192589   1.259817 -1.37 
TC1700001634.mm.1 Slc9a3r2    solute carrier family 9 (sodium/hydrogen exchanger), memb chr17  9.79 ± 0.08    9.77 ± 0.04    9.29 ± 0.11    9.13 ± 0.05    3.45E-06 0.2696   0.429899    4.47E-07   1.152596   1.413506 1.47 
TC0100001932.mm.1 Sntg1 syntrophin, gamma 1 chr1  4.56 ± 0.05 4.6 ± 0.02    4.39 ± 0.02    4.42 ± 0.01    1.75E-05   0.262288   0.817713 8E-05   1.159022   1.134222 1.14 
TC0X00000979.mm.1 Taf1 TAF1 RNA polymerase II, TATA box binding protein (TBP)-ass chrX  9.65 ± 0.04    9.58 ± 0.02    9.47 ± 0.02 9.5 ± 0.03   0.000374 0.4596   0.098655   0.037608   1.076672   2.507151 1.10 
TC0500002480.mm.1 Tlr1 toll-like receptor 1 chr5  4.73 ± 0.09 4.5 ± 0.15 5.17 ± 0.1    5.24 ± 0.16   0.000231   0.52315   0.242922   0.017664   1.05474   1.849461 -1.49 
TC0X00001069.mm.1 Tlr13 toll-like receptor 13 chrX  0.000179   0.096916   0.099846   0.01052   1.396013   2.500746 -1.41 
TC0X00003360.mm.1 Tlr7 toll-like receptor 7 chrX   2.76E-10   0.419005   0.682969    1.94E-11   1.084361   1.185169 -2.77 
TC0X00003359.mm.1 Tlr8 toll-like receptor 8 chrX   8.73E-09   0.638322   0.540684    7.92E-11   1.031388     1.28286 -3.24 
TC0X00003159.mm.1 Tmem29    transmembrane protein 29 chrX   6.62E-06   0.945843   0.868192    7.16E-06   1.001771   1.118753 1.15 
TC0X00003358.mm.1 Tmsb4x      thymosin, beta 4, X chromosome chrX  0.00035   0.729699   0.997069   0.037051   1.013136   1.085669 -1.23 
TC0400003957.mm.1 Tnfrsf1b    tumor necrosis factor receptor superfamily, member 1b chr4  0.000168   0.330839   0.962969   0.010323   1.118426   1.092478 -1.27 
TC1700000934.mm.1 Treml4 triggering receptor expressed on myeloid cells-like 4 chr17  0.000112   0.90006   0.505423   0.004745   1.003214   1.320073 -1.45 
TC0Y00000233.mm.1 Uty ubiquitously transcribed tetratricopeptide repeat gene, Y ch chrY 1E-15   0.510847   0.928372    1.09E-11   1.057423   1.102203 -14.30 
TC1000001490.mm.1 Wif1 Wnt inhibitory factor 1 chr10  0.000332   0.010192   0.689415   0.03393   1.229171   1.180451 -1.36 
TC0X00002775.mm.1 Xist inactive X specific transcripts chrX 
5.51 ± 0.1    5.15 ± 0.11    5.82 ± 0.08    5.82 ± 0.12    
7.45 ± 0.07 7.32 ± 0.1    8.88 ± 0.09    8.83 ± 0.17    
6.85 ± 0.19    6.82 ± 0.09    8.46 ± 0.12    8.64 ± 0.23    
5.38 ± 0.03    5.38 ± 0.03    5.17 ± 0.02    5.18 ± 0.04  
11.14 ± 0.08  11.12 ± 0.07  11.44 ± 0.06  11.42 ± 0.02    
7.85 ± 0.05    7.78 ± 0.07    8.18 ± 0.07    8.12 ± 0.07  
4.4 ± 0.09    4.31 ± 0.12    4.87 ± 0.11    4.92 ± 0.09    
4.94 ± 0.13    4.86 ± 0.04    8.76 ± 0.05 8.7 ± 0.14 
5.18 ± 0.1    4.88 ± 0.04    5.57 ± 0.09    5.34 ± 0.12  
13.54 ± 0.12  13.72 ± 0.12 4.8 ± 0.07    4.86 ± 0.09 1E-15   0.253671   0.579332    7.28E-12   1.170779     1.24905 448.17 
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TC1900000221.mm.1 
TC1900001131.mm.1 
Ms4a6c     membrane-spanning 4-domains, subfamily A, member 6C     chr19 
Ms4a7 membrane-spanning 4-domains, subfamily A, member 7 chr19 
 0.000544   0.861294   0.437281   0.042517   1.006964   1.402627 -1.60 
 0.00018   0.235499   0.27742   0.014092   1.181373   1.769716 -1.52 
TC1200002082.mm.1 Ltbp2 latent transforming growth factor beta binding protein 2 chr12  0.000706   0.129273   0.547912   0.047635   1.348297   1.274961 -1.32 
TC0400001607.mm.1 Map3k6     mitogen-activated protein kinase kinase kinase 6 chr4  0.000512   0.940658   0.872403   0.040621   1.001872   1.117188 1.35 
TC0Y00000224.mm.1 Mid1 clone MEX2A-1 Mid1 mRNA, partial sequence. chrY   1.65E-05   0.852168   0.264129    2.71E-05   1.007198   1.806624 -1.78 
TC1900000246.mm.1 Mpeg1 macrophage expressed gene 1 chr19   0.000283   0.366198   0.459311   0.023025   1.111058   1.371828 -2.14 
6.5 ± 0.13    6.41 ± 0.04    6.94 ± 0.08    6.74 ± 0.09   
7.14 ± 0.16    7.15 ± 0.08    6.72 ± 0.07 6.7 ± 0.04  
9.1 ± 0.14    8.91 ± 0.18    9.78 ± 0.11    9.92 ± 0.09    
9.14 ± 0.18    8.74 ± 0.22  10.05 ± 0.21  10.01 ± 0.35
6.52 ± 0.1    6.51 ± 0.11    6.96 ± 0.11    7.21 ± 0.21 
7.81 ± 0.16    7.74 ± 0.19 8.65 ± 0.2    8.77 ± 0.15 
TC0700004631.mm.1     0.000422   0.361163   0.334863   0.038067   1.111693   1.591462 -1.46 
TC1000003214.mm.1 
leukocyte immunoglobulin-like receptor, subfamily B (with T chr7 
leukocyte immunoglobulin-like receptor, subfamily B, memb chr10     0.000117   0.888289   0.623137   0.00485   1.004166   1.220048 -1.90 
Lilrb3 
Lilrb4 
Table 2.4. Characteristics of female XX and XY mice infused with AngII. 
Parameter XX XY 
Sham Ovx Sham Ovx 
Body weight (g) 25.6 ± 0.7 27.5 ± 0.6 25.1 ± 0.7 23.9 ± 0.7** 
Systolic Blood 
Pressure mmHg
123 ± 4 123 ± 3 131 ± 4** 129 ± 4** 
Serum 
Testosterone ng/ml 
0.11 ± 0.03 0.15 ± 0.03 0.36 ± 0.12** 0.11 ± 0.05* 
Serum 
Cholesterol mg/dl 
1964 ± 335 1934 ± 144 1405 ± 107 1721 ± 246 
Plasma Renin 
Concentration ng/ml
0.21 ± 0.11 0.26 ± 0.08 0.13 ± 0.06 0.25 ± 0.09 
Sex Organ Weights (g) 0.13 ± 0.02 0.04 ± 0.01* 0.11 ± 0.02 0.04 ± 0.01* 
Data are mean ± SEM from n=10-17/group. 
*, P<0.05 compared to Sham within genotype. 
**, P<0.05 compared to XX within surgical group. 
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Figure 2.1 Sex chromosome complement influences abdominal aortic gene expression 
patterns. (A) Left, total number of probe sets on arrays filtered to retain transcripts with 
reliable signal intensity (FDR; False Discovery Rate). Right, number of genes whose 
expression level was significantly altered by main effect of genotype (XX, XY), surgery 
(ovariectomy, OVX, sham surgery) and interaction between genotype and surgery. (B), 
Volcano plot illustrating fold change in gene expression (x-axis) and statistical 
significance (y-axis). Genes labelled in blue exhibited significant increase in XY 
compared to XX abdominal aortas; genes labelled in red exhibited significant increase 
in XX aortas. (C), RT-PCR of selected abdominal aortic genes illustrated in (B). A,B: 
Filtered array data analyzed by 2-way ANOVA. C, 2-way ANOVA; data are mean ± 
SEM from n = 5 mice/surgery group/genotype. *, P<0.05 compared to XX within 
surgical group. **, P<0.05 compared to sham within genotype. 
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Figure 2.2. An XY sex chromosome complement markedly promotes formation and 
severity of AngII- induced AAAs in female mice. (A), Internal abdominal aortic lumen 
diameters over time of AngII infusions from mice of each genotype (OVX groups; n = 
10-17 mice/genotype at study onset) that exhibited a 50% increase in lumen diameter 
over baseline, and that survived the 28 day infusion protocol. (B), Maximal external AAA 
diameters after 28 days of AngII infusion mice with an AAA (from A). Symbols represent 
individual mice with mean ± SEM as horizontal lines. (C), AAA incidence (which 
includes aneurysm rupture). The number of mice with an AAA/total number of mice in 
each group is illustrated above each bar of the histogram. (D), % ruptured AAAs. (E) 
Aortas from mice of each genotype. Data were analyzed by (A) two way repeated 
measures ANOVA, (B) unpaired t-test (C) and (D) Fisher's exact test. *, P<0.05 
compared to XX within surgical group. 
65
Figure 2.3. IL1β expression in abdominal aortas (A), bone marrow-derived 
macrophages (BMM, B) and plasma (C) of XX and XY Ldlr-/- females. For A, IL1β 
mRNA abundance was quantified by RT-PCR in abdominal aortas from XX and XY 
Ldlr-/- ovariectomized females. For B, cells were harvested from bone marrow of 
XX and XY Ldlr-/- females and differentiated in vitro to macrophages. IL1β 
concentrations were quantified in media of BMM cells of each genotype incubated 
with LPS. For C, plasma IL1β concentrations were quantified from XX and XY Ldlr- 
/- females infused with AngII for 28 days. Data were analyzed by Mann-Whitney 
test. Circles represent data from individual mice while mean ± SEM are illustrated 
by horizontal lines. *, P<0.05 compared to XX. 
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Figure 2.4. Aortas from XY females exhibited augmented MMP2 activity (A, B) and 
dihydroethidium (DHE) fluorescence (C,D). A, Zymograms of aortic extracts from 
XX and XY Ldlr-/- females infused with AngII for 1 day. B, MMP2 (64 kDa) activity 
quantified by densitometric scans of zymograms (n = 4/genotype). C, 
Representative images of DHE stained aortic explants from XX and XY Ldlr-/-
females incubated with vehicle (V) or AngII+testosterone (10 μM and 10 nM, 
respectively; T=testosterone). D, Quantification of DHE staining in aortic explant 
sections from XX and XY females. *, P<0.05 compared to XX (B, or within treatment 
group in D). **, P<0.05 compared to vehicle. 
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Figure 2.5. Severe AAA rupture in XY females administered dihydrotestosterone 
(DHT). Adult female XX (n=18) and XY mice (n=11) were administered DHT (0.16 
mg/d) for 2 weeks prior to and throughout AngII infusions. (A) % AAA rupture in 
XX and XY females. (B) Maximal AAA diameters at study endpoint. Symbols 
represent individual mice with horizontal lines representing mean ± SEM. Data 
analyzed by (A) Fisher’s exact test (B) Unpaired t-test. *, P<0.05 compared to 
XX+DHT. 
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Figure 2.6. Administration of testosterone (400 μg) to 1 day old neonatal female XY 
mice results in severe AAA rupture when adult XY females are infused with AngII. 
Females (n=6 XX, n=12 XY) were administered a single dose of testosterone within 
24 hours of birth, and then infused with AngII at 2 months of age. Top, % AAA 
rupture. Bottom, representative aortas from mice of each group. Data were 
analyzed using Fisher’s exact test. *, P<0.05 compared to XX. 
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Figure 2.7. mRNA abundance of GAPDH in abdominal aortas from XX and XY Ldlr-/-
females. Data were analyzed by 2-way ANOVA. Symbols represent individual mice, 
while horizontal lines represent mean ± SEM. 
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Figure 2.8. Immune/ inflammatory signaling is upregulated in the aortas of females 
with an XY chromosomal complement. The standardized gene expression values for 
each subject in each treatment group are heatmapped (scale bar: -2 to +2 standard 
deviations) for the top 50 most significant genes by the main effect of chromosome 
(two-way ANOVA, p ≤ 0.0005). 37/50 genes (left) are expressed more strongly in XY 
subjects. 86% of these (bolded symbols) have known roles in immune/ inflammatory 
processes (Gene Ontology annotation search; orange- promote signaling; blue- inhibit 
signaling). 
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Figure 2.9.  Aneurysm type as an index of severity of AAAs (top) and Kaplan Meier 
Survival Curve (bottom, OVX groups) from XX and XY Ldlr-/- females infused with 
AngII. Type 1, dilated lumen in the supra-renal region of the aorta with no thrombus; 
Type II, remodeled tissue in the supra-renal region that frequently contains thrombus; 
Type III, a pronounced bulbous form of type II that contains thrombus; Type IV, a form 
in which there are multiple aneurysms containing thrombus, some overlapping, in the 
suprarenal area of the aorta; Rupture, aneurysms from mice that died of verified 
rupture. Data are illustrated as percent of total mice within each group. 
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Figure 2.10. Abdominal aortas from XY females infused with AngII exhibit 
increased wall volume (top). Bottom, representative 3-D reconstruction from 
ex vivo ultrasound analysis of one AAA/genotype. Data were analyzed by 
unpaired t-test; data are mean ± SEM. 
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Figure 2.11. Morphology of abdominal aorta from XX versus XY females prior 
to AngII infusions. Representative abdominal aorta tissue sections from non- 
infused XX and XY females stained with hematoxylin and eosin. Scale bar 
represents 100 µm. 
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Figure 2.12. Representative AAA tissue sections from XY females infused 
with AngII exhibit pronounced CD68 immunostaining in areas exhibiting 
breaks in medial elastin. Scale bar represents 200 µm. 
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Figure 2.13. Sex chromosome complement has no significant effect on AngII- 
induced atherosclerosis in thoracic aortas. Data were analyzed by weighted 
two- way ANOVA. Symbols represent individual mice with mean ± SEM 
represented by horizontal lines. 
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Figure 2.14. Abdominal aortic lumen diameters (A) and survival plots (B) over 
days of AngII infusions of XX and XY Ldlr-/- females administered DHT. A, Data 
were analyzed by 2-way ANOVA with repeated measures on time. B, Kaplan 
Meier curve for survival of mice in each treatment group. Data are mean ± 
SEM from n=11-18 mice/genotype. 
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CHAPTER III. SPECIFIC AIM 2 
Sex chromosome complement defines diffuse versus focal angiotensin II-
induced aortic pathology (Published in ATVB) 
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Summary 
Objective-Aortic pathologies exhibit sexual dimorphism, with aneurysms in both 
the thoracic and abdominal aorta (AAA) exhibiting higher male prevalence.  
Women have lower prevalence of aneurysms, but when they occur, aneurysms 
progress rapidly.  To define mechanisms for these sex differences, we determined 
the role of sex chromosome complement and testosterone on the location and 
progression of angiotensin II (AngII)-induced aortic pathologies. 
Approach and Results-We used transgenic male mice expressing Sry on an 
autosome to create low density lipoprotein receptor (Ldlr) deficient male mice with 
an XY or XX sex chromosome complement.  Transcriptional profiling was 
performed on abdominal aortas from XY or XX males, demonstrating 1746 genes 
influenced by sex chromosomes or sex hormones.  Males (XY or XX) were either 
sham-operated or orchiectomized prior to AngII infusions.  Diffuse aortic aneurysm 
pathology developed in XY AngII-infused males, while XX males developed focal 
AAAs.  Castration reduced all AngII-induced aortic pathologies in XY and XX 
males.  Thoracic aortas from AngII-infused XY males exhibited adventitial 
thickening that was not present in XX males.  We infused male XY and XX mice 
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with either saline or AngII and quantified mRNA abundance of key genes in both 
thoracic and abdominal aortas.  Regional differences in mRNA abundance existed 
before AngII infusions, which were differentially influenced by AngII between 
genotypes.  Prolonged AngII infusions resulted in aortic wall thickening of AAAs 
from XY males, while XX males had dilated focal AAAs. 
Conclusions-An XY sex chromosome complement mediates diffuse aortic 
pathology, while an XX sex chromosome complement contributes to focal AngII-
induced AAAs. 
3.1 Introduction 
Aortic vascular diseases are life-threatening conditions that are not typically 
symptomatic, which is of concern since ruptures result in high morbidity and 
mortality. Amongst the various risk factors that have been identified for aortic 
vascular diseases, male sex has emerged as a positive risk factor for aneurysmal 
disease in the ascending aorta (AA) (Roman et al. 2017), distal thoracic aorta 
(TAA) (Cheung et al. 2017), and for abdominal aortic aneurysms (AAAs) 
(Pleumeekers et al. 1995; Zarrouk et al. 2013; Svensjo et al. 2013; Weiss et al. 
2014; Vardulaki et al. 1998; Pleumeekers et al. 1994).  Recent studies analyzing 
patients within the Genetically Triggered Thoracic Aortic Aneurysms and 
Cardiovascular Conditions (GenTAC) registry demonstrated that adult males with 
Marfan syndrome were more likely than females to have aortic root dilatation (by 
8%), aortic regurgitation (by 19%) and the prevalence of previous aortic dissection 
tended to be higher in males (by 7%) (Singh et al. 2017).  Similarly, TAAs are also 
more prevalent in men (Olsson et al. 2006).  Male sex is considered one of the 
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largest non-modifiable risk factors for AAAs, with estimates ranging from a 2-10 
fold greater prevalence in men compared to women (Weiss et al. 2014; Wilmink et 
al. 1998; Pleumeekers et al. 1994; Morris et al. 1994).  A higher prevalence of 
aortic vascular diseases in men is not restricted to aneurysms, as the incidence of 
acute aortic dissection is also higher in men than women (Clouse et al. 2004; 
Wenger et al. 1993; Maitusong et al. 2016).  Despite a uniformly lower incidence 
of various forms of aortic vascular diseases in women compared to men, 
paradoxically, women exhibit more rapid growth rates of both TAAs and AAAs 
than men, and aneurysms rupture at smaller sizes (Juvonen et al. 1997; Davies et 
al. 2002; Nienaber et al. 2004; Cheung et al. 2017; Grootenboer et al. 2009; 
Skibba, 2015; Sweeting et al. 2012; Thompson et al. 2013).  Mechanisms for 
these sex differences in aortic vascular disease development versus progressive 
growth have not been defined. Similar to humans, studies from our laboratory 
demonstrated that AAAs induced by infusion of angiotensin II (AngII) to 
hypercholesterolemic mice exhibit a high level of sexual dimorphism, with a 4-fold 
higher AAA prevalence in male compared to female mice (Henriques et al, 2004).  
Testosterone was identified as a primary contributor to higher AAA prevalence in 
AngII-infused male mice (Henriques et al. 2004; Henriques et al. 2008; Thatcher 
et al. 2014; Thatcher et al. 2015).  Moreover, administration of testosterone to 
neonatal female low density lipoprotein receptor (Ldlr) deficient mice infused with 
AngII augmented development of aneurysms in the ascending and abdominal 
aorta (Zhang et al. 2012).  Adult female mice exposed to testosterone as neonates 
maintained a high susceptibility to AngII-induced aortic vascular diseases (Zhang 
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et al. 2012).  In contrast, AAA incidence was markedly reduced when adult male 
mice were castrated (Henriques et al. 2004). These results suggest that while 
testosterone is a primary mediator of sexual dimorphism of experimental aortic 
vascular diseases, other differences between males and females may contribute 
to sexual dimorphism of vascular disease development and severity. In addition to 
sex hormones, recent studies demonstrated that an XY sex chromosome 
complement was sufficient to promote a high level of AAA susceptibility in female 
Ldlr-/- mice infused with AngII (Alsiraj et al. 2017).  Moreover, XY females 
exhibited increased aneurysm rupture, which rose to 73% when females were 
exposed to dihydrotestosterone to mimic an adult male milieu.  These results 
suggest that sex chromosome complement also has profound effects on the 
vasculature, which is of interest as women with Turner’s Syndrome (monosomy 
X) exhibit a 100-fold increased risk of aortic dissection (Wong et al. 2014). The 
purpose of this study was to define the relative role of sex hormones versus sex 
chromosome complement on the location and characteristics of aortic vascular 
diseases following AngII infusions. The four core genotype murine (FCG) model 
was utilized to assess the relative role of sex hormones versus sex chromosome 
complement on the formation and progression of AngII-induced AAAs.  This 
model produces mice in which the sex chromosome complement (XX versus XY) 
is varied independently of gonadal sex (testes versus ovaries). The FCG model 
was created from a natural mutation of the Sry gene (testis determining gene) on 
the Y chromosome of mice (XY-), where an Sry transgene was inserted onto an 
autosome for testes formation and fertility (XY-Sry) (Itoh et al, 2015). Breeding of 
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XY-Sry male mice to XX females produces FCG: XX and XY males, XX and XY 
females.  Since testosterone promotes AngII-induced AAs and AAAs in male mice 
(Henriques et al. 2004; Henriques et al. 2008), we performed studies on male 
Ldlr- /- mice with an XY and an XX sex chromosome complement in the presence 
or absence of male sex hormones. Since men experience a higher prevalence of 
AAs, TAAs, and AAAs than women, we hypothesize that testosterone and an XY 
sex chromosome complement promote vascular disease along the length of the 
aorta in male mice infused with AngII.   
3.2 Methods 
3.2.1 Mice.   
All studies using mice were approved by the institutional Animal Care and 
Use Committee at the University of Kentucky and conformed to the Guide for the 
Care and Use of Laboratory Animals published by the NIH.  Male transgenic mice 
with deletion of Sry from the Y-chromosome expressing Sry on an autosome (8-
12 weeks of age) were backcrossed 10 times on a C57BL/6J background 
(Stock#010905, The Jackson Laboratories, Bar Harbor MA) and bred to low 
density liproprotein receptor deficient (Ldlr-/-) females (Stock# 002207, The 
Jackson Laboratories, Bar Harbor MA) to generate Ldlr-/- male mice with an XY or 
an XX sex chromosome complement. DNA was extracted from ear or tail clips and 
subjected to PCR using a commercial PCR mix (Promega 2X Master Mix, 
cat#m7123, Fitchburg WI) and specific primers. For transcriptome analysis, male 
XY and XX Ldlr-/- mice (n = 4-5/group/genotype) were randomly assigned to sham 
and orchiectomized (ORC) groups.  Following surgery, mice were fed a Western 
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diet (TD88137, Harlan Teklad, Indianapolis, IN) for 2 weeks prior to euthanasia 
and tissue harvest.  For assessment of aortic vascular pathologies (Figure 1A), 
male XY and XX mice (n = 19-21/group/genotype) bred from transgenic male Sry 
mice were randomly assigned to sham and ORC groups.  In addition, we included 
XY male Ldlr-/- mice (n = 10) purchased from The Jackson Laboratories (Stock# 
002207, Bar Harbor MA) to compare to XY males generated from our transgenic 
Sry Ldlr-/- colony.  As there were no observed differences in data quantified from 
Ldlr-/- XY males (Sry-bred or from The Jackson Laboratory), data from XY males 
were pooled between strain sources.  Two weeks after surgery, mice were fed the 
Western diet for 1 week prior to implantation of osmotic minipumps and then 
through study endpoint.  Anesthetized mice were implanted subcutaneously with 
osmotic minipumps (Alzet model 1004, Durect Co., Cupertino, CA) for infusion of 
AngII for 28 days (1,000 ng/kg/min, Bachem, Torrance, CA).  Ultrasound was 
performed on anesthetized mice on day 0, 7, 14 and 27 of AngII infusions.  In this 
study, n = 6 sham-operated male XX mice, n = 2 ORC male XX mice, n = 2 sham-
operated male XY mice and n = 2 ORC male XY mice died from aneurysm rupture, 
and thus were not included in some AAA quantification measurements (internal 
aortic diameters, external AAA diameter).  For aortic regional mRNA abundance, 
male XY and XX Ldlr-/- mice (n = 6-8 mice/sex) were infused with saline or AngII 
(1,000 ng/kg/min) for 1 day prior to euthanasia and tissue harvest.  For prolonged 
infusion of AngII (Figure 1B), male XY and XX Ldlr-/- mice (n = 19 XY, n = 8 XX) 
were fed the Western diet for one week prior to implantation of osmotic minipumps 
containing AngII (1,000ng/kg/min) and the diet continued through study endpoint.  
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Ultrasound was used on day 27 of AngII infusions to define mice with an AAA 
(abdominal aortic lumen diameter > 50% increase compared to day 0 of infusions).  
For each genotype, all mice infused with AngII qualified with an AAA and thus 
continued in the study.  Osmotic minipumps were replaced with fresh AngII solution 
every 28 days in anesthetized mice.  Ultrasound was performed on anesthetized 
mice on day 0, 14, 27, 42, 56 and 70 of prolonged AngII infusions.  In this study, n 
= 9 male XY mice and n = 3 male XX mice died from AAA rupture and thus were 
not included in some measures of AAA quantification (e.g., ultrasound or maximal 
AAA diameters).  Thus, illustrated data for these measurements represent mice 
that survived the 70 days of AngII infusions.  At the end of each experiment, mice 
were euthanatized under anesthesia (ketamine/xylazine, 100:10 mg/kg, i.p.) and 
blood was collected via cardiac puncture.  
3.2.2 Orchiectomy.   
Male (8-12 weeks of age) XX and XY Ldlr-/- mice were orchiectomized 
under isoflurane anesthesia (2-3%) and given pre and post-operative analgesic 
(24 hr after surgery; flunixin; 2.5 mg/kg). Mice were shaved in the scrotum region 
and a depilatory cream (Nair, Inc.) applied to the area to remove hair, followed by 
sterilizing with povidone-iodine/ethanol (three times). A small incision was made in 
this region. Vas deferens were collapsed using a hemostat and the testes were 
removed. The vascular supply was ligated by cauterization using a high-
temperature fine-tip loop cauterizer and the hemostat was released. The wound 
site was monitored for bleeding, and the skin was closed by wound clips (Autoclip 
stapler). The site was then treated with povidone-iodine, and mice were allowed to 
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recover. The testes were manipulated but left intact in anesthetized sham-operated 
mice.  All mice were allowed to recover from surgery and to clear their endogenous 
testicular hormones for two weeks before the onset of AngII infusions.  
3.2.3 Measurement of plasma and serum components.   
Total serum cholesterol and testosterone concentrations were determined 
using enzymatic assay kits (Wako Pure Chemical, Richmond, VA, cat#439-17501; 
Alpco, Salem, NH, cat#55-TESMS-E01; respectively).  The renin concentration in 
plasma was measured by quantifying angiotensin I generated in the absence or 
presence of an excess of exogenous rat angiotensinogen (purified from 
nephrectomized rat plasma). Plasma was harvested from mice in ice-cold EDTA 
(0.2 M). Mouse plasma (8 μl) was incubated in buffer (Na2HPO4, 0.1M; EDTA, 
0.02 M; maleate buffer, pH 6.5; total volume of 250 μl) containing 
phenylmethylsulfonyl fluoride (2 μl/250μl reaction volume) for 30 minutes at 37°C 
in a shaking water bath.  The reaction was terminated by placing samples at 100°C 
for 5 min.  Angiotensin I was quantified by radioimmunoassay using a commercial 
kit (DiaSorin, CA-1553, Stillwater, MN).  Plasma renin concentration (ng/ml) is 
represented as the difference in angiotensin I levels in the absence versus the 
presence of exogenous angiotensinogen.      
3.2.4 Blood pressure measurements.  
Blood pressure was quantified using a non-invasive computerized tail-cuff 
method (BP-2000; Visitech Systems, Apex, NC) at baseline (prior to pump 
implantation) and during week 3 of AngII infusion. Measurements were recorded 
at the same time of the day for 5 days (2 days acclimation, 3 days of recording). 
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3.2.5 Quantification of AAAs. 
The abdominal aortic internal lumen diameters were quantified on day 0, 7, 
14, and 28 of AngII infusions using a Vevo 2100 high-resolution imaging system 
(VisualSonics, Inc.). AAA incidence was quantified from the abdominal aortic 
internal lumen diameter, and defined as a 50% increase in lumen diameter on day 
28 of AngII infusions (compared to day 0).  AAA incidence included mice that died 
from aneurysm rupture, which was visually confirmed post-mortem. Other 
measurements (ultrasound, maximal AAA diameters) included mice that survived 
the complete study protocol.  External abdominal aortic diameters were quantified 
on excised, cleaned tissue mounted on a black wax background.  A Nikon SMZ800 
dissecting microscope was used to obtain aorta images and the maximal external 
diameter of the abdominal aorta was quantified. Using the Vevo 2100 system with 
a 55-MHz probe, the three-dimensional volume analysis was performed on 
abdominal aortas of XX and XY males (n = 5 mice/genotype) that were infused 
with AngII for 3 months.  Aortas were scanned at the abdominal region (diaphragm 
to the ileac bifurcation) using the ultrasound ex vivo at 0.051 mm intervals with an 
imaging length of 14.986 mm, and a total of 295 images were collected. Each 
image was analyzed for wall and lumen volume, and images were combined to 
obtain the total volume of abdominal aortas. 
3.2.6 Quantification of AAs and TAAs. 
Arch areas were defined by drawing a 3-mm line from the left subclavian 
artery. Thoracic areas were defined by drawing a 9mm line from the end of the 
arch area to the diaphragm muscle. Arch and thoracic combined areas were 
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quantified by drawing a line around the borders and summing the total area of 
each. Measurements were performed using Nikon Elements Version 3.2.  
3.2.7 Quantification of atherosclerosis. 
Atherosclerosis was quantified en face in the aortic arch (Daugherty et al. 
2000). Lesions were summed and divided by the total arch area to calculate the 
percent lesion area.  Cleaned aortas were cut open longitudinally and mounted on 
a black wax background using insect pins (Fine Science Tools, cat# 26002-20) to 
quantify atherosclerosis in the aortic arch and the thoracic aorta.  
3.2.8 Quantification of aortic stiffness (pulse wave velocity, PWV).  
Aortic stiffness was assessed on anesthetized (2% isoflurane) male XY and 
XX mice (8 months of age, non-infused, n = 6 mice/genotype) that were placed 
supine on a heating board with legs secured to ECG electrodes (Du et al. 2015). 
Doppler probes (Indus Instruments, Webster, TX) were used to noninvasively 
quantify aortic velocities at the aortic arch and abdominal aorta.  PWV was 
calculated as the distance between the aortic arch and abdominal probes divided 
by the difference in thoracic and abdominal aortic pre-ejection times.  Data are 
presented as centimeters/second.   
3.2.9 Quantification of adventitial and medial diameter in thoracic aorta tissue 
sections. 
Thoracic aortic segments from XY and XX male mice (n = 3 mice/ group) 
infused with AngII for 28 days were formalin fixed, processed through a series of 
ethanol and xylene baths and embedded in paraffin.  Sets of serial 5 micron cross 
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sections were collected at intervals along each segment and stained with 
hematoxylin and eosin. Six tissue sections from each mouse were imaged using a 
Nikon Eclipse 80i microscope. The adventitial layer was defined by encircling a 
line around the borders of the outer layer of the aortic section. The medial layer 
was defined by encircling a line around the borders of the middle layer of the aortic 
section. Analysis was performed using Nikon Elements Version 3.2.  
3.2.10 RNA extraction and DNA microarrays. 
XY and XX male mice (8 weeks of age; n = 4-5 mice/ genotype) underwent 
sham surgery or ORC, and after two weeks, mice were placed on Western diet 
(TD88137, Harlan Teklad, Indianapolis, IN) for one week. RNA from abdominal 
aortas was extracted using the RNeasy fibrous tissue mini kit (Qiagen, cat # 
74704).  Harvested abdominal aortic RNA quality and quantity were measured by 
Agilent 2100 Bioanalyzer using RNA 6000 Nano Labchip kits (Agilent 
Technologies, Cat # 5067-151).  One RNA sample (subject #9) was excluded due 
to poor quality.  The remaining 17 samples had excellent quality and did not differ 
significantly by treatment group (RNA Integrity Number [RIN]: 9.64 ± 0.03; RNA 
concentration (ng/ul): 55.7 ± 7.4; 28s:18s ratio: 3.00 ± 0.07; all p-values for main 
effects of gene and surgery, as well as of interaction terms were n.s. [p > 0.1]).  
Extracted RNA was labeled and hybridized to Affymetrix Mouse Transcriptome 
Assay 1.0 arrays (one array per subject; n = 17). Signal intensities were calculated 
using the RMA algorithm (Bolstad et al, 2003) at the transcript level using 
Genomics Suite software (Partek, St Louis).  Data were transferred to flat files in 
Excel and associated with vendor-provided annotation data.  Pre-statistical filtering 
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retained unique, annotated probe sets with adequate signal intensity (signal 
intensity ≥ 4.2 on at least 3 arrays in the study).  Filtered signal intensities were 
analyzed by two-way ANOVA to identify significant main effects of genotype (XY 
versus XX), surgery (Sham vs ORC), as well as interaction. The False Discovery 
Rate (FDR) procedure (Hochberg et al. 1990) was used to estimate the error of 
multiple testing. Functional categorization for each expression pattern was 
determined with the prestatistically filtered gene list as a background using 
DAVID bioinformatic tools (Huang da et al. 2009).  Currently, DAVID does not 
support Affymetrix MTA 1.0 IDs, and therefore best match IDs from Affymetrix 
Mouse 1.0 Exon arrays were used, covering more than 90% of the filtered MTA 
data set.  Raw data are available through the Gene Expression Omnibus (GSE 
#:81580 www.ncbi.nlm.nih.gov/geo/).  
3.2.11 Real Time RT-PCR. 
After 1-day of saline or AngII infusion to XY and XX male Ldlr-/- mice (n = 
4-6 mice/ genotype/ treatment) RNA was extracted from abdominal and thoracic 
regions of the aorta using the RNeasy fibrous tissue mini kit (Qiagen, cat # 74704).  
cDNA was then synthesized using the qScript cDNA Supermix (Quanta 
Biosciences, cat# 95048-500). Real-time PCR was processed using the SYBER 
Green FastMix (Quanta Biosciences, cat# 95071-012) on a BioRad quantitative 
real-time PCR. mRNA abundance was determined using the ∆∆Ct method.  Gene 
expression was normalized to the housekeeping gene, beta-2-microglobulin. 
Primers sequences for the probed genes are listed in Table 1.  
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3.2.12 Statistical Analyses. 
Data are illustrated as mean ± SEM.  Data were analyzed using unpaired 
Student t-tests for two groups, by two-way repeated measures ANOVA on time for 
longitudinal data with between group factors of surgery or genotype, or by two or 
three-way ANOVA with between group factors of surgery, region, treatment or 
genotype. If differences existed between groups, a Holm-Sidak post hoc analysis 
was performed.  Incidence of AAAs and TAAs were analyzed by Fisher’s exact 
test when two groups were examined. Statistical analysis was performed using 
SigmaPlot software (Version 12.3) or GraphPad Prism 5. P≤ 0.05 was considered 
significant. 
3.3 Results 
3.3.1 Testosterone and/or Sex Chromosome Complement Influenced Abdominal 
Aortic Gene Expression Patterns and Aortic Stiffness. 
We demonstrated recently that an XY sex chromosome complement promoted 
expression of inflammatory gene pathways in abdominal aortas from female Ldlr-
/- mice (Alsiraj et al, 2017). Since previous studies focused on abdominal aortas 
of XX and XY females, in this study we used RNA extracted from abdominal aortas 
of XY and XX male mice (non-infused) that were gonadally intact (sham-operated) 
or orchiectomized (ORC) for Affymetrix Mouse Transcriptome Assay 1.0 analysis.  
A total of 1,746 genes exhibited highly significant differences (two-way ANOVA, 
P<0.01, Figure 2A). There was a significant main effect of sex chromosome (450 
genes, FDR = 0.32), castration (799 genes, ORC vs Sh, FDR = 0.14) and an 
interaction between sex chromosome and castration (708 genes, FDR = 0.24; 
91
Figure 2).  A frequency histogram of the number of genes (y-axis) found at different 
p-value cut-offs (x-axis), with chance depicted by the dashed line, illustrates the 
number of genes influenced by sex chromosome complement, castration, or by an 
interaction between sex chromosomes and sex hormones at different p-values 
(Figure 2).  Volcano plots of the chromosome effect with highly stringent cutoffs (> 
2-fold change, p < 0.01) demonstrated that, as expected, the expression of genes 
on sex-chromosomes was influenced strongly (Figure 2).  Using this level of 
stringency, five genes (Xist, Arntl, Npas2, Arhgap20, Ighv14-1) were increased 
significantly in abdominal aortas of sham-operated XX compared to XY males 
(Figure 2, Table 2).  In contrast, 51 genes were increased significantly in abdominal 
aortas of sham-operated XY compared to XX males (Table 2).  RT-PCR on mRNA 
extracted from abdominal aortas from mice of each genotype and surgical group 
confirmed microarray results for selected genes enriched in XX (Xist, Npas2, Arntl, 
Figure 3) or XY aortas (Cyp2e1, Kap, Figure 3).  Biological pathway analysis 
revealed several expression patterns, potentially related to aortic vascular 
diseases, that were increased in abdominal aortas of XY compared to XX males 
(immune response, acute inflammatory response), while other pathways were 
increased in abdominal aortas of XX compared to XY males (e.g., DNA binding, 
regulation of cell proliferation) (Figure 2, Table 3).  To determine if differences in 
gene expression patterns (e.g., extracellular matrix, Figure 2) between aortas of 
XY and XX males influenced aortic function, we quantified pulse wave velocity 
(PWV) as an index of aortic stiffness in non-infused XY and XX Ldlr-/- males. 
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Aortas from XY males exhibited significant increases in PWV compared to XX 
males (Figure 4).   
3.3.2 Aortic Aneurysmal Disease was Diffuse in XY Males and Localized in XX 
Males.    
At study endpoint, body weights of castrated (ORC) male mice infused with 
AngII were decreased significantly compared to sham-operated controls, 
regardless of genotype (Table 4; P<0.05).  Serum testosterone concentrations 
were similar in sham-operated XY and XX males infused with AngII (Table 4; 
P>0.05).  Castration resulted in significant decreases in serum testosterone 
concentrations of both genotypes, with no differences between genotypes (Table 
4; P<0.05).  Systolic blood pressures were not different between genotypes or 
surgical groups at baseline (XY sham, 111 ± 4; XY ORC, 109 ± 5; XX sham, 110 
± 3; XX ORC, 107 ± 2 mmHg), but increased significantly in AngII-infused XY 
compared to XX sham-operated males (Table 4; P<0.05), and this difference was 
eliminated by castration.  Plasma renin concentrations were not significantly 
different between groups (Table 4; P>0.05).  Atherosclerotic lesion surface area in 
the aortic arch was not significantly altered by castration or by sex chromosome 
complement in AngII-infused male mice (Table 4; P>0.05). 
Aortas from XY sham-operated AngII-infused males exhibited diffuse disease that 
typically extended from the aortic arch to the suprarenal aorta (Figure 5A, top left).  
In contrast, aortas from XX AngII-infused males exhibited aortic pathology that was 
generally restricted to the suprarenal portion of the abdominal aorta (Figure 5A, 
top right).  As an index of the extent of aortic pathology, aorta weights were 
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increased significantly in XY compared to XX males, with aortic weights decreased 
by castration in both genotypes (Figure 5B; P<0.05).  The area of the aortic arch 
was increased significantly in XY compared to XX AngII-infused sham-operated 
males (Figure 5C; P<0.05), with reductions in arch areas following castration of XY 
males.  The incidence of aneurysms in the aortic arch or thoracic aorta (TAAs) was 
markedly higher in XY (44%) compared to XX (8%) AngII-infused males (Figure 
5D; P<0.05).  This difference was abolished by castration, which resulted in almost 
complete ablation of AngII-induced TAAs in both genotypes. In contrast to diffuse 
aortic disease of XY males infused with AngII, XX males exhibited focal aortic 
disease within the suprarenal portion of the abdominal aorta, with significant 
increases in external AAA diameters that were abolished by castration (Figure 6A; 
P<0.05).  Similarly, abdominal aortic lumen diameters were increased significantly 
in XX compared to XY sham-operated males infused with AngII (day 28, Figure 
6B; P<0.05).  The high incidence of AAAs was not significantly different between 
XX and XY AngII-infused males (Figure 6C; P>0.05), and castration significantly 
decreased AAA incidences of both genotypes (Figure 6C; P<0.05). Larger AAAs 
of XX males were associated with slight, but insignificant increases in aneurysmal 
rupture (Figure 6D; P>0.05), which were also reduced by castration of XX males. 
Since XY, but not XX males exhibited considerable aortic pathology in the thoracic 
aorta, we characterized morphology of tissue sections prepared from thoracic 
aortas of XY and XX males infused with AngII. Thoracic aorta tissue sections from 
XY AngII-infused males exhibited pronounced thickening of the adventitia, which 
was not evident in thoracic aortas of XX males (Figure 7A, B). Adventitial 
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thickening of thoracic aortas from XY males was abolished by castration (Figure 
7A, B). In contrast, medial diameters were not significantly different between XY 
and XX males, and were not influenced by castration (Figure 7A, C; P>0.05).  
3.3.3 Aortic Genes Related to AAA Development Exhibited Region-specific and 
AngII-induced Differences in Abundance.     
Initial studies defined gene expression patterns in abdominal aortas from 
non-infused male XY and XX mice (Figure 2). To determine if differences in aortic 
disease development between XY and XX male mice are associated with regional 
differences in aortic gene expression, and whether AngII regulates aortic genes in 
a region-specific manner, we contrasted effects of short-term (1 day) infusions of 
saline versus AngII on abundance of genes within the thoracic versus abdominal 
aortas of male XY and XX Ldlr-/- mice. We chose short-term AngII infusions to limit 
the extent of overt aneurysm pathology between genotypes. Abundance of 
angiotensin converting enzyme (ACE), collagen 1a1, and thrombospondin (Thbs1) 
mRNAs were increased significantly in abdominal compared to thoracic aortas of 
XX, but not XY saline-infused male mice (Figure 8A-D; P<0.05). Moreover, 
abdominal aortas of saline-infused XX males exhibited significantly increased 
mRNA abundance of ACE, collagen 1a1, and Thbs1 compared to abdominal 
aortas of saline-infused XY males (Figure 8A, C,D; P<0.05).  Infusion of AngII 
resulted in significant elevations in mRNA abundance of matrix metalloproteinase 
2 (MMP2), collagen 1a1, and Thbs1 in thoracic, but not abdominal aortas of XY 
male mice compared to XY saline-infused controls (Figure 8B-D; P<0.05).  In 
contrast, abdominal aortas of XX males did not respond to AngII with increased 
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expression of MMP2 or Thbs1. However, mRNA abundance of collagen 1a1 was 
decreased significantly by AngII in abdominal aortas of XX males.  As a result, 
following AngII infusions, marked regional differences in expression levels of 
MMP2, collagen 1a1, and Thbs1 were evident, with increased expression levels in 
thoracic compared to abdominal aortas of XY and XX male mice (Figure 8B-D; 
P<0.05).  The magnitude of AngII-induced changes in the regional expression 
levels of these genes were more pronounced in XY than XX male mice. 
3.3.4 Regional Differences in AngII-induced Aortic Vascular Diseases Between XY 
and XX Males Persisted with Aneurysm Progression. 
Despite a lower prevalence of TAA and AAA development in women 
compared to men, previous studies demonstrated that aneurysm growth rates are 
more aggressive in women, and aneurysms may rupture at smaller sizes 
(Juvonen et a. 1997; Davies et al. 2002; Nienaber et al. 2004; Cheung et al. 
2017; Grootenboer et al. 2009; Skibba, 2015; Sweeting et al. 2012; Thompson et 
al. 2013). Therefore, we examined progression of aortic vascular diseases in 
response to 3 months of prolonged AngII infusions in XY and XX males.  Increased 
abdominal aortic lumen diameters of XX males persisted with prolonged AngII 
infusions (Figure 9A; P<0.05).  Surprisingly, dilated abdominal aortas of XX males 
were not associated with significantly larger AAA diameters at study endpoint 
(Figure 9B; P>0.05). These results suggest divergent aneurysm remodeling 
between genotypes.  Similar to 28 day AngII infusions, XY males infused with AngII 
for 3 months exhibited diffuse aortic disease (Figure 9C), resulting in significant 
increases in aorta weight (Figure 9D; P<0.05) and incidence of TAAs compared to 
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XX males (Figure 9E; P<0.05). Since maximal AAA diameters were not different 
between XY and XX males, but aneurysms of XX males were more dilated, we 
performed ex vivo ultrasound analysis of AAA 3-D structures following prolonged 
AngII infusions (Figure 10, representative 3-D images of AAA from each group in 
C).  AAA wall volumes were increased in XY compared to XX males (Figure 10A), 
while AAA lumen volumes were increased significantly in XX compared to XY 
males (Figure 10B).       
3.4 Discussion 
The key novel findings of this study are: (1) Male sex hormones, coupled 
with an XY sex chromosome complement result in development of diffuse aortic 
disease associated with adventitial thickening in response to AngII infusions. (2) 
In contrast, an XX sex chromosome complement in phenotypic male mice results 
in focal aneurysmal disease within the suprarenal abdominal aorta.  (3) These 
regional differences in aortic vascular disease development are associated with 
differences in abundance of genes implicated in aneurysmal disease between 
thoracic versus abdominal aortas of XY and XX male mice. (4) Short-term infusion 
of AngII superimposes pronounced regional differences in aortic gene expression 
in both genotypes, with greater differences in XY males. (5) Focal suprarenal AAAs 
of AngII-infused XX males progress to exhibit pronounced aortic lumen dilation, 
while progressing AAAs of XY males infused chronically with AngII have thickened 
vascular wall volumes and aortas exhibit diffuse disease. It is well established that 
male sex is a significant non-modifiable risk factor for development of AAAs, with 
men exhibiting a 2-10-fold higher prevalence than women (Weiss et al. 2014; 
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Wilmink et al. 1998; Pleumeekers et al. 1994; Morris et al. 1994).  Recent results, 
performed on a large population of well-characterized patients with Marfan 
syndrome, also exhibited a higher prevalence of aortic root dilatation and 
regurgitation in men compared to women (Roman et al. 2017).  Moreover, using 
data from the Swedish national healthcare registers from 1987 to 2002, the 
incidence of TAA was 52% in men compared to 28% in women (Olsson et al. 
2006).  Collectively, these studies indicate that men exhibit a higher prevalence of 
vascular disease localized to different regions of the aorta compared to women.  
A variety of mechanisms for these differences have been proposed, ranging from 
influences of sex hormones and their receptors (Villard et al. 2017), differences in 
aortic stiffness (Tong et al. 2013), hemodynamic influences, and basic differences 
in aortic size between sexes (Lindquist et al. 2017; Lo et al. 2014; Sweet et al. 
2011; Lederle et al. 1997). Of interest, sex chromosome abnormalities, such as 
Turners syndrome (monosomy X), are associated with a higher risk of aortic 
dissection (Wong et al. 2014), another aortic vascular disease that exhibits higher 
prevalence in men than women (Meszaros et al. 2000).  Recent studies from our 
laboratory demonstrated that an XY sex chromosome complement, when inserted 
in phenotypic females with low circulating testosterone, was sufficient to increase 
the incidence and severity of AngII-induced AAAs (Alsiraj et al. 2017). We also 
noted that exposure of XY females to dihydrotestosterone, to mimic a male-like 
milieu, resulted in a striking level of aneurysm rupture (Alsiraj et al. 2017). In this 
study, we used male mice with an XY or XX sex chromosome complement, as 
males experience testosterone exposures throughout life and testosterone has 
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been demonstrated to increase AngII-induced AAAs in male or female mice 
(Henriques et al. 2004; Henriques et al. 2008; Zhange et al. 2012). Our results 
demonstrate that testosterone, through a sex chromosome-dependent (XY) 
mechanism, promotes the presence of diffuse aortic vascular disease in male mice 
infused with AngII.  In contrast, aortas from XX males exhibit focal aortic pathology 
manifest within the suprarenal region of the abdominal aorta, as has been typically 
described for AngII-induced AAAs that occur in females (Daugherty et al. 2000). 
These striking differences in regional location of AngII-induced aortic pathology 
were both sex chromosome and sex hormone-mediated. 
Several potential mechanisms have been suggested to contribute to sex 
differences in aortic vascular disease development (Makrygiannis et al. 2014). In 
this study, gene expression analysis exhibited 1746 genes that were differentially 
expressed in abdominal aortas of non-infused XY and XX males according to sex 
hormone (e.g., influenced by castration), sex chromosome complement, or by an 
interaction between these factors.  Pathway analysis of gene array data identified 
genes related to extracellular matrix, acute inflammatory response, regulation of 
cell proliferation and the immune response may relate to differences in AAA 
susceptibility between males and females. Of the aortic genes exhibiting 
pronounced differences based on sex chromosome complement, Xist, the RNA 
gene within the X chromosome that is the effector of the X-inactivation process, 
confirms the validity of sex chromosome manipulation in XX males.  Arntl (BMAL1) 
and Npas2, genes enriched in aortas from XX compared to XY males, are genes 
expressing proteins that are core components of the circadian clock apparatus.  To 
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our knowledge, there is minimal information related to influences of circadian 
rhythm on AAA formation and/or rupture.  Abdominal aortas from XY males had 
higher mRNA abundance of Cyp2e1 (a member of the cytochrome p450 enzyme 
family) and Kap (kidney androgen-regulated protein) compared to XX males.  It is 
unclear if these differences in abdominal aortic gene expression between XY and 
XX males are related to aneurysm outcomes of the current study.An intriguing 
difference between XY and XX males infused with AngII was the large adventitial 
thickening that occurred in the thoracic aorta of XY, but not XX males.  Increased 
adventitial thickening in response to AngII infusions in thoracic aortas may have 
contributed to the observed augmented aortic stiffening of XY males (Bersi et al. 
2016). Since blood pressures were increased significantly in XY compared to XX 
males infused with AngII, it is possible that hemodynamic differences contributed 
to these divergent morphologic responses and susceptibility to AngII-induced 
TAAs between genotypes. However, blood pressure was similar in AngII-infused 
sham and castrated males, even though TAA incidence was markedly reduced by 
castration. These results suggest that blood pressure may not be the primary 
contributor to the development of diffuse aortic vascular pathologies of XY males.  
Previous investigators demonstrated a large number of genes (1475) that are 
differentially expressed in the ascending versus descending aortas of female mice 
(Pfaltzgraff et al. 2014). These differences were ascribed to developmental origins 
of cells within distinct regions of the aorta.  Specifically, smooth muscle cells of the 
ascending aorta develop from cardiac neural crest and second heart field (Sawada 
et al. 2017), descending aorta cells develop from somites while those of the 
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abdominal aorta are derived from mesodermal origin (Majesky et al. 2007). These 
differences have been suggested to contribute to diverging physiologic and 
pathophysiologic responses of the aorta, including regulation of the extracellular 
matrix (Thieszen et al. 1996; Majesky et al. 2007; Thatcher et al. 2015). Notably, 
previous studies indicate that cells of mesodermal origin that populate the 
abdominal aorta express androgen receptors (Cunha et al. 1981), and recent 
studies indicate increased expression of androgen receptors in abdominal aortas 
of patients with an AAA compared to control aorta (Villard et al. 2017). In this 
study, with the exception of collagen 1, XY and XX males exhibited the opposite 
patterns of gene expression in abdominal versus thoracic aortas, with increased 
thoracic gene expression in XY males, and increased abdominal gene expression 
in XX males.  Notably, infusion of AngII resulted in robust regional differences in 
expression patterns of several genes with more robust regional differences (e.g., 
higher in thoracic than abdominal) in aortas from XY males exhibiting diffuse 
disease in response to the peptide.  It is unclear if embryonic origins of vascular 
wall cells contribute to the observed regional differences in aortic gene expression 
patterns or the regional responses to AngII. Despite a lower prevalence of aortic 
vascular disease in women than men, women with AAAs or TAAs appear to exhibit 
more progressive aneurysmal growth, with a propensity to rupture at smaller 
aneurysm sizes (Cheung et al. 2017; Lo et al. 2014; Thompson et al. 2013; 
Sweeting et al. 2012; Larsson, 2011; Mofidi et al. 2007; Solberg et al. 2005).  
Previous results from our laboratory demonstrated that castration of male mice 
with established AngII-induced AAAs resulted in aneurysm remodeling, with thin 
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walled AAAs of castrated males compared to muscularized aneurysms of 
intact males (Zhang et al. 2015). Results of the current study agree with 
previous findings, in that AAAs of XY males had large wall volumes as they 
continued to grow.  In addition, the diffuse nature of aortic vascular pathology 
of XY males persisted with prolonged AngII infusions.  In contrast, XX males 
exhibited dilated thin walled AAAs with prolonged AngII infusions, 
suggesting an increased propensity of weakened aortas to rupture. These 
results indicate that sex chromosome-mediated influences on aortic vascular 
biology may contribute to differences in the progression of aortic vascular 
disease between sexes. A limitation of the model used in these studies is that 
it does not define whether the observed phenotype results from genes 
residing on the Y or second X chromosome (that escape X-inactivation). 
Moreover, XX males that are derived from this breeding strategy are infertile 
and have small testes because they lack the Y chromosome genes that are 
responsible for spermatogenesis. However, as XX mice have serum testosterone 
concentrations that are not significantly different from male XY mice (Table 4), 
it is unlikely that these differences influenced experimental findings. 
In conclusion, this is the first demonstration that sex chromosome complement, 
coupled with sex hormones (e.g., testosterone), modulate the region-specific 
development of aortic pathology in response to AngII.  An XY sex chromosome 
complement in males resulted in diffuse aneurysmal disease along the aorta, while 
a male XX sex chromosome complement mediated focal abdominal aortic 
aneurysmal disease.  These regional differences in aortic vascular disease 
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according to sex chromosome complement were dependent on the presence of 
male sex hormones.  Regional differences in expression levels of genes implicated 
in aneurysm development between thoracic versus abdominal aortas from XY and 
XX males may contribute to divergent aneurysm susceptibility and regional 
location of aortic pathology between sexes in response to AngII. Finally, aneurysm 
progression and remodeling were differentially regulated by sex chromosome 
complement, with XX males exhibiting thin walled AAAs and XY males exhibiting 
thickened AAAs and diffuse aortic disease from prolonged AngII infusions. These 
studies suggest that sex differences between men and women in development and 
progression of aortic vascular diseases may arise from the complex interplay 
between sex hormones and sex chromosome complement in defining regional 
aortic gene expression, diffuse versus focal aortic pathology, and differential 
aneurysm remodeling of aortic vascular diseases. 
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Table 3.1.  Primer sequences for RT-PCR. 
 Gene Primer sequence 
ACE Forward: 5’-AGGTTGGGCTACTCCAGGAC-3’ 
Reverse: 5’-GGTGAGTGTTGTCTGGCTTC-3’ 
MMP2 Forward: 5’-GGGGTCCATTTTCTTCTTCA-3’ 
Reverse: 5’-CCAGCAAGTAGATGCTGCCT-3’ 
Collagen1 Forward: 5’-GCTCCTCTTAGGGGCCACT-3’ 
Reverse: 5’-CCACGTCTCACCATTGGGG-3’ 
Thbs1 
Xist 
Kap 
Cyp2e1 
Arntl 
Npas2 
Forward: 5’-CAATTTTCAGGGGGGTGCTGC-3’ 
Reverse: 5’-CCGTTCACCACGTTGTTGTC-3’ 
Purchased from QIAGEN catalog#330001 PPM68756B 
Purchased from QIAGEN catalog#QT00113484 
Purchased from QIAGEN catalog#QT02280278 
Purchased from QIAGEN catalog#QT00101647 
Purchased from QIAGEN catalog#QT00108647 
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Table 3.2. Upregulated genes in XY vs. XX males 
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Table 3.3. Biological pathways upregulated in XY and XX males 
Upregulated in XY compared to XX 
1. Polyamine biosynthetic process (4 genes): Amd2, Azin1, Odc1, Srm 
2. Nuclear pore (6 genes): Ipo7, Kpna1, Kpna2, Nup50, Nup88, Nup93 
3. Purine ribonucleotide binding (31 genes): Abcf2, Atp2b1, Baz1b, Btaf1, 
Cars, Cct2, Cct3, Cdk6, Ctps, Ddx21, Ddx3y, Dgkg, Eif2s3y, Eif4a1, 
Gnai1, Gnl3, Hsp90ab1, Hspa4, Iars, Ide, Insr, Map2k3, Map3k6, Mat2a, 
Psmc5, Rras2, Sar1a, Sgk1, Srp54a, Srp54b, Srp54c 
4. tRNA binding (4 Genes): Cars, Mettl1, Xpo5, Yars 
5. Nuclear lumen (16 genes) Ccnl2, Cfl2, Ddx21, Gnl3, Mbd1, Nop2, Nop56, 
Polr2l, Pop4, Psmc5, Sfpq, Srp54a, Srp54b, Srp54c, Srp72, Srrt 
6. Nucleolus (8 genes): Ddx21, Gnl3, Mbd1, Nop2, Nop56, Pop4, Srp72, 
Wdr74 
7. Transition metal ion binding (32 genes): Adamts1, Adamts9, B4galt4, 
B4galt5, Baz1b, Cars, Dgkg, Dnaja2, Galnt11, Galnt7, Herc2, Iars, Ide, 
Kdm5d, Klf13, Klf9, Luc7l, Mat2a, Mbd1, Mbnl2, Nr4a3, P4ha1, Polr2l, 
Prnp, Sec23b, Slc30a1, Spire1, Sqstm1, Ubr2, Uty, Zdhhc14, Zfp597 
8. Protein amino acid N-linked glycosylation (3 genes): Mgat2, Prkcsh, Stt3b 
9. Extracellular matrix part (7 genes): Ccdc80, Col1a1, Col1a2, Col4a1, 
Col5a2, Lamc1, Sparc 
10.  Immune response (7 genes): Ccl6, Ccl9, Cfb, Fcgr2b, Fcgr3, Il31ra, Tlr13 
11.  Acute inflammatory response (4 genes): Cd163, Cfb, Fcgr3, Stat3 
12. Skin development (3 genes): Aars, Col1a1, Col5a2 
13. Defense response (6 genes): Cd163, Cfb, Fcgr2b, Fcgr3, Stat3, Tlr13 
14.  Melanosome (3 genes): Pdia4, Pdia6, Snd1 
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Table 3.3. (continued) 
Upregulated in XX compared to XY 
1. Ribosome (8 genes): Mrpl23, Mrpl52, Rpl18a, Rpl36, Rplp1, Rplp2, 
Rps10, Ubc 
2. DNA binding (20 genes): Arap1, Ddx3x, Ercc2, Foxd1, Gli1, Kcnip3, 
Kdm5c, Msx1, Nr1h2, Nr3c2, Pold2, Polr2e, Polr2f, Relb, Sry, Stra13, 
Thap3, Zfp395, Zfp593, Zfp687 
3. Intracellular non-membrane-bounded organelle (18 genes): Arhgap6, 
Camk2n1, Cdk5rap2, Eml2, Fgd1, Grm3, Homer3, Ifltd1, Myl6, Nudt16, 
Pdlim2, Rpl13, Rpl35a, Rpl37a, Rps16, Sntg2, Ssh3, Ttf1 
4. Positive regulation of macromolecule metabolic process (8 genes): 
C1qtnf2, Jun, Pawr, Pax1, Pias3, Rarg, Six4, Ttf1 
5. Postsynaptic density (3 genes): Camk2n1, Grm3, Homer3 
6. Structural constituent of ribosome (4 genes): Rpl13, Rpl35a, Rpl37a, 
Rps16 
7. Death (6 genes): Dapk2, Pawr, Pdcd7, Serpinb9b, Spr, Traf2 
8. Regulation of cell proliferation (6 genes): Ada, Jun, Pawr, Rarg, Six5, 
Wnt2 
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Table 3.4. Characteristics of XY and XX male Ldlr-/- mice infused with AngII. 
  XY Sham XY ORC XX sham XX ORC 
     
Body weight (g) 28.6 ± 1  23.9 ± 0.6 ** 31.3 ± 1  28.3 ± 0.8 ** 
Serum testosterone 
(ng/ml) 1.77 ± 0.85  0.07 ± 0.02 ** 1.53 ± 0.64 0.14 ± 0.02 ** 
Plasma Renin 
Concentration (ng/ml) 0.37 ± 0.16 0.32 ± 0.09 0.25 ± 0.04 0.29 ± 0.05 
Total serum 
cholesterol (mg/dl) 1617 ± 242 1450 ± 320 1797 ± 140 1670 ± 115 
Systolic blood 
pressure (mmHg) 132 ± 3  135 ± 4 119 ± 4 * 135 ± 3 ** 
% Atherosclerotic 
lesion in aortic arch 21  ± 2 20  ± 3 19 ± 3 17  ± 2 
 
Data are mean ± SEM from n = 9-
20/group.    
*, P<0.05 compared to XY within surgical treatment.       
**, P<0.05 compared to sham within 
genotype.     
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Figure 3.1.  Graphic depiction of experimental design for studies focused on the 
formation (A) versus the progression (B) of AngII-induced AAAs. 
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Figure 3.2. Sex chromosome complement, sex hormones, and an interaction 
between these factors influence gene expression patterns in abdominal aortas of 
XY and XX males. A, Total number of probe sets on arrays filtered to retain 
transcripts with reliable signal intensity. B, Volcano plot illustrating fold change in 
gene abundance (x-axis) and statistical significance (y-axis). Genes labelled in 
blue exhibited significant increase in XY compared to XX abdominal aortas; genes 
labeled in red exhibited significant increase in XX aortas. C, Frequency histogram 
of the number of genes (y-axis) found at different p-values (x-axis). Chance is 
illustrated by the dashed line. D, Biological pathway analysis (DAVID) of gene 
expression comparing pathways upregulated in XY or XX abdominal aortas. Data 
are mean ± SEM from n = 4-5 mice/genotype. 
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Figure 3.3.  RT-PCR analysis of mRNA abundance of key genes in abdominal 
aortas from male XY and XX mice (sham, orchiectomized, ORC).  A-C, mRNA 
abundance of genes (A, Xist; B, Arntl; C, Npas2) exhibiting increased expression 
in gene arrays from abdominal aortas of XY compared to XX male mice.  D,E, 
mRNA abundance of genes (D, Cyp2e1; E, Kap) exhibiting increased expression 
in gene arrays from abdominal aortas of XY compared to XX male mice.  Data are 
mean ± SEM from n = 4-5 mice/group.  *, P<0.05 compared to XY within surgical 
group as defined by two-way ANOVA with genotype and surgery as between group 
factors.  **, P<0.05 compared to sham-operated within genotype as defined by 
two-way ANOVA with surgery and genotype as between group factors and Holm-
Sidak post hoc analysis. 
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Figure 3.4.  Pulse Wave Velocity (PWV) from male XY and XX Ldlr-/- mice. Data 
are mean ± SEM from n = 6 mice/group.  *, P<0.05 compared to XY as defined by 
Student’s t-test.   
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Figure 3.5. An XY sex chromosome complement mediates diffuse aortic vascular 
disease, while an XX sex chromosome complement is associated with discrete 
aneurysmal disease in abdominal aortas of male AngII-infused mice. A, Aortas 
from XY and XX sham-operated males infused with AngII. B, Aorta weight 
normalized to body weight. C, Area of the aortic arch. D, Incidence of thoracic 
aortic aneurysms (%) in mice of each genotype and group. Data are mean ± SEM 
from n = 10-13 mice/genotype/group who survived the 28 day protocol. *, P<0.05 
compared to XY within sham-operated determined by two-way ANOVA with sham 
and genotype as between group factors with Holm-Sidak post hoc analysis (B,C) 
or by Fisher’s exact test (D). **, P<0.05 compared to sham-operated within 
genotype determined by two-way ANOVA with sham and genotype as between 
group factors with Holm-Sidak post hoc analysis. 
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Figure 3.6. An XX sex chromosome complement results in focal AAA pathology of 
increased size compared to XY males infused with AngII. A, Maximal AAA external 
diameters. Symbols represent individual mice with lines representing mean ± SEM. 
B, Internal diameters of abdominal aortas at selected intervals during infusion of 
AngII. Data are mean ± SEM of mice surviving the 28 day infusions. C, AAA 
incidence (percent above each bar). Numbers in boxes under each bar are mice 
with an AAA/total number of mice per group. D, % Aneurysm rupture (percent 
above each bar). *, P<0.05 compared to XY within sham-operated determined by 
two-way ANOVA with Holm-Sidak post hoc analysis (A,B) or by Fisher’s exact test 
(C,D). **, P<0.05 compared to sham-operated within genotype determined by two-
way ANOVA with Holm-Sidak post hoc analysis (A,B) or by Fisher’s exact test 
(C,D). 
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Figure 3.7. Thoracic aortas from XY males, but not XX males, exhibit adventitial 
thickening in response to AngII infusions. A, Representative thoracic aorta tissue 
sections from XY and XX sham-operated and orchiectomized (ORC) males infused 
with AngII for 28 days. Boxes are areas illustrated at higher magnification. B, 
Quantification of the adventitial layer of thoracic aorta tissue sections from mice of 
each group. C, Quantification of the medial layer of thoracic aorta tissue sections 
from mice of each group. Data are mean ± from 6 tissue sections from n = 3 
mice/group. *, P<0.05 compared to XY within treatment group determined by two-
way ANOVA with surgery and genotype as between group factors, with Holm-
Sidak post hoc analysis. **, P<0.05 compared to sham within genotype determined 
by two-way ANOVA with surgery and genotype as between group factors, with 
Holm-Sidak post hoc analysis. Scale bar represents 100 µm. 
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Figure 3.8. mRNA abundance of key genes implicated in aneurysm development 
in thoracic versus abdominal aortas from XY and XX male mice infused with either 
saline or AngII-infused (1 day). A, Angiotensin converting enzyme (ACE) mRNA 
abundance. B, Matrix metalloproteinase 2 mRNA abundance. C, Collagen 1a1 
mRNA abundance. D, Thrombospondin 1 mRNA abundance. Data are mean ± 
SEM from n = 5 mice/group/sex. *, P<0.05 compared to thoracic within genotype 
determined by three-way ANOVA with region, treatment or genotype as between 
group factors and Holm-Sidak post hoc analysis. **, P<0.05 compared to XY within 
aortic region determined by three-way ANOVA with region, treatment or genotype 
as between group factors and Holm-Sidak post hoc analysis. $, compared to saline 
within region and genotype determined by three-way ANOVA with region, 
treatment or genotype as between group factors and Holm-Sidak post hoc 
analysis. 
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Figure 3.9. XX males exhibit dilated AAAs while XY males exhibit diffuse aortic 
disease with prolonged AngII infusions (3 months). A, Internal lumen diameters of 
suprarenal aorta at selected intervals of AngII infusions. B, Maximal AAA external 
diameters at study endpoint. Symbols represent individual mice with lines mean ± 
SEM. C, Aortas from mice in each group at study endpoint. D, Aorta weight 
normalized to body weight. E, Incidence of thoracic aortic aneurysms in mice of 
each genotype. Data are mean ± SEM from n = 5-10 mice/group. *, P<0.05 
compared to XY determined by Student t-test (A-D) or Fisher’s exact test (E). 
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Figure 3.10.  Ex vivo ultrasound analysis of AAAs from XY and XX male mice 
infused with AngII for 3 months.  A, Wall volume.  B, Abdominal aortic lumen 
volume.  C, Representative 3-D reconstructions of AAAs of mice from each 
genotype.  Data are mean ± n = 5 mice/group that survived the study protocol.  *, 
P<0.05 compared to XY as defined by Student’s t-test. 
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CHAPTER IV. GENERAL DISCUSSION 
4.1    Summary 
The purpose of this study was to examine the role of sex chromosomes 
versus sex hormones in mediating the sexual dimorphism of AngII-induced 
abdominal aortic aneurysms (AAAs) in hypercholesterolemic female and male 
mice. 
First, we sought to examine the role of sex chromosomes in the absence 
of male testosterone on gene expression patterns in abdominal aortas of 
hypercholesterolemic female (non-infused) mice. We found that 88 genes were 
expressed differentially in the abdominal aorta of XX versus XY females and the 
presence of an XY sex chromosome complement in female mice increased the 
expression of genes within inflammatory pathways in the abdominal region of the 
aorta. These results suggest that sex chromosome regulation of inflammatory 
gene expression patterns may play a role in development of AAAs. 
Next, we investigated whether sex chromosomes regulate the 
development of AngII-induced AAAs. Based on previous research demonstrating 
that male AngII-infused mice have a higher AAA incidence than females 
(Henriques TA, Huang et al. 2004), we hypothesized that the presence of an XY 
sex chromosome complement in female mice promotes AngII-induced AAAs. Our 
data suggest that the presence of an XY sex chromosome complement in female 
mice does indeed increase the incidence and severity of AngII-induced AAAs. 
123
Previous studies demonstrated that the removal of androgen by castrating 
male mice decreased the incidence and severity of AngII-induced AAAs and that 
the administration of dihydrotestosterone (DHT) increased AAA formation in 
female mice (Henriques TA, Zhang X et al. 2008). These results demonstrate 
that both sex hormones (e.g., testosterone) and sex chromosome complement 
(XY) contribute to sexual dimorphism of AngII-induced AAAs. To further examine 
if androgen exerts similar effects to promote AAAs in XX versus XY females, we 
androgenized the females of each genotype by giving them the same dose of 
testosterone. The hypothesis was that administration of androgen would 
augment the AAA formation both in XX and XY female mice. We administered 
DHT to adult hypercholesterolemic XX and XY female mice before and 
throughout AngII infusions. Although both XX and XY females exhibited a high 
incidence of AAAs, XY females displayed increased mortality due to an 
astonishingly high rate of aneurysm rupture. 
Recent studies from our laboratory showed that a single dose of 
testosterone to hypercholesterolemic neonatal female mice increased their 
susceptibility to AngII-induced AAAs once they became adults (Zhang X et al. 
2012). However, adult XX females that became susceptible to AAAs from early 
life testosterone exposures had low circulating testosterone levels, suggesting 
that testosterone exposures differentially influence AAA development depending 
on sex chromosome complement. We therefore examined effects of neonatal 
testosterone administration to XX and XY female mice on adult susceptibility to 
AngII-induced AAAs. We administered testosterone to one-day old XX and XY 
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females and infused them with AngII once they became adults to examine their 
susceptibility to AAAs. Although there was no difference between XX and XY 
females exposed to testosterone as neonates in AAA incidence, more than half 
of the XY females died due to aneurysm rupture. 
Next, we investigated the role of sex chromosomes in aortic aneurysm 
pathology in the presence or absence of endogenous male testosterone by using 
XX and XY hypercholesterolemic male mice. First, we examined the role of sex 
chromosome complement on gene expression patterns of abdominal aortas from 
male (non-infused) mice. We found 450 genes that were expressed differentially 
in abdominal aortas of XY versus XX males. Analysis of gene pathways 
determined these differential genes were involved in the extracellular matrix, 
acute inflammatory response, cell proliferation regulation pathways, and the 
immune response pathway. Further, we found that after 28 days of AngII 
infusion, an XY sex chromosome complement in male mice induced diffuse 
pathology along the entire length of the aorta while an XX sex chromosome 
complement promoted restricted focal aneurysm pathology in the abdominal 
region of the aorta. Moreover, XY males, but not XX males, infused with AngII 
manifest thickening in the adventitial layer of the thoracic region of the aortas. 
Additionally, we infused XY and XX males with saline or AngII for one day and 
examined mRNA abundance of key genes involved in aortic pathology from the 
abdominal and thoracic regions of the aorta. There were regional differences in 
mRNA abundance of aneurysm-related genes between genotypes that were 
potentiated with AngII. Finally, following prolonged infusion of AngII, males with 
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an XY sex chromosome complement had diffuse AAAs with thickened aortic 
walls, while males with an XX sex chromosome complement had discrete focal 
AAA with a thinned wall aorta. 
Overall, these studies support a role for sex chromosome complement in 
the sexual dimorphism of AngII-induced AAA in hypercholesterolemic mice. An 
XY sex chromosome complement promotes diffuse and severe aneurysm 
pathology following AngII infusion while an XX sex chromosome complement 
contributes to focal aneurysm pathology located to the suprarenal abdominal 
aorta. Moreover, sex chromosome effects were associated with differences in 
regional and AngII-induced abundance of mRNAs involved in AAA development 
and progression. 
4.2  Importance of studying the role of sex chromosomes in disease 
There are many diseases that are sexually dimorphic. The National 
Institutes of Health has recently stressed the significance of biological sex in 
disease prevention and development, urging scientific researchers to include both 
sexes, males and females, in the experimental design. Most studies examining sex 
differences focus on the role of gonadal hormones. However, gonadal hormones do 
not fully vindicate all sex differences. 
Sex chromosome complement, in addition to gonadal hormones, may be a 
primary mediator behind the sexual dimorphism of various chronic diseases. To 
demonstrate the importance of sex chromosome effects, during the early stages 
of embryo development, male and female pre-gonadal embryos are different in 
size; XY embryos are larger and developmentally more advanced (Burgoyne PS, 
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Thornhill AR et al. 1995; Burgoyne PS 1993). Additionally, even before gonadal 
differentiation, the genes of male and female blastocysts are expressed 
differentially (Bermejo-Alvarez P, Rizos D, Rath D et al. 2010). Moreover, the 
phenomenon of X chromosome inactivation only partially occurs during the 
preimplantation period (Bermejo-Alvarez P, Rizos D, Rath D et al. 2010), resulting 
in upregulation of more than 80% of the X-linked genes in female embryos 
(Bermejo-Alvarez P, Rizos D, Rath D et al. 2010). 
In adult females, the presence of two X chromosomes can create gene-
dosage differences when compared to males with only one X chromosome. 
These gene-dosage differences is balanced by the process of X-inactivation, by 
silencing the transcription of one of two X chromosomes in all cells (Okamoto I et 
al. 2011; Penny GD et al. 1996; Payer B and Lee JT, 2008). However, some of 
the genes on the X chromosome could escape the X-inactivation (Carrel L et al. 
1999; Yang F et al. 2010). Although the Y chromosome is small and has less 
genes than other chromosomes, genes within the male specific region of the Y 
chromosomes have still been associated with several cardiovascular diseases 
(Bloomer LD, Nelson CP et al. 2013). 
4.3 AAA is a sexually dimorphic disease. 
Male sex is one of the strongest risk factors for AAAs, with men exhibiting 
four to ten fold higher prevalence than women (Weiss, Mahlmann et al. 2014; 
Wilmink, Quick et al. 1998; Peumeekers, Hoes et al. 1994; Morris, Hubbard et al. 
1994). Multiple studies from our laboratory and others have demonstrated that 
male testosterone is a primary contributor to profound differences in susceptibility 
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to AAAs between adult male versus female mice and rats (Henriques TA, Huang 
et al. 2004; Henriques TA, Zhang X et al. 2008; Zhang X et al. 2012; Zhang X et 
al. 2015; Cho BS Upchurch GR et al. 2009; Huang CK, Chang C et al. 2015; 
Davis JP, Upchurch GR et al. 2016). However, it is unclear if testosterone by 
itself is sufficient to explain the sexual dimorphism of AAAs. For example, our 
laboratory has shown that a single dose of testosterone to neonatal female mice 
was sufficient to make adult females susceptible to AngII-induced AAAs without 
the need to see the testosterone for the whole life, which is needed in males 
(Zhang X et al. 2012).  
Additionally, multiple studies have shown that sex chromosomes may 
contribute to sexual dimorphism of certain phenotypes and diseases (Robinson 
DP, Huber SA et al. 2011; Ji H, Zheng W et al. 2010; Gioiosa L, Chen X et al. 
2008; Chen X, Wang L et al. 2015; Li J, Chen X et al. 2014). Recent studies 
have demonstrated that blood pressure responses to AngII infusion in mice 
influenced by sex chromosome complement (Ji H, Zheng W et al. 2010). 
Moreover, Turner’s Syndrome, or monosomy X in females, is associated with a 
100-fold increase in risk of aortic dissection and rupture (Wong, Zacharin et al. 
2014; Bondy CA 2008). Furthermore, several genes of the renin-angiotensin-
system are on the X chromosome, which suggest a possibility of gene dosage 
effects for genes that escape X-inactivation. 
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4.4 Mechanisms of sex chromosome effects on AAA 
4.4.1 Role of sex chromosome complement on aortic gene expression 
Our data indicate that the presence of an XY sex chromosome 
complement in female mice without AngII infusion enhanced the expression of 
genes involved in inflammatory pathways in the abdominal aorta, and this was 
associated with increased oxidative stress and matrix metalloproteinase (MMP) 
activity when the female mice were infused with AngII. Moreover, XY females 
infused with AngII exhibited higher AAA incidence and the pathology was diffuse 
and more severe. Additionally, administration of testosterone to XY females, in 
order to mimic the male environment, resulted in an immense rate of aneurysmal 
rupture.  
Also as a part of this study, we decided to use intact male mice with an XY 
or XX sex chromosome complement (meaning phenotypically male mice 
exposed to testosterone throughout life). Without AngII infusion, there were 450 
genes in the abdominal aorta that were influenced by sex chromosome 
complement between XX and XY males. Analysis of gene array data using 
DAVID pathway analysis revealed that these genes are involved in pathways that 
might relate to the sex differences between males and females in susceptibility to 
AAAs. Similar to our findings, other studies using the four core genotype mouse 
model have shown that sex chromosomes influence gene expression in other 
tissues like heart and the central nervous system (Du S, Itoh N et al. 2014; Li J, 
Chen X et al. 2014). Interestingly, differences in gene expression due to sex 
chromosome complement in the abdominal aorta were different in males 
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compared to females (e.g., not the same genes and/or pathways were found in 
XX females versus XX males). This may be explained either due to the difference 
of sex hormones between males and females or due to the presence of the Sry 
gene in males as previous studies have demonstrated that this gene regulates 
blood pressure and gene expression of several components of the renin 
angiotensin system in male rats (Ely D, Boehme S et al. 2011; Araujo FC, 
Milsted A et al. 2015).  
Of interest, from the gene microarray data, two clock genes, Arntl and 
Npas2, were highly up-regulated in abdominal aortas from XX males compared 
to XY males. Additionally, these genes were down regulated with castration, a 
pattern that matches the AAA phenotype. Arntl, also known as Bmal1, is a 
transcription factor that is part of the clock machinery. Arntl binds to E-box 
promoters of Npas2, which regulates downstream clock genes like Pers and Cry 
(Kristin Eckel-Mahan and Paolo Sassone-Corsi 2013). It is unclear if these genes 
have protective or detrimental effects on AngII-induced AAAs. A recent study 
suggested that Bmal1 in smooth muscle cells regulates the circadian rhythm of 
blood pressure (Xie Z, Gong MC et al. 2015). Several studies have shown that 
aortic smooth muscle cells undergo oscillation in the expression of clock genes 
(McNamara P, Seo SB et al. 2001; Nonaka H, Emoto N et al. 2001). In our gene 
expression studies, aortas harvested for the microarray were collected from the 
mice in the morning between 9:30 am and 11:30 am and it is not known if the 
expression of the clock genes are also different at other time points between XX 
and XY mice. Further studies need to be conducted to confirm this. Currently, 
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there is a dearth of publications about clock genes and aneurysms; however, 
several studies have reported that aneurysm rupture and dissection demonstrate 
a circadian pattern (Manfredini R, Portaluppi F et al. 1999; Manfredini R, Boari B 
et al. 2004; Killeen S, Neary P et al. 2007; Vitale J, Manfredini R et al. 2015). As 
AAA ruptures mostly peak in the morning, it has been suggested that the 
morning high sympathetic activity could lead to increases in aortic shear stress 
and rupture (Manfredini R, Boari B et al. 2004). By coincidence, even the king of 
Great Britain, George II, who died in 1760 due to the first identified aortic rupture, 
was reported to have died in the morning around 6 am (Leonard JC 1979). 
4.4.2 Role of sex chromosomes on inflammation 
AAA is a vascular disease that is characterized with inflammation. In our 
study we found that XY females infused with AngII have a higher incidence and 
more severe AAAs than XX females, and this was associated with increased 
inflammatory responses. Specifically, XY females had increased gene 
expression of interleukin-1β (IL-1β) and toll like receptor 8 in the abdominal aorta 
as well as increased plasma concentrations of IL-1β when infused with AngII. 
Also, abdominal aortas of XY females following AngII infusion had higher MMP-2 
activity and oxidative stress. Similarly,  XY males infused with AngII had diffuse 
and more severe aneurysm pathology along the length of the aorta with higher 
AngII-induced MMP2 mRNA abundance in thoracic aorta  than XX males, which 
may indicate that an XY sex chromosome complement promotes aortic pathology 
by enhancing  inflammatory responses to AngII.  
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4.4.3 Role of sex chromosomes on the location of aortic pathology 
Many studies, human and experimental, illustrated that males have a 
higher prevalence of vascular diseases localized at different regions of the aorta 
compared to females (Roman, Weinsaft et al. 2017; Olsson, Granath et al. 2006; 
Lederle et al. 2001; Weiss et al. 2014; Wilmink et al. 1998; Peumeekers et al. 
1994; Morris et al. 1994; Henriques TA et al. 2004; Henriques TA et al. 2008). 
According to a study of more than 14,000 cases of thoracic aortic diseases in 
Europe, the incidence of thoracic aortic aneurysm was doubled in men compared 
to women (Olsson, Granath et al. 2006). Our results indicate that sex 
chromosome complement has an important role in determining the location of the 
AngII-induced pathology in the aorta. As mice with an XY sex chromosome 
complement when infused with AngII developed diffuse pathology along the 
aorta, while mice with an XX sex chromosome complement developed discrete 
focal aneurysm only in the abdominal region of the aorta. In males, this 
phenotype was mediated by both sex hormones and sex chromosome 
complement as there was no difference between castrated XY and XX males, 
this is in line with previous results from our laboratory demonstrating that 
testosterone is needed in normal XY males to maintain high susceptibility to 
AngII-induced AAAs (Henriques TA et al. 2004; Henriques TA et al. 2008; Zhang 
X et al. 2012). It is unclear if these results relate to humans as the majority of 
data from humans are derived from measurements of the intralumenal diameter 
in the infrarenal region of the aorta. Our data raise the concern and urge the 
need to perform multiple measurements along the length of the aorta. 
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4.4.4 Role of sex chromosomes on aortic wall thickness 
Interestingly, thoracic aortas from XY males infused with AngII have a 
thicker adventitial layer than XX males. Also, XY males infused with AngII had 
higher systolic blood pressures than XX males, which was not different between 
sham and castrated groups in the XY males. Since the thoracic aortic aneurysm 
incidence was reduced with castration, this suggests that blood pressure is not 
the primary cause behind the development of diffuse aortic vascular pathologies 
in XY males.  
Differences in aortic wall thickness between XX and XY males may 
suggest that males and females have differing levels of aortic components (e.g., 
muscle versus adventitia) within the aortic wall, and to our knowledge there is no 
study that has made these types of comparisons. In fact, women with an AAA 
have a poorer prognosis and AAAs rupture at smaller sizes (Grootenboer et al. 
2009; Skibba et al. 2015; Sweeting et al. 2012; Thompson et al. 2013), which 
could be due to a thin aortic wall because of lower expression of elastin and 
collagen. 
In this study, we found that XY males have higher expression of key genes 
involved in aneurysm formation in the thoracic aorta while XX males have higher 
expression in the abdominal aorta. It has been reported that different locations of 
the aorta have different gene expression patterns (Pfaltzgraff ER, Shelton EL et 
al. 2014). Furthermore, recently, it has been shown that different regions of the 
aorta are populated by smooth muscle cells derived from diverse embryonic 
origins (Sawada H, Daugherty A et al. 2017). This divergence could be the cause
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behind variance in the physiological and pathological reactions of the aorta 
(Thieszen, Rosenquist et al. 1996; Majesky et al. 2007). In our study the 
patterns of gene expression in abdominal versus thoracic aortas was enhanced 
with only one day of AngII infusion. These differences in gene expression might 
contribute to the diffuse versus focal vascular pathology observed between the 
two genotypes, XX and XY.  
Although women have lower risk of aortic aneurysms, paradoxically, 
aneurysms progress more rapidly and tend to rupture at smaller sizes in women 
(Cheung et al. 2017; Lo et al. 2014; Thompson et al. 2013; Sweeting et al. 2012; 
Larsson et al. 2011; Mofidi et al. 2007; Solberg et al. 2005). In this study, we 
found that XY males developed AAAs with thick aortic  walls that continued to 
expand  with prolonged infusion of AngII. On the contrary, XX males developed 
dilated AAAs that were restricted to the abdominal region of the aorta, and that 
exhibited profound lumen dilation and thin walls with prolonged AngII infusion. 
These results are in agreement with previous findings from our laboratory, which 
showed that normal XY males with existing AngII-induced AAAs remodel to thin 
walled AAAs after removal of  endogenous androgen by castration (Zhang X et 
al. 2015). This observed difference in wall thickness of AAAs between the two 
sex chromosome complements, with thin walled AAAs in females may contribute 
to increased aneurysm rupture (Cheung et al. 2017; Lo et al. 2014; Thompson et 
al. 2013; Sweeting et al. 2012; Larsson et al. 2011; Mofidi et al. 2007; Solberg et 
al. 2005).  
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4.5 The interaction of sex chromosomes and sex hormones 
4.5.1 The interaction of sex chromosomes and sex hormones in experimental 
animals 
Our laboratory previously demonstrated that androgen is a primary 
mediator of AngII-induced AAAs (Henriques TA et al. 2004; Henriques TA et al. 
2008; Zhang X et al. 2012; Zhang X et al. 2015). In this study we found that sex 
chromosome complement has a prominent role to promote the formation and the 
severity of AngII-induced AAAs as well. In females, unlike males, this role was 
independent of gonadal hormones. XY females, either sham or ovariectomized, 
had high AAA incidence, similar to the incidence of normal XY male mice. 
However, male mice appear to continuously require the sex hormone, 
testosterone, to maintain susceptibility to AngII-induced AAA, as AAA incidence 
goes down to the level of females with orchiectomy (Henriques TA et al. 2004; 
Henriques TA et al. 2008, Alsiraj Y et al. 2017).  
The high AAA incidence of XY females could be due to a modest level of 
testosterone, although this level was at least ten fold lower than that of normal 
XY males. However, this level of testosterone in females, coupled with the 
presence of the XY sex chromosome complement, might have a synergistic 
effect and be detrimental enough to make the “weak” female aorta susceptible to 
AAA, as it has been reported that female aortas have a lower capacity to absorb 
force than male aortas (Ninomiya OH, Tavares Monteiro JA et al. 2015). 
Additionally, our laboratory demonstrated previously that a single dose of 
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testosterone to normal XX females when they are one-day old was sufficient to 
permanently promote the formation of AAAs later in life (Zhang X et al. 2012).  
Since testosterone is known to promote  the susceptibility of AngII-induced AAAs 
and the testosterone concentration was modestly higher in XY females, we 
androgenized the two genotypes by exposing XX and XY female mice to the 
same dose of androgen. This was done either by a single dose of testosterone 
injected to one- day old neonates or by continuous diffusion of DHT for 6 weeks 
through an implanted DHT tablet under the skin of adult XX and XY female mice. 
Our results demonstrate that despite the high incidence of AAAs in both XX and 
XY females, the administration of testosterone to female mice with an XY sex 
chromosome complement increased the rate of aneurysm rupture to the highest 
level that we have ever seen (73%).  
This high level of AAA rupture in XY females is even higher than that of 
XY males infused with AngII (Daugherty A et al. 2000; Henriques TA et al. 
2004; Henriques TA et al. 2008). This may be due to the dose of testosterone 
or the type of androgen used in these experiments, as DHT is the most potent 
androgen and has an augmented effect compared to testosterone. Alternatively, 
it may be due to the anatomical nature of the female aorta, as it has been 
reported that there are sex differences in the size and the vessel biomechanical 
properties between males and females. Male aortas are reported to be stronger 
than female aortas, and have a higher failure load and failure tension than female 
aortas (Ninomiya OH, Tavares Monteiro JA et al. 2015). Also, it has been shown 
that female aortas have higher peak wall rupture risk than male aortas (Larsson 
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E et al. 2011). Furthermore, women with AAAs are known to have poor prognosis 
compared to males as their AAAs grow faster and rupture at a smaller size than 
male AAAs (Grootenboer et al. 2009; Skibba et al. 2015; Sweeting et al. 2012; 
Thompson et al. 2013). Thus, we conclude that putting  male factors, namely XY 
sex chromosome complement and testosterone, into females increased AAA 
susceptibility and severity resulting in the AAAs of females to rupture at a very 
high rate.  
Conversely, in males, the XY sex chromosome complement required 
testosterone to enhance the susceptibility to AngII-induced AAAs. We found that 
XY males have diffuse aneurysm pathology in both thoracic and abdominal 
aortas compared to XX males that have discrete focal abdominal aneurysms. 
Notably, both XY and XX males lose their susceptibility to AngII-induced 
pathology when castrated, which is in agreement with previous results 
(Henriques TA et al. 2004; Henriques TA et al. 2008). The requirement of 
testosterone in males to induce AngII-induced AAAs could be due to the 
presence of the Sry gene in males, or due to early surges of  testosterone levels 
during fetal and neonatal life (Motelica-Heino I, Castanier M et al. 1988; Klinga 
K, Bek E  et al. 1978; Tomlinson C, Macintyre H et al. 2004). Early life 
exposures to testosterone in males may have an organizational influence to 
imprint the requirement for continuous testosterone exposures to maintain the 
“activational effect” of testosterone in adults. 
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4.5.2 The interaction of sex chromosomes and sex hormones in humans 
In contrast to experimental AAA studies in animals, in which it is well 
established that testosterone plays an important role in AAA formation and 
progression, in humans this association is not so clear, with only one study 
reporting that low testosterone levels were associated with AAA (Yeap et al. 
2010). This group reported that serum total testosterone levels in men with an 
AAA were 14.5 nmol/ liter compared to 15.5 nmol/ liter in men with no AAA, and 
concluded that testosterone levels are negatively associated with the 
development of AAA (Yeap BB, Hyde Z et al. 2010). In this study, there is only a 
1 nmol/ liter difference in total testosterone level between non AAA and AAA 
patients which does not necessarily indicate that low testosterone levels can 
cause AAAs. In fact, the normal testosterone level in men ranges from 9-38 
nmol/ liter (Fischbach FT, Dunning MB III, 2009 Manual of Laboratory and 
Diagnostic Tests, 8th ed). This means that testosterone levels within this range 
are sufficient to maintain the features of male sex, including the beneficial and 
non-beneficial ones, and thus men with an AAA reported by Yeap et al most 
likely had normal serum testosterone levels. Additionally, the reported 
testosterone levels in these human studies were measured in men with an AAA. 
Typically, AAAs are detected by ultrasound screening which is recommended for 
men at or above the age of 65 (Mussa FF 2015). Thus, it is unclear if serum 
testosterone levels were influenced  before the formation of an AAA. Since the 
testosterone level before or at the time of AAA formation is unknown, the 
relationship between testosterone levels and AAA development are not clear. 
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Possibly, the decline in testosterone levels of aging male AAA patients suggests 
that sex chromosomes, either alone or in combination with sex hormones, may 
contribute to the development and progression of AAAs. Previous data from our 
laboratory show that a single dose of testosterone to female neonates was 
enough to enhance the AAA susceptibility in adult female mice (Zhang X et al. 
2012). In contrast to men, women tend to have an imbalance in their estrogen 
to testosterone ratio after menopause (Dai W, Li Y et al. 2012; Rohr UD 2002), 
which could explain, besides aging, why AAA incidences in women increase 
(e.g., higher testosterone to estrogen ratio) with age with more propensity to 
aneurysm rupture (Grootenboer et al. 2009; Skibba et al. 2015; Sweeting et al. 
2012; Thompson et al. 2013). 
4.6 Importance of including sex chromosomes in genome wide association 
studies (GWAS) 
Previous studies have suggested a genetic contribution to AAA 
development, as people with a family history of AAA have a tenfold increased 
chance of developing the disease (Johansen K and Koepsell T 1986). In an 
Australian ultrasound screening study of siblings, AAA patients reported that 43% 
of their siblings were males and were also diagnosed with having an AAA 
(Frydman G, Walker PJ et al. 2003). Similarly, a small study in Sweden that 
screened 108 siblings of AAA patients found that 16 of them with an AAA were 
brothers (van der Lugt A, Kranendonk SE et al. 1992).  Additionally, in a multi-
national study looking at familial aggregation of AAAs in families that have at 
least two individuals with AAAs, 77% of the affected cases were males and most 
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were brothers (Kuivaniemi H, Shibamura H et al. 2003). The high rate of disease 
transmission between the male siblings suggests a Y chromosome influence in 
transmission of the disease. However, our study is the first to provide direct 
evidence of the role of sex chromosomes in the sexual dimorphism of AAA.  
Sex chromosomes are usually neglected and not included in genome wide 
association studies (GWAS) and these studies tend to focus only on autosomal 
genes (Wise AL, Gyi L, Manolio TA 2013). This is usually due to technical 
difficulties including statistical test selection, random X-inactivation, attribution, 
and the phenomenon of escape from X-inactivation. The omission of sex 
chromosomes from GWAS could overlook multiple genes on the sex 
chromosomes that might contribute to the development and progression of 
several diseases. Results from our studies, which support a role for sex 
chromosomes in disease development, provide an impetus to include the sex 
chromosomes in future GWAS analyses.  
Taken together, our data indicate that sex chromosome complement 
regulates aortic gene expression, responses to AngII and disease development, 
with an XY sex chromosome complement increasing the incidence and the 
rupture of diffuse aortic aneurysm pathology that progressed with thickened 
aortic walls while an XX sex chromosome complement was associated with focal 
AAA development that progressed with profound luminal dilation and thin aortic 
walls. Effects of an XY sex chromosome complement were exacerbated by 
testosterone administration, meaning there is a complex interaction between sex 
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chromosomes and gonadal hormones in regulating vascular diseases and 
specifically AAAs.  
4.7 Clinical Significance 
It is important to understand the interplay between gonadal hormones and 
sex chromosome genes, specifically pertaining to their role in the regulation of 
the cardiovascular system. Our studies show that genes regulated by the sex 
chromosome complement may affect vascular biology to enhance inflammation 
and augment the response to AngII. Searching for the genes that are regulated 
genes of sex chromosomes and which affect AAA development may uncover 
sex-specific treatments for this and other AngII-related diseases.  
The transgender population is on the rise, but studies on adverse effects 
from the chronic use of sex hormone therapy on the opposite sex chromosome 
complement are scarce. Of these, recent data suggest increased risk of 
cardiovascular diseases in transgender women (Elamin et al. 2010). However, 
the effect of chronic use of sex hormone therapy on the cardiovascular system in 
transgender people has not been thoroughly investigated.  In addition, the use of 
sex hormone therapy for other reasons has also increased, specifically 
androgen use to improve sex drive and to improve the performance ability in 
elderly and in young males and females.   
Our results suggest that sex chromosome complement influences aortic 
disease development, with an XY sex chromosome complement having a large 
influence in promoting aneurysm development and severity. These effects were 
exacerbated when coupled with testosterone. Information from these studies 
141
should help in the future to develop sex specific therapies against aortic 
aneurysms and other vascular diseases. 
4.8  Future directions 
Results from these studies demonstrate that the presence of an XY sex 
chromosome complement in female mice was sufficient to increase the incidence 
and the rupture rate of diffuse aortic aneurysm pathology, and that AAA 
formation and severity were augmented by androgen treatment. Further, it was 
found that XY males develop diffuse aortic disease along the entire length of the 
aorta while XX males develop discrete focal aneurysm pathology in the 
abdominal aorta. Moreover, XX and XY male mice exhibited regional differences 
in aortic gene expression patterns that were also regulated by sex and AngII. 
However, we did not address whether these effects were due to the presence of 
the Y chromosome or due to the absence of the second X chromosome. 
Therefore, a novel study should look to define whether genes on the Y 
chromosome or gene dosage effects from the second X chromosome influence 
the development and progression of AngII-induced vascular diseases. I suggest 
use of the trisomy mouse model (Chen X, Williams-Burris SM et al. 2013), which 
allows addition of a Y chromosome to an XX female, or an X chromosome to an 
XY male. The trisomy model can be generated by mating a normal XY male to an 
XY- female (this female is generated from the 4 core genotype mouse model). 
According to Chen X et al. 2013, about 30% of the female offspring produced 
from this breeding scheme would have XXY- sex chromosome complement. 
XXY- females would then be mated to XY-(Sry+) males (this male is generated 
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from the 4 core genotype mouse model) to produce offspring that have the 
following genotypes, XX, XY, XXY, XYY phenotypic females that have ovaries 
and XX, XY, XXY, XYY phenotypic males that have testes. By comparing XX 
females to XXY females, or by comparing XY males to XXY males against AAA 
will enable delineation of whether the presence of the Y chromosome or the 
absence of the second X chromosome influences development and/or 
progression of AngII-induced vascular diseases. If results from these studies 
show that the X chromosome has a protective role against AngII-induced AAAs, 
these findings then can be confirmed by the use of the XY* mouse model, a 
model for Turner’s syndrome or monosomy X, a disease associated with high 
risk of aortic dissection in females with one X chromosome (Wong, Zacharin et 
al. 2014; Bondy CA 2008). This model produces mice with one X chromosome 
or two X chromosomes, each in the absence or presence of a Y chromosome, 
which will result in XX and XO females that have ovaries and XY and XXY males 
that have testes (Burgoyne PS, Mahadevaiah SK et al. 1998). By studying the 
AAA in XX versus XO females, this study will confirm the protective role of X 
chromosome genes in aortic aneurysm, which could possibly open the door for 
studies that search for the genes influenced by X chromosome genes that make 
the monosomy X females predisposed to aortic pathologies, which can be tested 
by looking for genes that are upregulated or downregulated by AngII in the 
presence or absence of the second X chromosome. The XY* mouse model can 
be created by mating XY* males to normal XX females. The XY* male is a male 
mouse has a Y chromosome that has been re-arranged structurally. This Y 
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chromosome has an aberrant pseudoautosomal region (PAR) that recombines 
alternately with the PAR of the X chromosome during meiosis (Burgoyne PS, 
Mahadevaiah SK et al. 1998).  
Furthermore, after identifying the sex chromosome (X or Y) that has the 
protective or the detrimental role in aortic aneurysm, we should move to define 
the role of sex chromosomes (the detrimental or the protective ones) in 
aneurysm progression as AAA is usually detected after it has been established 
and progressed, due to ultrasound screening recommendations for men aged 65 
to 75 years with a history of smoking (Hirsch AT, Haskal ZJ, Hertzer NR et al. 
2006). The progression studies could be done by using the same mouse models 
with prolonged AngII infusion and monitor the AAA progression by ultrasound.  
The ultimate goals for these future studies are finding therapies that blunt the 
progression of AAAs. Results from our studies indicate that sex chromosomes 
determine differences in genes within the abdominal aorta that are either located 
on the X chromosome and are known to escape X-inactivation, or are located on 
the Y chromosome. These genes are either transcription or translation factors, 
making them not easy to use as targetable therapy because they control a wide 
range of genes on the autosomes. However, the autosomal genes that are 
regulated by genes of the sex chromosomes could be used as potential 
therapeutic targets. Furthermore, if we can identify genes that are influenced by 
sex chromosomes, sex hormones, or by AngII in pivotal cell types, this will help 
in developing a sex-specific therapy that could provide efficacy against the 
144
formation and/or progression of AngII-induced AAAs in male versus female mice 
which could be applied to humans to blunt AAA progression and/ or rupture. 
Another interesting future study should look at the role of clock genes, 
specifically, Arntl and Npas2 in AngII-induced AAA. It would be of interest to look 
to the expression of these genes in XX versus XY mice in different segments of 
the aorta that are collected at different times of day, and based on the 
information from this experiment, studies could be initiated that disrupt the 
circadian rhythm to see its role in AngII-induced AAAs. Alternatively, we can 
delete these genes from aortic smooth muscle cells and see their influence on 
AngII-induced AAAs in males versus females. 
4.9    Limitations of the study 
First, we were unable to distinguish if the observed phenotype is due to 
the presence of the Y chromosome or due to the absence of the second X 
chromosome. 
Second, XX males from the four core genotype model are sterile and have 
small testes due to the absence of the Y chromosome which has genes that are 
responsible for sperm production. Nonetheless, the levels of serum testosterone 
were not statistically different between XX and XY males. 
Third, XY females are transiently fertile and have a modestly higher level 
of serum testosterone than XX females, but this level was at least ten fold lower 
than the testosterone levels of normal males. Additionally, we normalized the 
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testosterone level between XX and XY females by giving both genotypes the 
same dose of androgen. 
4.10    Concluding remarks 
Findings of this dissertation demonstrate that sex chromosome 
complement influences aortic gene expression as well as the development and 
the severity of aortic aneurysmal diseases that form in response to AngII infusion 
in hypercholesterolemic male and female mice. An XY sex chromosome 
complement in phenotypic females was sufficient to promote the formation of 
AngII-induced AAAs. Mimicking the male environment, testosterone exposure to 
XY female mice increased the severity of AAAs by increasing the rupture rate to 
up to 73%. Male mice with an XY sex chromosome complement developed 
diffuse aortic aneurysms along the entire length of the aorta while XX males were 
found to develop discrete focal aneurysm pathology restricted to the suprarenal 
region of the aorta and both genotypes (XY and XX males) lost the susceptibility 
to the disease after castration (Figure 4.1). These results demonstrate, for the 
first time, that the sex chromosome complement has an immense impact on AAA 
susceptibility, and that these effects are augmented by testosterone.   
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Figure 4.1 Illustration of the role of sex chromosomes on AngII-induced AAA 
susceptibility in mice. On the left, the large black arrow means a higher rate of 
rupture in female XY mice compared to female XX mice. Basal aortic pictures 
were adapted from Servier Medical Art. 
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